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ABSTRACT
The transmembrane envelope glycoprotein, gp46 of maedi visna virus (MVV)
was proposed to mediate membrane fusion between the virus and cell and between
infected and uninfected cells on the basis of analogy with other viruses.
In order to look at the relationship between fusion and gp46, which is difficult
to purify in quantity from virus preparations, recombinant gp46 (rgp46) was made.
This first required cloning of the part of the MVV (strain EV1) env gene which encodes
gp46. Sequence comparison with other viruses showed that gp46 is a typical
transmembrane fusion protein, with a hydrophobic N-terminal fusion peptide. This
putative fusion peptide was highly conserved between different MVV isolates although
gp46 as a whole was only about 80% conserved.
rgp46 was expressed as fusion proteins in yeast and in bacteria, but could only
be prepared at low yield and purity principally due to its toxicity to host cells.
Immunised animals raised antibodies to rgp46 and sera from MVV-infected sheep
specifically reacted with rgp46, whereas serum from uninfected sheep did not.
A fusion assay was developed using MVV to determine the effect of serum on
MVV-mediated fusion. A significant difference was shown between the activity of sera
from MVV-infected and uninfected sheep in the fusion assay: Serum from uninfected
sheep generally enhanced fusion at low dilutions of serum (<1:64) and had no effect at
higher dilutions, whereas serum from MVV infected animals tended to inhibit fusion at
low serum dilutions (< 1:16) and enhance at higher dilutions.
The effect of serum in the fusion assay was shown to be principally mediated
by IgG and correlated with serum ELISA activity against a rgp46 preparation. This
suggested a relationship between the presence of antibodies to gp46 and fusion
modulatory activity.
These results may have important implications in consideration of potential
vaccines and also in understanding how the virus can continue to replicate and
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CHAPTER 1: Introduction and literature review
1.1: MAEDI-VISNA VIRUS
Maedi-visna virus, (MVV), (also known as visna virus), is a lentivirus, a
member of the same sub-family of non-oncogenic retroviruses that includes the
human, simian, bovine, and feline immunodeficiency viruses, (HIV, SIV, BIV, and
FIV), caprine arthritis encephalitis virus, (CAEV), and equine infectious anemia
virus, (EIAV). (Narayan et al., 1980, Popovic et al., 1984, Letven et al., 1985,
Gonda et al., 1987, Pedersen et al., 1987). The lentiviruses are enveloped viruses
with a genome consisting of a positive stranded RNA molecule which encodes the
three major structural genes 5'-gag-pol-env -3' (Sonigo et al., 1985, Wain-Hobson et
al., 1985). The env gene encodes the envelope glycoptoteins (transmembrane and
external), gag encodes the viral core proteins and a viral RNA binding protein, and
pol encodes a complex of enzymes involved in reverse transcription of the viral
RNA to proviral DNA and integration of the proviral DNA. In addition, a number of
small open reading frames encode regulatory proteins involved in the complex
regulation of lentiviral gene expression (Vigne et al., 1990, Cullen 1992). A
diagram of the structure of MVV is shown in Figure 1.1.
Maedi-visna virus causes a slow progressive fatal disease of sheep with a
prolonged incubation period of months to years. Its name, derived from Icelandic,
describes two of the principal clinical manifestations of the disease; maedi -
shortness of breath and visna - wasting (Siggurdsson, 1954, Siggurdson and Palsson,
1958). The same virus is responsible for both maedi, the pulmonary form of the
disease with dyspnea and loss of lung function, and visna, the neurological form
which appears as loss of coordination, encephalopathy and eventually paralysis of
the hind limbs. The range of clinical signs, which develop only gradually, make
early diagnosis difficult in the absence of serological evidence of infection
(Siggurdson and Palsson, 1958, Watt et al., 1992). Loss of condition or wasting may
be the first sign of the disease before the more severe pulmonary and/or neurological
symptoms become manifest. Inflamed joints (arthritis) or mammary tissue (mastitis)
may also be seen in some MVV infected sheep.
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Figure 1.1: Stucture of MVV
The same strain of MVV can cause different disease conditions in susceptible
breeds or infection can be asymptomatic. It is clear that the genetic background of
the host can have a direct effect on the progression and outcome of infection by the
virus (Houwers et al., 1989).
Replication and cytopathic effect (CPE) of MVV differs depending on vims
strain (Trowbridge et al., 1976) as well as on the source and maturation state of the
host cell (Gendelman et al., 1986). Different MVV isolates may also differ in their
ability to induce disease. Lairmore et al., (1987), showed that MVV isolates which
were cytopathic for alveolar macrophages in vitro were pathogenic when inoculated
into neonatal lambs. However it should be noted that the strains they used were
isolated from MVV-infected animals suffering from lymphocytic interstitial
pneumonitis. A correlation was shown between pathogenicity and in vitro CPE on
macrophages but not on choroid plexus or fibroblast cells.
1.1.2: Epidemiology
MVV was first described and isolated in Iceland (Siggurdsson, 1954,
Siggurdson and Palsson, 1958). It appears that asymptomatic MVV-infected sheep
of Karakul breed which were imported from Germany in 1933 brought the infection
to Iceland (Siggurdsson, 1954). Infection of the susceptible indigenous population
of Icelandic sheep with MVV resulted in epidemic outbreaks of MVV disease with a
mortality of 10-20% per year on many farms. It is likely that Icelandic farming
practices whereby large numbers of sheep were housed together at certain times of
the year contributed to the rapid spread of the disease. Today the disease has been
eradicated from Iceland by culling all infected sheep flocks but MVV infection still
occurs in sheep in many other parts of the world (Adams and Gorham, 1986, East et
al., 1987). Often the infection does not become apparent and no disease symptoms
appear within the normal lifespan of sheep (Cutlip, Jackson and Laird, 1977, de Boer
et al., 1979) but in some flocks the disease is a major cause of morbidity and
sickness and is therefore of economic importance (Watt et al., 1990, Dawson, 1980).
The virus is spread in colostrum, milk or bronchoalveolar secretions. It
therefore passes to sucking lambs and also passes horizontally particularly between
sheep housed in close proximity.
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1.1.3: In vitro culture of MVV
In vitro MVV can be grown in monocyte/macrophage cells or fibroblast-like
cells derived from a variety of foetal or adult ovine tissue such as choroid plexus,
synovial membrane, or skin. MVV induces a cytopathic effect with the formation of
syncytia. It replicates to fairly high titre in vitro and infectious virus can be
recovered from the supernatant. It should be noted, however, that the strains which
grow well in vitro in fibroblasts are tissue culture adapted strains.
1.1.4: Replication of MVV in vivo
In vivo MVV replicates initially at the site of infection, probably the lung,
and subsequently spreads. Infection and replication occurs preferentially in cells of
the macrophage/monocyte lineage and dendritic cells causing a non-cytopathic,
persistent infection of these cells in the bone marrow, blood, and inflamed tissues
(Narayan et al, 1982, Gendelman et al., 1985). In contrast to the in vitro situation, in
vivo expression of the viral RNA and proteins is restricted to a minimal rate except
under certain conditions, such as activation of an infected monocyte, when
replication is stimulated (Narayan et al., 1983, Gendelman et al., 1985, Gendelman
et al., 1986). As macrophages are terminally differentiated cells with a relatively
short lifespan, (about 3 months for alveolar macrophages, longer for some other
tissue macrophages), it is likely that other cells are infected and provide a reservoir
for lifelong persistence of the virus. One theory is that proviral DNA becomes
integrated into the genome of myeloid stem cells in the bone marrow where infection
becomes established early after infection of the sheep (Narayan and Jolly, 1990).
Alternatively non-productive infection of non-macrophage cells such as fibroblasts
may provide a harbour of persistency escaping immune surveillance by shutting
down expression of viral proteins.
Little cell free virus is detectable in infected sheep (Kennedy-Stoskopf et al.,
1989). This may be due to the inability of field isolates to grow in vitro in the
indicator lines used, or it may be that there is very little cell free virus in vivo and
thus the majority of virus spread would be intracellular. During disease, replication
becomes amplified and more virus can be isolated, especially from inflammatory
lesions.
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1.1.5: Immune responses to lentivirus infection
All arms of the immune system are involved in the response to infection by
viruses. In addition to antibody, cell mediated immunity, phagocytes, complement,
and interferon all play an important role in immune defence. However viruses
exploit weaknesses in the host defences evading, avoiding or subverting the antiviral
forces. The lentiviruses have evolved mechanisms of escaping immune destruction
by all three of these strategies; despite the formation of both cellular and humoral
immune responses, neither arm of the immune system seems to be able to
indefinitely control the replication and spread of the virus and eventually most
infected individuals develop pathological symptoms. The long clinically latent
period during lentivirus infection suggests that for a long time the immune system
may be able to control virus infection even though it is unable to clear it. During this
time the virus may continue to replicate albeit at a restricted rate and eventually the
cumulative adverse effects resulting from persisting virus on the immune system
mean that the virus can no longer be controlled. The host immune responses may
ultimately cause clinical disease rather than any direct effects of the virus, many of
the symptoms being the result of chronic inflammatory effects. Whilst the immune
response is sufficient to cause long-term tissue damage it is unable to clear the virus
which suggests the immune response to MVV is inappropriate. Nevertheless the
clinically latent period gives hope that augmenting the immune response to further
shift control in favour of the immune system may enable virus clearance or at least
prevention of disease.
1.1.6: Immune response to MVV infection
Some MVV infected animals may take more than six months to seroconvert,
others may seroconvert and later become seronegative, others may never seroconvert
( Houwers and van der Moulen, 1987). As a result of viral persistence in apparently
seronegative carriers MVV may reappear in a flock from which seropositives have
been culled (Houwers and van der Moulen, 1987). Despite the presence of
neutralising antibody the virus may persist and continue to replicate. Some infected
animals remain seropositive for life which is indicative of persistence and low level
production of virus. Also virus can be isolated from the circulating blood monocytes
of infected sheep at all times after infection (Narayan et al., 1982, Gendelman et al.,
1986, Gendelman et al., 1985).
MVV specific lymphocyte proliferative responses have been reported in
sheep persistently infected with MVV (Reyburn et al., 1992). In most animals the
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major lymphocyte subset in PBMCs shown to proliferate in response to viral antigen
were CD4+ T-lymphocytes although in some sheep CD8+ were also shown to
respond.
1.1.7: Virus neutralisation
The binding of antibodies to viruses can result in loss of infectivity or
neutralisation. Production of neutralising antibodies is a protective immune
response which occurs early in most viral infections. The molecular principles
underlying antibody neutralisation are less well understood than the other effector
functions of antibodies e.g. opsonisation and complement activation. Neutralisation
of viruses can occur by various mechanisms depending on factors such as the nature
of the virus, the epitope recognised, the antibody isotype, the cell type/receptor for
the virus and the virusrantibody ratio. Neutralising antibodies may act at various
stages in the virus life cycle. Mechanisms of neutralisation include aggregation of
virions, prevention of binding to the cell receptor and inhibition of events following
attachment such as fusion of viral and cellular membranes and secondary uncoating
of the virion.
Neutralisation is an in vitro phenomenon and cannot necessarily be
extrapolated to in vivo activity. Neutralisation assays test the ability of a serum or
antibody to reduce virus infectivity in vitro. The neutralisation titre is normally
considered to be the highest dilution of serum/antibody at which the infectivity of
the virus is reduced by 50% as measured by CPE, detection of viral antigen or
reverse transcriptase assay. A large number of factors affect the result of
neutralisation assays. These factors include the viral genotype used, the cell type
used to propagate the virus stocks, the target cells used in the assay, the parameters
used to measure virus production, and the time course of the assay.
Although neutralising antibodies may be demonstrated by in vitro assays,
their in vivo role in prevention of virus infection or disease progression is not well
understood. This is particularly true in cases where disease progression continues
despite the presence of neutralising antibody, e.g. HIV or MVV. This is complicated
by the fact that most studies have used assays against standard strains rather than
testing the ability of the infected individual's serum to neutralise their own virus
isolates.
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1.1.8: Neutralisation of MVV
In studies with experimentally infected sheep it has been reported that there
is a delay between the detection of non-protective complement fixing antibodies, (1-
2 months p.i.), and the detection of neutralising antibody (~6 months p.i.)
(Gudnadottir and Kristindottir, 1967). This time interval is variable even between
different sheep experimentally infected with the same inoculate of virus. Other
workers report detection of neutralising antibodies 3-4 weeks after experimental
infection (Narayan et al., 1977 Griffin et al., 1978) but this may be the result of the
route of experimental infection; Griffin et al., (1978), inoculated each sheep
intracerebrally with 108pfu of MVV-1514.
Antibody titres are also variable, (1:32 to 1:1024 in studies by Petursson et
al., 1976). Often any neutralising antibodies detected are of very low affinity
(Gudnadottir, 1990) and are inefficient at neutralisation (Kennedy-Stoskopf and
Narayan, 1986). Assay techniques require prolonged incubation of virus with
serum/antibody prior to addition to cells. In vitro MVV binds to cells within five
minutes of incubation and attachment is maximal within fifteen minutes incubation.
Incubation of MVV with neutralising antiserum for fifteen minutes does not reduce
infectivity (Kennedy-Stoskopf and Narayan, 1986). This suggests that in vivo
binding of virus to target cells may be more rapid than neutralisation and may be one
reason why neutralising antibodies are not protective. The same authors showed that
in vitro neutralisation involved IgG subclass 1 and was complement independent.
At first MVV neutralising antibodies are directed only against strain
restricted envelope epitopes but the strain specificity broadens with time (Narayan
etal., 1981).
1.1.9: ADCC
Monoclonal antibodies against envelope glycoproteins have been shown to
mediate lysis of infected cells (antibody dependent cell mediated cytotoxicity or
ADCC) by NK cells, K cells or macrophages. Antibody bound to an infected cell is
recognised by Fc gamma receptors on these immune cells and activates them to kill
the infected cell. Some antibodies which direct ADCC have been localised to
specific epitopes of HIV env, e.g. aa 644-653 and 579-604 of gp41 (Tyler et
al., 1990), but it is likely that any antibody that recognises viral antigen on an
infected cell would be able to direct ADCC provided it is of the right isotype.
ADCC responses may be important in restricting viral replication early in
infection (Sawsyer et al., 1990). In the case of HIV antibodies capable of inducing
ADCC appear may be less strain specific than neutralising antibodies (Lyerly et al.,
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1987). The same is likely to be true for MVV.
In sheep IgG2 mediates ADCC (Grant, 1975). Recent work by Bird and
Reyburn (Personal communication), suggests there may be a specific deficiency in
IgG2 against MVV proteins in the MVV-infected sheep although both subclasses are
produced against other antigens by the MVV-infected sheep and immunisation of
uninfected animals with recombinant MVV proteins induces both IgGl and IgG2
antibodies. It is not known yet whether this deficiency occurs very early in infection
when it would be particularly disadvantageous to the host.
If there is sufficient antibody coating the cell surface it may activate
complement by the alternative pathway and the infected cell may be lysed by
complement lysis complexes. This antibody dependent complement mediated
cytotoxicity has been demonstrated using sera from MVV-infected sheep against
MVV infected cells (Reyburn et al., 1992).
1.1.10: Enhancement of infection by anti-envelope antibodies
The best known example of antibody dependent enhancement of infection is
by Dengue virus, an enveloped virus, which uses non-neutralising antibody to
enhance infection of monocytes/macrophages via binding to the Fc receptor
(Halstead, 1988).
HIV infection can be enhanced by antibody mediated via Fc receptors
(Takeda et al., 1988) or complement receptors (Robinson et al., 1988) which may
also enable infection of cells not expressing the normal HIV receptor CD4 (Homsy
et al., 1989). Very low concentrations of antibody (0.05 - 5ng/ml) have been shown
to enhance infection with limiting dilutions of virus (Perno et al., 1990). Antibodies
against two immunodominant regions of HIV gp41 may be particularly important in
complement mediated antibody dependent enhancement (C-ADE) of HIV infection
as synthetic peptides to which these monoclonal antibodies bind not only blocked the
C-ADE mediated by these human mabs but also blocked C-ADE by polyclonal anti-
HIV serum whilst other peptides did not. (Robinson et al., 1990b, Robinson et al.,
1991). These two domains are highly conserved between all HIV-1, HIV-2 and SIV
envelope proteins sequenced to date.
1.1.11: Hidden Epitopes
If functional epitopes are hidden the virus may escape neutralisation and the
immune system may instead be wasting effort making antibodies of limited antiviral
function. If of higher affinity these antibodies may actually be inhibiting the binding
of neutralising antibodies.
The virus most closely related to MVV, CAEV, does not induce detectable
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neutralising antibodies in the host, even though antibodies develop to all the CAEV
proteins and there is no evidence to suggest impairment of the host immune system
(Crawford and Adams, 1981, Klevjer-Anderson and McGuire, 1982). It has been
suggested that the epitopes responsible for CAEV neutralisation are masked from the
immune system.
1.1.12: Antigenic variation
One mechanism by which to escape either the humoral or cell mediated
immune response is by antigenic drift or shift. In all lentiviruses antigenic variation
occurs because frequent point mutations occur during replication due to the error-
prone reverse transcriptase which lacks editing function. The greatest divergence
between variants is seen within the env gene (Hahn et al., 1985, Clements et al.,
1988). Antigenic variation may enable virus to escape immune surveillance by
allowing the generation of neutralisation escape mutants. In the presence of strain
specific neutralising antibody viral variants (or recombinants) with mutated epitopes
which no longer bind the circulating neutralising antibody have a selective
advantage.
The higher the frequency a viral variant reaches the higher the probability of
its recognition and neutralisation. Consequently variants found at low frequency
will have a selective advantage and will increase in frequency until they too are
countered by the immmune response. A longitudinal study of HIV variation by
Holmes et al., (1992), showed that generally the most frequent sequence that appears
then disappears completely probably due to neutralisation. In both EIAV and MVV
antigenically distinct env variants arise progressively during infection and always
precede their associated neutralising antibodies (Scott et al., 1979, Salinovich et al.,
1986). In EIAV, as in HIV, neutralising antibodies seem to eradicate the strain of
virus against which they have arisen. However, in MVV the original strains of virus
do not completely disappear and parental strains can still be detected late in
experimental infection long after the emergence of new variants (Lutley et al., 1983).
In MVV, and other lentiviruses, a small number of base changes, deletion
insertion, or changes in glycosylation patterns may have a profound effect on the
ability of antibodies to neutralise the virus by altering the tertiary structure of the
envelope protein thus exposing new epitopes and burying previous ones, rather than
creating new antigenic sites (Stanley et al., 1987, Salinovich et al., 1986).
Although EIAV is structurally and morphologically similar to the other
lentiviruses, the disease pathogenesis is significantly different. EIAV infection is
typified by viral persistence, with recurrent episodes of fever due to the sequential
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evolution of new variants escaping neutralisation by the antibodies directed against
previous variants which results in an acute hemolytic crisis coinciding with a rapid
round of replication by the new viral variant (Issel and Coggins, 1979, Montelaro et
al., 1984, Salinovich et al., 1986). Distinct antigenic variants of EIAV are
associated with each disease episode. The time taken for new EIAV variants to arise
which can escape host immune defences can be as short as 28 days as clinical
episodes may appear at 4-8 week intervals (Salinovich et al., 1986). It is likely that
emergence of new variants is associated with episodic disease in other lentiviral
infections; minor and short-lived upsurges of viremia are seen in some asymptomatic
HIV-infected patients (Nowak et al., 1991) and also in SIV-infected Rhesus
monkeys (Martin et al., 1990). In the latter case recurrent antigenemia has been
shown to be predictive of disease (Martin et al., 1990).
In MVV it has been reported that antigenically distinct virus strains take 1-2
years to appear in the persistently infected animal (Clements et al., 1980, Scott et al.,
1979). There is no reported evidence that the emergence of new variants is
associated with episodic disease. In sheep persistently infected with MVV mitogen
activation of a cannulated lymph node induces a surge of MVV in the afferent
lymph, but this appears to be due to activation of immune cells rather than being
related to a change in the virus antigenicity (Bird and Blacklaws, Personal
communication).
MVV escape mutants can be generated in vitro by passaging virus in the
presence of monospecific neutralising antibody (Clements et al., 1988). The variants
which emerge are closely related to the parental strain differing by only a few
changes localised in the 3' end of gp!35 in the env gene. Many of the same point
mutations were common amongst different variants isolated showing the occurrence
of antigenic drift in a progressive manner. Mutations other than in env were rare and
random, conveying no apparent selective advantage. In vivo common changes from
parental to variant mutants in different sheep suggests that there is selective pressure
on particular changes (or mutational hotspots).
Antigenic variation in vivo was only detected in 25% of infected sheep in
antigenic cross-reactivity studies by Thormar et al., (1983), and Lutley et al., (1983).
This low rate of variation would be insufficient for it to be an important mechanism
for persistence. It may be that the methods used for detecting variation give a low
estimate of the rate of antigenic variation. Using RNA footprinting, or peptide
mapping it has been shown that MVV variants do emerge in infected animals (Scott
et al., 1979, Clements et al., 1988). As described above, although MVV antigenic
variants do arise the presence of neutralisation antibodies to a virus strain does not
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enable it to be completely cleared and the parental strain may still be detected late in
infection. (Narayan et al., 1978, Ellis et al., 1987, Clements et al., 1988). One
reason for this may be that bone marrow and other cell types which contain
integrated provirus may act as a reservoir of the original strain as well as emerging
variants (Gendelman et al., 1985). The inability of the immune response to confine
the virus to latently infected cells may in part be due to the emergence of variants
that are no longer neutralised by antibodies against the parental strain. This gives
the new strain time to spread before the host can mount an effective immune
response. The restricted replication of MVV in vivo may account for the apparently
gradual rate of variation (discussed below) compared to EIAV where a variant
escaping immune control replicates very rapidly.
Large numbers of HIV variants exist both between and within patients as
determined by nucleic acid sequence analyses. The envelope gene is the most
divergent of the HIV genes especially in the hypervariable regions of env (Starcich et
al., 1986, Hahn et al., 1985). Both convergent and divergent evolution of HIV env
sequences have been reported (Holmes et al., 1992). HIV variants can be generated
experimentally in vitro and in vivo by selective pressure (McKeating et al., 1988,
Naraet al., 1990).
In HIV immunoselective pressure varies over the course of infection as
immune dysfunction/deficiency develops during disease progression. Different
types of variant strain tend to appear at particular stages in the course of disease.
Strains with with slow replication kinetics and low cytopathicity ("slow, low
strains") predominate in infected individuals who are clinically healthy (Fenyo et al.,
1988, Tersmette et al., 1988, Albert et al., 1989). Progression to the disease state of
AIDS is associated with a shift in the predominant strains of virus to "rapid, high
strains" (rapid replication kinetics, increased cytopathicity) (Fenyo et al., 1988,
Tersmette et al., 1988). This suggests that early in infection the "slow, low" variants
are better able to replicate in the presence of an active immune system and have a
selective advantage over the "rapid, high" variants. As the total number of
antigenically distinct viral strains increases over time the total number of CD4+ cells
goes down. To start with specific CD4+ cells replicate in response to virus, but then
as CD4+ cell numbers decline later in the course of HIV infection the total virus
population escapes regulation by the immune system and consequently the faster
replicating strains begin to predominate over the earlier slow growing strains.
Nowak et al. (1991) go as far as to suggest that viral antigenic diversity is the
cause not a consequence of AIDS. They proposed that the immune system is only
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able to mount an effective response against HIV quasispecies (populations of closely
related genomes) within a range of diversity but that once the population of viral
strains exceeds the "diversity threshold" the immune system is no longer able to
control viral regulation.
1.1.13: Antigenic variation and escape from cell mediated immunity
Antigenic variation can also allow escape from specific T-cell activity.
Presentation of viral peptides in the context of MHCII induces activation and
proliferation of T-cells expressing a T-cell receptor (TCR) which binds the
peptide/MHCII ligand. Antigenic variation resulting in presentation of an altered
peptide may alter the affinity of the TCR for the peptide/MHC complex and
therefore alter the T-cell response. For example, HIV variants which escape CTL
(cytotoxic T-lymphocyte) recognition by generating an epitope which no longer
stimulates a CTL response have been reported (Phillips et al., 1991).
A recent paper by Sloan-Lancaster et al., (1993) demonstrated that
presentation of an altered peptide by antigen presenting cells to a cytotoxic T-cell
clone, which had been selected against an immunogenic peptide, either reduced the
affinity such that the TCR did not bind the altered peptide and the T-cell clone did
not respond or such that the TCR bound peptide but only at low affinity which
induced partial activation and subsequent anergy of the T-cells. These cells
consequently became unable to respond to the altered peptide or to the original
immunogenic peptide. Whether this in vitro phenomenon, namely, induction of
clonal anergy occurs in vivo has yet to be investigated. If it occurs in vivo it is
possible that mutant/variable viral peptides presented by APCs actually provide
protection by inducing anergy of T-cells responsive to previous virus variants.
1.1.14: Avoidance of the immune system : Latency
Some virus infected cells escape elimination by the immune system because
synthesis of viral antigen is restricted by tight regulation of viral gene expression, i.e.
by virus latency. Virus latency is possible due to the highly regulated expression of
lentiviral genes controlled by complex mechanisms involving transcriptional as well
as post-transcriptional events (reviewed by Allan, 1992).
At the clinical level, lentiviral latency may last many years, e.g. HIV
infection has on average a clinically latent period of 8-12 years during which time
the individual remains in good health and generally maintains normal levels of CD4
cells. Similarly MVV infection may have no clear pathological signs until years
after infection. However during the clinical period virus replication may actually be
continuing albeit at a low level. Apart from possible infection of haematopoietic
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stem cells, (Kaczmarski et al., 1992), the lentiviruses infect cells with a relatively
short life in comparison to the neurones in which latent herpes virus persists,
therefore it may be necessary for replication to be ocurring in at least some of the
infected cells at all times for the virus to infect new cells and survive in the host.
HIV-1 RNA can be detected in infected individuals at all stages in disease
suggesting some virus replication is continuing even during the clinically
asymptomatic phase when the majority of infected cells are harbouring latent virus
(Harper et al., 1986, Schnittman et al., 1991). The lymph node cells are more likely
to be producing infectious virus than cells in the blood (Pantaleo et al., 1993,
Embretson et al., 1993).
In the case of MVV, in situ hybridisation shows that transcription is
markedly restricted in vivo compared to productively infected cells in culture (Haase
et al, 1977, Geballe et al., 1985, Brahic et al., 1987). There is also post-
transcriptional regulation of antigen expression (Gendelman et al., 1985, Stowring et
al., 1985). In cell culture the level of virus transcription and production is directly
related to the rate of synthesis of proviral DNA (Haase et al., 1982) suggesting that
there is no negative control acting upon viral transcription and translation in vitro.
1.1.15: Subversion/destruction of the immune system
One way to escape immune destruction is to actually destroy components of
the immune system. As their names imply, the immunodeficiency viruses have the
most severe detrimental effects on the immune system. This may be by direct
destruction of immune cells, by causing dysfunction of infected or uninfected cells
and/or by the effects of chronic stimulation of the immune system.
HIV infection leads to a myriad of immunologic defects resulting in AIDS.
There is depletion of CD4 positive lymphocytes, dysfunction of remaining CD4
cells, abnormal cytokine production, B-cell hyperreactivity, clonal defects of certain
V|3 subfamilies, defects in antigen presentation, anergy in CD8+ cells and other
immunologic disorders. Some of these abnormalities may be a direct result of CD4
cell infection or be a result of HIV infection of other immune cells in particular cells
of the monocyte macrophage lineage.
Altered CD4:CD8 cell ratios and T-cell numbers are often seen in MVV
infected animals, although there is no evidence that MVV directly affects CD4+ T-
cells. Watt et al., (1992), reported that the number of T-cells was significantly
increased in the lungs of MVV infected sheep but the CD4:CD8 ratio was similar to
the ratio in uninfected lungs. However in synovial fluid of MVV arthritic joints
CD8+ cells were the primary cells and a decreased CD4:CD8 ratio was seen in the
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peripheral circulation of diseased animals. In HIV a decreased CD4:CD8 ratio
results from destruction of CD4 cells, whereas in MVV infected sheep depressed
CD4:CD8 ratios were found due to decreased numbers of CD4 cells and/or increased
numbers of CD8 cells (Kennedy-Stoskopf et al., 1989). In MVV-infected lymph
nodes significantly increased numbers of CD8 cells with only a slight increase in the
number of CD4 cells resulting in a significantly decreased CD4:CD8 ratio have been
reported (Watt et al., 1992).
1.1.16: Chronic inflammation as a response to persistent infection
Lentivirus infection, like any persistent antigen (e.g. asbestos fragments in
the lung), results in the local production of excessive chemotactic factors which
recruit leucocytes to areas of inflammation (Koenig et al., 1986, Lairmore et al.,
1987). Recruitment of lymphocytes may serve to promote tissue damage and further
accelerate the influx of monocyte/macrophages into the lesion. The inflammatory
process thereby provides an influx of cells which may either already be carrying
virus or which are susceptible to infection. In addition the incoming cells may be
responsible for tissue injury and clinical symptoms. For example, in other viral
infections cytotoxic T-cells have been shown to clear virus but augment pulmonary
disease (Cannon et al., 1988). Successful treatment of HIV-lymphocytic interstitial
pneumonia (LIP) patients by steroid therapy (immunosuppressive), (Morris et al.,
1987), and the prevention of MVV induced encephalomyelitis in immunosuppressed
sheep (Nathanson et al., 1976) supports the critical role of the inflammatory process
in lentiviral disease. Increased virus and antigen loads have also been shown to
correlate with disease severity both in MVV, (Brodie et al., 1992), and in HIV
infection (Schnittman et al., 1990). Antigen challenge caused virus reactivation in
MVV infected sheep (B.A. Blacklaws and P.Bird, personal communication)
suggesting that the inflammatory or DTH response increases virus production which
in turn induces inflammation that, unless controlled, could give a downward spiral in
disease progression.
Chronic inflammation triggered by the anti-viral immune response probably
leads to the lesions described in MVV which eventually cause manifest disease
(Griffin et al., 1978). Post-infection immunisation with whole inactivated virus
enhances the severity of visna disease whilst immunosuppression reduces the
inflammatory lesions (Nathanson et al., 1985, Georgsson et al., 1976).
Similar inflammatory pathologies to those described for MVV have been
reported in the lung , joints, and CNS of patients infected with HIV (Scott et al.,
1984, Joshi et al., 1985, Rynes et al., 1987, Sharer, 1992). In HIV, as in MVV,
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infected alveolar macrophages are likely to be involved in the induction of
immunoproliferative and inflammatory reactions as they are targets for CD8+
cytotoxic T-cells (Plata et al., 1990).
It has been suggested that MVV may predispose the lung to certain
secondary infections (Watt et al., 1992, Brodie et al., 1992). Whether this is a
particular property of MVV infection or may result from any chronic inflammatory
condition is not clear. Note for example that asthma sufferers, in whom the lung
suffers chronic inflammation, are predisposed to lung infections (Corrigan and Kay,
1992).
1.1.17: Summary of Section 1.1
In summary the lentiviruses have evolved a range of strategies to enable persistence
and avoid immune clearance. MVV differs from HIV in that there is no significant
destruction of one particular subset of immune cells. Nevertheless the immune
system is unable to clear MVV and the virus continues to replicate in the face of
active immune responses. Eventually continued persistence of MVV leads to
pathological changes probably resulting from tissue damage by the inflammatory
response. There appears to be a delicate balance between the immune system and
MVV infection/replication. The control of this balance remains to be elucidated.
1.2: RELEVANCE OF IMMUNE RESPONSES WHICH AFFECT FUSION
1.2.1: Correlation of fusion inhibitory antibodies with disease state in
HIV infection
A humoral immune response to HIV envelope has been shown to affect
disease outcome. Symptom-free HIV-positive individuals are more likely to have
higher neutralising antibody titres than symptomatic patients (Weber et al., 1987,
Robert-Guroff et al., 1987). The presence of antibodies to the putative
immunosuppressive region of HIV gp41 has also been linked to the absence of
disease symptoms (Klasse et al., 1988).
A study by Brenner et al. (1991) suggested that there is a relationship
between the presence of HIV syncytium inhibiting antibodies and the clinical
outcome in children infected with HIV. 65% (15/23) of a group of children who had
detectable antibodies to HIV by western blotting had syncytium inhibitory
antibodies. All of the eight children with lymphocytic pneumonitis had syncytium
inhibitory antibody titres of 1:40 to 1:320, whereas only two of seven children with
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opportunistic infections had syncytium inhibitory activity and these two both had
syncytium inhibitory titres of 1:20. Whether syncytium inhibiting antibodies play a
role in the pathology of lymphocytic pneumonitis or whether this state is more likely
to induce syncytium inhibitory antibodies cannot be determined from this study.
1.2.2: Vaccines
An immune response to the envelope glycoproteins appears to be a vital part
of the immune response to enveloped viruses. Experience with a number of viruses
has shown that eliciting an immune response to the envelope proteins may be an
important way to induce immunity to that virus or to decrease the severity of disease
and aid virus clearance if infection does occur. For example, vaccinia virus
recombinants which express paramyxovirus F protein induce a protective immune
response (Merz et al., 1980). Similarly vaccination with a recombinant fowlpox
virus expressing the F protein of the paramyxovirus Newcastle disease virus, (NDV),
protects against subsequent challenge with NDV (Taylor et al., 1990). Also, a
recombinant canarypox virus expressing measles virus F and HA glycoproteins
protected dogs against subsequent challenge with canine distemper virus, which is
closely related to measles virus (Taylor et al., 1992). Interestingly the host-restricted
fowlpox recombinant which could not replicate in the vaccinee induced a similar
level of measles virus neutralising antibodies and resistance to CDV infection as the
equivalent replication competent vaccinia recombinant.
To be effective vaccines must induce protective immunity so that upon
exposure the immune system rapidly recognises and destroys the pathogen.
Immunisation must present, in the correct form, those elements of the pathogen
which can elicit a protective immune response taking into account that some
elements of the pathogen may elicit immune responses which negate those that are
beneficial. Obviously it is better for a vaccine not to include such negative elements.
Not only are the epitopes included important but also the titre of antibody induced.
Antisera against HIV which are neutralising against a moderate viral dose have been
shown to enhance infection at low m.o.i.s (Perno et al., 1990). If this phenomenon
also occurs in vivo vaccination which induces only a low anti-viral titre might have
the opposite to the desired effect.
1.2.3: Potential problems of using inactivated virus vaccines with altered
envelope glycoprotein immunogenicity
The importance of inducing a balanced immune response to viral envelope
glycoproteins has been shown by experience with several human vaccines.
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Vaccination with formalin inactivated measles virus served to potentiate rather than
prevent infection by inducing immunity to the H protein but not the F protein
(Fulginiti et al., 1967). Formalin inactivated respiratory syncytial virus also induced
an unbalanced immune response which exacerbated disease (Murphy and Walsh,
1988). The problem appeared to be that a high concentration of anti-viral antibodies
was raised only to non-protective epitopes. The use of vaccines with such altered
immunogenicity primes for an accelerated immune response against non-protective
epitopes so upon subsequent infection effective resistance is not provided but
immune complexes may form with subsequent complications such as an Arthus
reaction in the lung which can contribute to potentiation of disease.
1.2.4: Immunisation with HIV envelope
The protection demonstrated by vaccines based on HA and F glycoproteins is
one reason why the HIV-1 envelope glycoprotein has been the major target of HIV
vaccine development to date.
Many test animals immunised with HIV-1 envelope-derived immunogens
elicit a type-specific neutralising response (Matthews et al., 1986). Numerous
attempts have been made to raise cross-reactive neutralising antibodies against
conserved regions of gpl20 using viral envelope or sub-units (e.g. Girard et al.,
1991, Berman et al., 1990). Antisera raised against the principal neutralisation
determinant (PND) in the gpl20 V3 loop can inhibit HIV replication and inhibit
syncytium formation in vitro, but only in a type-specific manner, even though the 3D
structure of the V3 loop and the amino acids at the top of the loop are conserved
(Palker et al., 1988, Goudsmit et al., 1988, Javaherian et al., 1990). To date studies
have not uncovered a dominant neutralising epitope from a conserved region which
suggests that potential broadly neutralising epitopes are inaccessible to antibodies.
A cross-reactive epitope (with reference to different strains of HIV) has been
found in gp41; a synthetic peptide representing the region from 735-752 of HIV
gp41 is recognised by antisera from HIV positive patients and induces antibodies
which neutralise a range of HIV-1 isolates (Kennedy et al., 1986, Chanh et al., 1986,
Dalgliesh et al., 1988). When an engineered poliovirus chimaera containing this
epitope was used to immunise rabbits antibodies specific for HIV gp41 were elicited,
as measured by peptide binding assays and by Western blotting (Evans et al., 1989).
The antisera also neutralised a range of HIV-1 isolates and inhibited HIV induced
cell-to-cell fusion. As well as demonstrating the possibility of a broadly-reactive
vaccine this shows the potential of using poliovirus to present HIV antigens.
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1.2.5: Development of HIV vaccines
A number of vaccine studies have been conducted in chimps using a variety
of immunogens. In the first experiments, from 1985-1989, vaccination did not
protect from challenge infection (Reviewed by Girard and Eichberg, 1990).
However neutralising antibodies were low or absent and cellular immunity was weak
at the time of challenge. Berman and colleagues (1990) succeeded in protecting
chimpanzees from infection by improving the properties of the immunogen and
immunisation schedule and inducing a good titre of neutralising antibody
particularly against the principal neutralising domain (PND) of gpl20. A consistent
correlation between neutralising antibodies to the PND and protection from
challenge infection with a homologous HIV strain has been shown (Emini et al.,
1990 and 1992), but have been shown not to protect against a distinct strain of HIV
(Fultz et al., 1987). This corresponds to in vitro assays where neutralisation by
antibodies to the PND are type-specific.
Protection against heterologous strains of HIV has yet to be acheived.
Although neutralising antibodies against the PND are important for protection
against homologous strains, other forms of anti-viral immunity, which are less
strain-specific, need to be induced. One option would be to identify more epitopes
such as the gp41 epitope described above which can neutralise a range of strains and
perhaps to include a range of peptides representing different groups of strains to
induce a series of antibodies which together might be broadly protective.
1.2.6: A universal vaccine against enveloped viruses ?
As there are such striking similarities between the different virus fusion
proteins it is very likely that the actual mechanism of fusion when it is finally
worked out will be very similar. Although this suggests a possibility of a single
vaccine or chemotherapeutic agent to prevent or treat infection by all fusogenic
viruses, it also appears that some normal cellular mechanisms of membrane fusion
may be very similar to viral mediated fusion and therefore may also be a target for
any potential cross-species anti-virals. Therefore there is still a need to further
elucidate viral fusion mechanisms and to identify specific viral components which
may act as conserved targets and which are accessible to antibodies to prevent
infection. It may be that no such targets exist.
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1.3: VIRUS MEDIATED MEMBRANE FUSION
Surrounding the virion of enveloped viruses is an envelope or viral
membrane which consists of host derived lipid bilayer containing virus encoded
envelope proteins. In order for enveloped viruses to infect a cell fusion of the viral
and cell membrane must occur thus releasing the capsid into the cytoplasm of the
new host cell.
Membrane fusion can also occur late in the infection cycle when viral
proteins become expressed in the cell membrane and may mediate fusion of infected
cells with neighbouring uninfected cells. Cell-to-cell fusion results in the formation
of large multinucleate cells called syncytia. Cell fusion and the formation of
multinucleate syncytial cells in vivo can result in localised tissue damage and be a
major cause of pathology. For example, the major CPE on cells in culture by
measles virus is syncytium formation, whilst in vivo, a similar mechanism may
enable cell-to cell spread of virus which sometimes results in a more serious
complication of measles infection, giant cell pneumonia (Mitus et al., 1959).
Another example of fusion related cytopathology is by HIV which causes giant cell
formation followed by rapid cell death. This may be one way by which susceptible
cells are lost during HIV infection (Lifson et al., 1986a, Sodroski et al., 1986,
Lifson, 1986b).
1.3.2: In vitro virus-induced cell fusion
When a high m.o.i. of fusogenic virus is added to susceptible cells in vitro,
fusion from without (FFWO) can occur. FFWO occurs rapidly and is independent of
virus replication. This is shown by the fact that it can be mediated by non-infective
virus as long as the viral membrane integrity is maintained and also can occur with
cells in which the virus is unable to replicate (e.g. MVV can cause FFWO in hamster
kidney cells). MVV can cause fusion from without at a multiplicity of 4 virions per
cell (Harter and Choppin, 1967).
Fusion from within (FFWI) occurs late in the viral life cycle. It involves
fusion of infected cells with neighbouring uninfected cells. FFWI is inhibited by
metabolic inhibitors. This shows the requirement for the synthesis of new virus
specific macromolecules for FFWI to occur. Expression of the virus receptor on the
uninfected cell is also necessary for FFWI to occur.
FFWO is a convenient method for studying membrane fusion in vitro. The
degree of cell fusion seen by FFWO in vitro is variable and is dependent on a
number of factors. The extent of cell fusion and size of polykaryons increases with
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virus concentration and with degree of confluence of monolayered cells. Cell
susceptibility is also an important factor. It is affected by number, availability and
type of virus cell surface receptors, by the lipid composition of the cell membrane
and the nature of the cytoskeletal network of the cells as well as by a number of ill-
defined factors such as cell passage number, time from subculture to virus exposure
and stage in the cell cycle.
1.3.3: Virus-mediated membrane fusion
Entry of the virus into the host cell is a multi-step process. Infection is
initiated by attachment of the virus to the prospective host cell bringing the opposing
membranes into close proximity to allow the next step, membrane fusion, to
proceed. Binding of the virus to the target cell is generally via the interaction of a
viral attachment protein with a specific molecule (receptor) expressed on the surface
of the target cell. Different viruses exploit different cell surface molecules as
receptors (Reviewed by Lentz, 1990). For example, influenza HA binds to sialic
acid containing receptors on the target membrane, HIV gpl20 mediates virus
binding to CD4 molecules expressed only on certain immune cells, whilst MVV
interacts with MHCII and may use it as a receptor (Dalziel et al., 1991). The
specificity of the virus:receptor reaction is in part responsible for restricting the cell
types which the virus is able to infect (including species specificity). However, it is
clear that secondary receptors or other binding mechanisms may also be used as
viruses sometimes infect cells where the usual receptor cannot be detected e.g. HIV
infection of CD4 negative glial cells. In addition antibody or complement can
mediate binding of virus to cells expressing FcR or complement receptors.
Binding of the virus to the host cell holds the two membranes close together
as a prerequisite to membrane fusion but is not sufficient alone to trigger membrane
fusion. Viral receptor binding and membrane fusion are mediated by proteins which
form spike-like projections from the viral envelope. In some viruses two sub-units
derived from a single glycoprotein or two separate proteins which are generally
linked non-covalently or by di-sulphide bonds mediate binding and membrane
fusion.
Two separate activation steps regulate virus fusion and ensure that assembly
and entry functions do not interfere with one another. Typically the functions
required for virus entry are not activated before the final stages in virus maturation
and release from the cell. For most enveloped viruses a host-cell-mediated limited
proteolysis of the viral fusion protein makes it sensitive to the later activation event.
In some cases the cleavage generates a fusion protein that is activated upon receptor
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binding thereby resulting in fusion directly with the target cell surface (e.g. HIV or
MVV). In other cases the acidic conditions of the endosome following receptor
mediated endocytosis are required for activation and fusion occurs with the
endosomal membrane. This difference can be used to classify viral fusion reactions
into two general groups; pH independent and low pH dependent, respectively.
Some pH independent viruses such as the herpesviruses have been shown to enter
the cell by either route i.e. by fusion with the plasma membrane or via the endosome.
1.3.4: pH dependent virus fusion
Virus families which are dependent on an acid pH to enable fusion to occur
include orthomyxoviruses, e.g. influenza virus, togaviruses, e.g. Semliki Forest
Virus (Lobigs and Garoff, 1990), and flaviviruses e.g. Dengue vims (Halstead,1988,
Summers et al., 1989). Semliki Forest Vims was the first vims used to delineate the
acidic/endocytic fusion pathway which has proved to be very similar for all these
viruses. Vims particles bind to cell surface receptors and are endocytosed in coated
pits and coated vesicles (receptor mediated endocytosis). As the endosome becomes
acidic to effect its normal function the low pH induces a conformational change in
the envelope glycoprotein(s) converting it to its fusogenic form so that virus-host
membrane fusion takes place. Fusion with the endosomal membrane releases the
nucleocapsid into the cytoplasm.
In the case of Influenza virus the low pH induces an irreversible
conformational change in the HA glycoprotein which converts it to its fusogenic
form. (This will be described in much greater detail below). Similarly low pH
triggers Semliki forest vims to fuse by inducing irreversible conformational changes
in the viral spike protein which mediates fusion.
1.3.5: pH independent virus fusion
Paramyxoviruses, herpesviruses, and some retroviruses fuse with cells in a
pH independent manner. The mechanism by which pH independent fusion reactions
occur remains to be elucidated. As with pH dependent fusion it is mediated by
specific fusion glycoproteins in the viral membrane and receptor binding precedes a
conformational change which then allows fusion to occur. Fusion is thought to be
mediated by a very hydrophobic region at the amino-terminal end ofthe F1 sub-unit
in the case of paramyxoviruses or of the transmembrane envelope glycoprotein in the
retrovimses (Richardson et al., 1980, Richardson and Choppin, 1983, Stein et al.,
1987. Retrovirus fusion will be discussed in some detail in section 1.3.9.
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1.3.6: The mechanism of membrane fusion
Because of the stability of the lipid bilayer membrane structure, fusion of two
membranes is an energetically unfavourable event. The first requirement for fusion
is to overcome the electrostatic force which repels two membranes and to bring them
close together (Rand, 1981). It is thought that destabilisation of the structure of the
opposing membranes is the next step in fusion. Changes in molecular organisation
to create an area of lipid bilayer free of integral proteins may be necessary. Then
there must be mixing of the two membranes and finally reformation of a stable lipid
bilayer.
It has been suggested that membrane destabilisation occurs by the calcium
induced formation of domains of crystalline acidic phospholipids within the
surrounding non-crystalline lipid. (Reviewed by Poste and Pasternak, 1978). The
boundaries of crystalline domains on adjacent membranes may represent sites at
which fusion occurs (Papahadjopoulos et al., 1974). Fusion susceptibility of a
membrane has been shown to be dependent on the phospholipid type, density and
orientation. This may be accounted for by the fact that some phospholipids
crystallise at concentrations within physiological ranges while others do not.
1.3.7: Mechanism of virus membrane fusion
Although the exact mechanism is unknown it appears that viruses make use
of envelope glycoproteins to disrupt membrane stability and induce fusion.
Attachment of the virus to its receptor is temperature independent, whilst fusion of
the virus envelope to the cell membrane is optimum around 37°C and is much slower
at reduced temperatures. Although it is generally accepted that fusion is inhibited
below 18°C, Stegmann and colleagues, (1990), showed that fusion of influenza virus
with liposomes could still occur at 0°C albeit very slowly. This suggests a
requirement for fluidity of the membrane lipids as this is inhibited at low
temperatures. The lateral movement of intramembranous particles within the
membrane also seems to be important. For example, red blood cell ghosts treated
with anti-spectrin antibodies to cross-link the protein and prevent it clustering in the
membrane are not able to be fused by Sendai virus. The opposite effect is shown by
exogenous proteolytic enzymes which release membrane proteins from the
contractile cytoskeletal networks and can fuse human erythrocytes in the absence of
any virus. However not all chemically induced cell fusion seems to depend on
proteolytic breakdown of the membrane skeleton, and there is no evidence that viral
membrane fusion relies on a breakdown of the membrane skeleton. Nor is there
evidence that a functional membrane skeleton is required for viral fusion to cells
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since treatment with Cytochalasin-B, which is a cytoskeletal inhibitor, permits initial
fusion of the virus. Cytochalasin-B blocks subsequent cell-to-cell fusion, but this
merely confirms the expectation that participation of the membrane associated
microfilament system is required to enable the transport/organisation of newly
synthesised viral membrane proteins necessary for cell-to-cell fusion. Whilst
disturbance of microfilament function suppresses virus-induced cell fusion,
disruption of microtubules enhances cell fusion (Yamamoto et al., 1984).
All viral fusion proteins are glycosylated. The glycosylation pattern of the
envelope glycoprotein is determined by the host cell and can affect the host range of
the progeny virions (Feizi and Larkin, 1990) perhaps by affecting the interaction
with carbohydrate-binding proteins on the target cell surface. Glycosylation is also
important in defining secondary or tertiary structure of the fusion proteins. For
example, it has been shown in mutation studies that, whilst individual glycosylation
sites on HIV gp41 are dispensable, if glycosylation of all the sites is prevented the
conformation of env products is altered and fusion activity is lost (Dedera and
Ratner, 1992, Fenouillet et al., 1993). However, enzymatic removal of glycans from
the mature HIV envelope glycoproteins, under non-denaturing conditions,
diminishes but does not abolish virus binding to its receptor nor infection of
susceptible cells (Fenouillet et al., 1989).
1.3.8: Influenza virus as a model for virus membrane fusion
Influenza hemagluttinin (HA) is the best characterised of all the viral fusion
proteins. Because of this a number of models for the mechanism of viral fusion have
been proposed based on studies with influenza vims.
The Influenza HA spike protrudes from the membrane and is responsible for
virus binding to the cell as well as for membrane fusion, and is active even in the
absence of any other viral proteins (White, 1982a). HA is an integral membrane
protein composed of three 84kDa subunits. Each subunit is composed of two
polypeptides HA1 and HA2 linked by di-sulphide bonds. The external structure of
the spike extends 135A from the viral membrane with a long highly alpha-helical
stem region composed mainly of HA2 supporting a large globular domain composed
of HA1 (Wilson et al., 1981, Weiss et al., 1988). Domains in HA1 mediate receptor
binding, whilst a very hydrophobic region at the NH2-terminal end of HA2, called
the fusion peptide, mediates fusion. The fusion peptide is highly conserved in HAs
from different influenza virus strains and mutations within it alter or abolish fusion
activity (Daniels et al., 1985, Gething et al., 1986). At neutral pH the amino-
terminal three residues of the fusion peptides are inside the spike at the subunit
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interface whilst the next 14 residues wrap around the stem held by a network of
hydrogen bonds (Wilson et al., 1981). At pH values needed to trigger fusion an
irreversible conformational change occurs exposing the HA2 amino-terminal fusion
peptides which are then able to insert into the outer leaflet of an opposing membrane
to initiate fusion (Harter et al., 1989, Brunner, 1989).
At acid pH influenza virus can fuse with liposomes which do not contain
receptors for HA demonstrating that the receptor binding function of HA1 is not
vital for fusion (Stegmann, White and Helenius, 1990, White et al., 1982b). In the
absence of sialic acid (or ganglioside) receptors HA2 may be bringing the
membranes close together by inserting its N-terminal end (following low pH induced
exposure of the hydrophobic fusion peptides) into the target membrane whilst its C-
terminal end is anchored in the viral membrane. The role of the spike proteins may
be simply to bring the two membranes close enough together to perturb their
hydration shells thereby permitting contact between the lipids in the two membranes
(Rand, 1981).
The fusogenic state seems to be a transient intermediate in the series of
changes induced by low pH. Whilst the first conformational change of HA on
exposure to low pH exposes the hydrophobic fusion peptides and allows fusion to
occur, the later conformational change(s) appear to inhibit fusion and also make the
HA become sensitive to protease digestion (Stegmann, White and Helenius, 1990).
It may be that following its role in viral fusion this allows the HA to be degraded in
the lysosome to prevent its recycling from the endosome to the cell surface thus
evading detection by antibody until after virus replication has occurred.
The primary conformational change occurs very rapidly upon acid exposure
and is followed almost instantaneously, even at 0°C, by attachment of the virus to
the target membrane most likely by insertion of the exposed fusion peptides into the
target bilayer. The next detectable event is fusion between the viral and target
membrane which occurs following a lag of less than 1 up to 30 minutes depending
on temperature, pH and membrane lipid composition. The lag involves a series of
changes in the virus-target membrane complex which are continuous, additive and
irreversible (Stegmann, White and Helenius, 1990). The lag does not involve further
intra-molecular changes in HA but may reflect reorganisation, (rotational and lateral
movements of HA within the plane of the viral membrane of the molecules within
the membrane), the net result of which is thought to be aggregation of HA spikes to
form a fusion complex. Following the lag phase further changes in the virus-target
membrane complex result in merger of the two membranes. Unlike the earlier steps
in fusion this final stage is not low pH dependent. The HA complex may be forming
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a fusion pore which allows fusion to begin from its centre and then to open
outwards. Electrophysiological and electron microscopic studies back up the
existence of an HA fusion pore (Spruce et al., 1991, Burger et al., 1988).
As the ectodomains of HA do not dissociate Stegmann et al., (1990),
proposed a model in which the HA trimers tilt upon contact with the target
membrane to allow at least one of the fusion peptides of each trimer to come into
contact and insert into the target membrane. Another model suggests that the trimers
remain upright and that the fusion peptides project into the fusion pore acting as a
solvating mechanism and promoting lipid mixing (Ellens et al., 1990).
Recent work by White and colleagues, (1992), suggests that the
transmembrane domain of the fusion protein may have an important role in fusion.
Ultimately fusion releases the contents of the viral envelope into the
cytoplasm, and mixes the phospholipids derived from the membrane of the previous
host cell with those of the new host cell, whilst the domains previously on the
outside of the virus remain within the endosome where they will be degraded.
1.3.9: Retrovirus fusion
The retroviruses also enter into cells by pH independent membrane fusion
which is mediated by envelope glycoproteins (Stein et al., 1987). The retroviral
envelope glycoprotein is produced as a precursor polypeptide which, after processing
and glycosylation, is cleaved at a basic site in the C-terminal half of the molecule to
form the mature transmembrane subunit, (TM), and surface subunit, (SU) (Reviewed
by Hunter and Swanstrom, 1990). In the lentiviruses the SU subunit is non-
covalently bound to the TM subunit. The external subunit mediates viral binding to
the cell surface receptor which then acts in concert with the TM subunit to mediate
fusion of the viral envelope with the cell plasma membrane. As retroviruses bind to
a wide range of receptors their SU glycoproteins are correspondingly extremely
divergent. However the fusion mechanism is likely to be broadly similar
irrespective of cell surface receptor and, although the primary sequences of retroviral
TM proteins are poorly conserved, they do share common tertiary structural features
(Gallagher et al., 1989).
Retrovirus membrane fusion is a multi-step process involving both the
products of env. This is confirmed by the range of different mutations of env which
have been shown to affect the ability of HIV to mediate membrane fusion as judged
by syncytium formation in vitro. Such mutations can be divided into two groups;
mutations that disrupt binding to the cell surface receptor and mutations that affect a
post binding fusion event. Similarly neutralising antibodies against the envelope
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glycoproteins may act to block infection at either the binding or post-binding fusion
event.
As HIV is now the best studied of the retroviruses more is known about the
structure and function of the envelope glycoproteins for this virus and this will be
described in some detail in the following paragraphs. Studies of HIV may be
applicable to the other lentiviruses.
1.3.10: The HIV envelope glycoproteins - structure and function
The envelope glycoprotein of HIV is multi-functional having evolved for the
function of gaining entry of the virus into the host cell in the face of negative
selection by the host immune responses. It is responsible for receptor binding,
fusion, immunomodulation, and it has packaging signals to enable incorporation into
the virus.
The HIV envelope glycoprotein is synthesised as a 160kDa precursor which,
following oligomerisation, is proteolytically processed to form the mature envelope
glycoprotein subunits, the transmembrane glycoprotein, gp41, and the external
glycoprotein, gpl20, which remain non-covalently associated (McCune etal., 1988).
Intracellular transport and processing proceeds through the rough endoplasmic
reticulum and golgi complex and generates a protein highly glycosylated with
asparagine N-linked carbohydrates (Allan et al., 1985). Proteolytic cleavage of
gpl60 occurs prior to viral assembly and budding (McCune et al., 1988) and has
been shown to be vital for fusion but not for transport to the cell surface or for
binding to CD4 (Earl et al., 1991, Freed et al., 1989).
The envelope glycoprotein consists of interspersed variable and conserved
domains (Starcich et al., 1986, Willey et al., 1986). In the constant domains
conservation is greater than 80% whereas in the variable domains it may be as little
as 20-30%. Conservation of domains presumably indicates selective pressure to
maintain those sequences suggesting that these are functional domains or (partly)
that there is a lack of selective pressure for divergence so that conserved sequences
may represent non-immunodominant areas. In contrast variable domains suggest
areas where there is no requirement to maintain a specific sequence, a non-functional
region, and where the appearance of new variants may give that strain of virus a
selective advantage (as discussed in Section 1.1.14). The envelope cysteine residues
are strongly conserved between strains of HIV-1 and are neccessary for the
functional integrity of the envelope (Freed et al., 1991a, Tschachler et al., 1990, Syu
etal., 1991).
Both envelope sub-units are required for infection; gpl20 binds to the viral
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cell surface receptor (Lasky et al., 1987), whilst gp41 mediates the subsequent
fusion of the viral membrane with the cell membrane (Kowalski et al., 1987).
Receptor binding - gpl20:CD4 interaction
HIV predominantly infects cells that express CD4 since this molecule serves
as a receptor for HIV and is therefore critical in determining the cellular tropism of
the virus (Dalgleish et al., 1984, McDougal et al., 1986). CD4 is found on some
immune system cells including a subset of T-lymphocytes, on
monocytes/macrophages, Langerhans cells, dendritic cells and some cells in the
brain. A conformational epitope in the carboxyl-terminal region of gpl20 forms the
binding domain for CD4 (Lasky et al., 1987 , Olshevsky et al., 1990 , Ho et al.,
1991) and binding can be blocked by monoclonal antibodies against CD4 (Dalgleish
et al., 1984) or by soluble CD4 (Deen et al., 1988).
Human cells which are refractory to HIV infection become infectable if they
are made to express CD4 by transfection with a cDNA clone encoding CD4
(Maddon et al., 1986). However, the differences in the ability of different strains to
infect different cell lines, and the inability to infect CD4+ (transfected) cells from
other species indicates that other proteins, or a hypothetical "second receptor", may
be required in addition to CD4 for efficient infection and these may interact
differently with different strains of virus (Maddon et al., 1986, Cann et al., 1990,
Aoki et al., 1990, Ashorn et al., 1990. A candidate for the secondary factor is a
cellular tryptase-like protease which is thought to cleave the gpl20 V3 loop between
residues 308-331 after binding of gpl20 to CD4. (Hattori et al., 1989, Kido et al.,
1991). This is supported by evidence that HIV syncytium formation is blocked by
tryptase inhibitors. A 44kDa cell surface protein of unidentified function has been
implicated as a possible secondory factor (Ebenbichler et al., 1993).
HIV cell tropism is further complicated by the fact that gpl20 may also bind
to galactocerebroside and galactosyl-sulphatide expressed on the surface of
oligodendrocytes and other neural cells (Harouse et al., 1989a and 1989b). These
molecules may act as alternative receptors for HIV and allow infection of these CD4
negative cells.
The HIV transmembrane envelope glycoprotein, gp41
The HIV transmembrane envelope glycoprotein, gp41, is known to be
important in viral membrane fusion. It consists of a C-terminal region to the
cytoplasmic side of the membrane, a membrane spanning region, (the
transmembrane domain) which acts as a stop transfer signal and membrane anchor
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(Earl et al., 1991), and an N-terminal region to the outside of the membrane, (the
ectodomain).
The fusion peptide
The hydrophobic amino terminal end of gp41 (residues 1-28) is vital for
fusion. It contains a conserved fusion motif homologous to that of other viral fusion
proteins (Gallaher, 1987, Gonzalez-Scarano et al., 1987). The fusion proteins of the
paramyxoviruses and orthomyxoviruses include a phenylalanine-x-glycine, (F x G),
motif. This motif is found twice in HIV-1 and once in HIV-2 and SIV near the N-
terminal end of the TM glycoprotein (Bosch et al., 1989). Mutations within any of
the first 29 residues of gp41 affect syncytium formation: generally, mutations which
decrease the hydrophobicity of the fusion peptide reduce or abolish syncytium
formation whereas exchange of more hydrophobic residues for the wild-type
sequence enhances syncytium formation ( Bosch et al., 1989, Helseth et al., 1990,
Freed etal., 1990).
Cotransfection of wild type and mutant envelope expression vectors showed
that a mutation at the second amino acid of gp41 dominantly interferes with
syncytium formation and infection by wild-type envelope glycoproteins even in the
presence of a great excess of wild type proteins (Freed et al., 1990). This indicates
that multiple envelope protein:CD4 interactions are required for syncytium
formation and virus infection which is consistent with the fusion pore model as
suggested for influenza virus (discussed earlier).
Oligomerisation of envelope glycoproteins
It is thought that the envelope protein forms non-covalently linked
homodimers in the endoplasmic reticulum (from sedimentation values) which may
later assemble into tetramers (Earl et al., 1990, Pinter et al., 1989, Schawaller et al.,
1989). It has been shown that the first 129 aa of the HIV-1 gp41 ectodomain are
important for the assembly of env protein oligomers (Earl et al., 1990a) and that
after gpl60 cleavage the interaction is maintained between gp41 molecules but, from
cross-linking studies, there is no evidence that gpl20 sub-units interact with each
other (Earl et al., 1990b) . Work with other viruses has shown that oligomerisation
of the envelope glycoproteins is essential for ER transport (Copeland et al., 1986,
Gething et al., 1986, Einfeld and Hunter, 1988). Multimerisation of the envelope
glycoproteins may also be important for fusion activity (Schwaller et al., 1989, Serl
et al., 1990). Co-expression studies have shown that mixed dimers can form
between the envelope glycoproteins of HIV-1 and HIV-2 or SIV (Doms et al., 1990).
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This suggests the presence of a conserved structural domain and indeed the gp41
ectodomain is the most conserved region of the envelope protein between HIV-1,
HIV-2 and SIV (Doms etal., 1990).
The carboxy-terminal region of the fusion peptide is a "leucine zipper"-like
motif (Delwart et al., 1990). Such motifs have been shown to be involved in
protein:protein interactions, which suggests that this region may be important for
oligomerisation. However it has been shown that mutations within the leucine
zipper can affect HIV fusion and infectivity whilst oligomerisation does not appear
to be altered (Dubay et al., 1992).
The cytoplasmic domain
Sequences on the C-terminal side of the membrane appear not to be
necessary for fusion function but may be important in envelope processsing
(Kowalski et al, 1987) and for ensuring incorporation of the envelope glycoproteins
into the budding virus (Gebhardt, et al., 1984, Dubay et al., 1991). In vivo there
must be selective pressure to retain the untruncated cytoplasmic tail, although in
vitro , truncation of the cytoplasmic domain to 15-20 aa can increase the ability of
the HIV-1, HIV-2 and SIV to replicate (Kodama et al., 1989).
gp41:gpl20 association
The association of gpl20 with gp41 is necessary for infection. Following
proteolytic processing of the env precursor gpl60, non-covalent interactions
maintain multiple contacts between the N-terminal of gpl20 and the external portion
of gp41 (Kowalski et al., 1987, Willey et al., 1988, McPhee et al., 1989). Computer
models suggest that the TM subunit may form a knob-like structure which associates
with a socket-like structure in gpl20 (Schulz et al., 1992).
Changes in the envelope glycoproteins following receptor binding
Binding of gpl20 to the CD4 receptor appears to reduce the affinity of the
gpl20/gp41 interaction. This may result in dissociation of gpl20 and exposure of
the gp41 fusogenic domain as the initial stage in virus-cell or cell-to-cell fusion
(Moore et al., 1990).
gpl20 is shed from infectious virions independently of CD4 binding,
predominantly as the virus particle matures and buds from the infected cell (shown
by EM) and also as they age (Gelderblom et al., 1985, Gelderblom et al., 1987). The
rate and extent of HIV-1 gpl20 dissociation before and after CD4 binding is highly
variable but is low in most primary isolates of HIV-1 (Kirsh et al., 1990, Moore et
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al., 1990, Moore et al., 1992). Shedding of gpl20 has been shown to correlate with
a loss of viral infectivity (McKeating et al., 1991).
Some of the gpl20 appears to be resistant to sCD4-induced dissociation, a
similar fraction to that which is resistant to shedding with age. These resistant
molecules perhaps are required to continue holding the two membranes together
whilst the other molecules dissociate to allow the fusion process to occur. This fits
in with the case of most C-type retroviruses, (oncoviruses), where a small proportion
of their TM and SU subunits are covalently linked by an intramolecular disulphide
bond with the remainder being non-covalently associated (reviewed by Schulz et al.,
1992).
The gp41 glycoprotein appears to be degraded more rapidly in the cell
membrane following gpl20 dissociation compared to gp41:gpl20 together (Helseth
et al., 1990). Thus gpl20 dissociation may be advantageous to the virus by reducing
viral antigen on the cell surface after infection until replication.
It has been shown that the V3 loop region of gpl20, formed by a disulphide
bridge between two conserved cysteine residues at amino acids 303 and 338
(Leonard et al., 1990), is also necessary for fusion. Although most of the amino
acids within the V3 loop are hypervariable between different strains of HIV, a highly
conserved motif is located in the middle of the loop (LaRosa et al., 1990). Whilst
the cysteine residues forming the V3 loop are crucial in determining the proper
conformation required for processing and CD4 binding, mutations of the conserved
amino acids of the V3 loop either block completely or greatly reduce HIV-induced
fusion without influencing envelope glycoprotein synthesis, processing, transport or
binding to CD4 (Freed et al., 1991, Freed and Risser 1991, Helseth et al., 1990,
Tschachler et al., 1990, Chiou et al., 1992). Neutralising antibodies to this region of
the V3 loop can block HIV-1 infection and inhibit fusion without preventing gpl20
binding to CD4 (Skinner et al., 1988). It is thought that cellular endopeptidases
cleave gpl20 within this region and that this is a vital step in the fusion process. The
V3 domains of all published HIV-1, HIV-2 and SIV sequences contain a trypsin,
chymotrypsin or aspartic acid protease cleavage site near the crown of the V3 loop
(Clements et al., 1991). Antibodies to this region neutralise and inhibit cleavage
(Schulz et al., 1991). Furthermore syncytium formation by HIV infected cells is
blocked by protease inhibitors (Hattori et al., 1989).
It may be that dissociation of gpl20 from gp41 is partly an in vitro artefact
and that it may be cleavage of the V3 loop following gpl20:CD4 binding which
induces the conformational change which allows exposure of the fusion peptide to
the opposing membrane.
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1.3.11: Membrane fusion and cytopathicity of HIV
There is some evidence that HIV interaction with the plasma membrane of
CD4+ cells causes alterations in the membrane (Fermin and Garry, 1992). Although
HIV penetration was shown to be predominantly via fusion with the plasma
membrane EM ultrastructural studies showed that virus attachment appeared to
initiate formation of a coated pit (Fermin and Garry, 1992). Viral
attachment/penetration was also shown to disrupt the plasma membrane. Effects
included partial separation of the bilayers, and formation of pores, perturbations or
membrane thickenings. The mechanism by which HIV disrupts the plasma
membrane is unclear.
HIV may have similarities with several lytic viruses including myxoviruses
and togaviruses which encode proteins that form functional transmembrane ion
channels. It has been suggested that the extreme C-terminal end of HIV gp41
resembles the S4 ion-transducing segment of monovalent cation channels (Garry et
al., 1991, Miller et al., 1991). Synthetic peptides representing this region of gp41
alter ion fluxes and are cytotoxic in micromolar concentrations (Miller et al., 1991).
Thus HIV infection may result in insertion or activation of a transmembrane channel
which allows the influx of ions , water and perhaps also other molecules (Miller et
al., 1991, Cloyd and Lynn, 1991). Following HIV infection cells may become
swollen and lose viability (Garry, 1989). This is sometimes referred to as
"ballooning" degeneration and may be responsible for the death of single or
syncytial HIV infected cells , perhaps by induction of apoptosis (Garry, 1989) or by
disruption of cellular functions due to osmotic effects and an irreversable loss of the
ability of the cell to maintain volume homeostasis. Cellular changes associated with
apoptosis have been reported to occur in cultures infected with HIV prior to the
synthesis of most viral proteins. Sufficient numbers of virions interacting with a cell
may cause membrane alterations lethal to the cell. This could account for the ability
of UV irradiated virus to kill cells (Rasheed et al., 1986). On the other hand ionic
changes induced by infection with a low number of virions could be compensated
initially by the cellular ion transport systems but these may be swamped following
de novo synthesis of viral membrane proteins resulting in ionic changes and finally
degeneration or lysis of the infected cell.
Proteins encoded by HIV may also affect the movement of ions by
mimicking neurotoxins which interact with transmembrane ion channels (Garry et
al., 1991, Werner etal., 1991).
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Blocking of syncytium formation by monoclonal antibodies against leucocyte
adhesion factor (LFA-1) indicated that this molecule is involved in HIV-1 membrane
fusion (Hildreth and Orentas, 1989, Valentin et al., 1990). HIV can infect T cells
from a leucocyte adhesion deficiency patient, which are deficient in expression of
LFA-1, but these cells do not form syncytia (Pantaleo et al., 1991) suggesting that
LFA-1 may be required for cell-to-cell fusion but not for virus to cell fusion. More
recently Golding et al. (1992) reported that initial cell-to-cell fusion (CD4/envelope
mediated) did not require LFA-1, but it was required for syncytia formation in
lymphoid cells. It was suggested that LFA-1 may be acting to stabilise aggregates of
cells to allow syncytium formation. Aggregates of non-lymphoid adherent cells may
be stabilised by other molecules e.g. integrins involved in adherence, and thus may
able to form syncytia in the absence of LFA-1.
Syncytium formation by HIV in vitro is also dependent on the presence of
serum factors (Ushijima et al., 1992). The requirement for serum is not species
specific in that the addition of foetal calf, rabbit or human serum to serum-free
medium restored fusion by HIV-1 MOLT-4 cells added to uninfected MOLT-4 cells.
Fibrinogen, fibronectin, and alphaglobulin were identified as being involved in the
promotion of HIV-induced fusion. Both fibrinogen and fibronectin are coagulation
factors present at high concentrations in serum (2-4mg/ml fibrinogen and
approximately 300|ig/ml of fibronectin in human serum) Both these proteins are
known to mediate cell attachment (Ruoslahti and Pierschbacher, 1987, Auffray and
Navotny, 1986). These two proteins include the tetrapeptide motif R-G-D-S which
represents the cell attachment site. The same sequence is present in the MHC
antigens and in HIV-1 gpl20. The additional factors may be involved in stabilising
the interaction between cells to enable syncytium formation but are not required for
infection.
1.3.12: Hypothetical mechanism of HIV membrane fusion
The mechanism of HIV membrane fusion may be hypothesised drawing
together the available information as discussed above;
The viral and cell plasma membrane are brought close together by gpl20
binding to CD4 (or some other receptor) which, dependent upon the correct tertiary
and quaternary structure of the membrane glycoproteins gpl20 and gp41, causes a
conformational change in gpl20:gp41 exposing the fusion peptide of gp41 which
may insert in the opposite membrane linking the two. It may be necessary for the
CD4:gpl20 complex to move aside in order for the fusion peptide to gain physical
access to the opposing membrane. The dissociation of gp41 from gpl20 , and/or of
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gp41 from core proteins may be necessary to enable this, as lateral mobility of gp41
within the viral membrane may be restricted by the interaction between the C-
terminal tail and the core proteins. Translocation of the TM glycoproteins within the
membranes may enable the formation of a fusion pore causing disruption of the
stable lipid bilayers, mixing, and reformation of lipid bilayers in a different plane, as
hypothesised for influenza fusion pores. The formation of coated-pit-like structures
at the virus/plasma membrane interaction site may also be important for fusion as
coated pits contain proteins involved in cellular fusion pathways which are necessary
for endocytosis. It may be that the viral fusion pore components, i.e. the envelope
glycoproteins, and the cellular fusion pore components interact in some way to
enable destabilisation of the two membranes, mixing and reformation of the lipid
bilayer.
A common mechanism involving the fusion protein NSF (N-ethylmaleimide-
sensitive fusion protein) may underlie diverse types of fusion events in eukaryotes
including in the pathway of endocytosis (Malhotra et al., 1988). NSF appears to
assemble with other proteins to form an active multi-subunit "fusion machine". It
may be that the viral transmembrane protein is involved in such an assembly which
mediates membrane fusion. Perhaps in addition to using host cellular machinery for
RNA and protein synthesis the virus is also very efficient at hijacking cell proteins
involved in fusion pathways.
The influenza fusion pore appears to be a tight structure which does not
allow ions or water through, but it appears that in HIV the structure may allow water
and ions through. Alternatively, HIV glycoproteins may alter water and ion balance
by acting as calcium channels; Calcium channels are involved in membrane fusion
between intracellular vesicles, and the C-terminal end of gp41 is "calcium channel¬
like". Similar properties have not been identified for influenza glycoproteins.
The disruption of ion transport which occurs late in infection after synthesis
of viral proteins may be by a different mechanism altogether, perhaps by expression
of envelope proteins interfering with recycling of cellular integral membrane
proteins and leading to progressive loss of important cellular functions. For
example, it has been suggested that the fibrinogen receptor is down regulated on
HIV-infected cells (Ushijima et al., 1992) An alternative reason for this disruption
of ion transport may be that envelope proteins might interact with cellular fusion
pore proteins on cell surface and disrupt ion exchange.
1.3.13: Conserved features of virus membrane fusion
Many of the features of fusion are similar amongst all the fusogenic viruses.
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The viral fusion proteins are in a class of integral sub-unit proteins which are
characterised by a three-domain structure with a large hydrophilic carbohydrate
containing domain on the external surface of the membrane, a small, uncharged
hydrophobic domain spanning the membrane and a fairly small hydrophilic domain
on the internal side of the membrane. Similar proteins in eukaryotic cells have
enzyme or recognition activities e.g MHC antigens.
Proteolytic processing of the envelope glycoprotein precursor gives rise to
two proteins which remain associated (non-covalently or by di-sulphide bonding).
The heterodimer subunit combines into trimers or tetramers; Vesicular Stomatitis
virus protein G which mediates binding and fusion associates into trimers (Crise et
al., 1989), Semliki Forest virus E1-E2 heterodimers trimerise (Fuller, 1987), whilst
HIV envelope proteins most likely form tetramers (Pinter et al., 1989, Schawaller et
al., 1989, Earl et al., 1990). Proteolytic maturation, glycosylation and
oligomerisation are vital for fusion but not for processing or transport of the
envelope proteins to the cell surface. A conformational change is required to trigger
fusion. This is thought necessary to expose the N-terminal hydrophobic region of
the glycoprotein, the fusion peptide, to the target membrane. This conformational
change may be induced by binding of the associated envelope glycoprotein (HN/HA
or surface glycoprotein) to its specific receptor and/or by a drop in pH.
The fusion peptide, a stretch of relatively hydrophobic amino acids within a
membrane anchored subunit, has been identified as a key feature of most viral fusion
proteins. Fusion peptide sequences are short, 16-26 a.a., and relatively hydrophobic.
If modelled as alpha-helices they display one face with a high hydrophobicity index
and a back face that has hydrogen bonding potential (White, 1990). Fusion peptides
are highly conserved within but not between virus families. There are no major
features that distinguish the fusion peptides of acid dependent from neutral pH
fusion proteins (White, 1992). Therefore it seems that it is the tertiary structure of
the protein which is dependent on the low pH for correct exposure/conformation.
The fusion peptide is thought to insert into the opposing membrane destabilising the
lipid bilayer to initiate fusion.
Some non-viral proteins which have a role in fusion have many similarities
with the viral fusion proteins e.g. PH-30 a sperm surface antigen involved with
fusion with the oocyte (Primakoff et al., 1987, Blobel et al., 1990, Blobel et al.,
1992). PH-30 is thought to be involved in both binding and fusion. It is a complex
of two integral membrane proteins formed by cleavage of larger precursors and has a
typical fusion peptide.
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CHAPTER 2: Cloning and Sequencing of DNA encoding EV1 en46
2.1: INTRODUCTION
The env gene encodes the envelope glycoprotein which is subsequently
cleaved into the external surface envelope glycoprotein (gp 135) and the
transmembrane envelope glycoprotein (gp46). The aim of this work was to clone the
whole of the region encoding the transmembrane envelope glycoprotein, (hereafter
referred to as gp46), of MVV strain EV1. I wished firstly to sequence gp46 of strain
EV1 for comparison with other strains and to try to identify conserved epitopes on
gp46 which might be involved in fusion. The cloning was planned bearing in mind
that I wished subsequently to express the gene to produce recombinant protein for
studies on the immune response of MVV infected animals to gp46.
By analogy with other viruses it is likely that gp46 plays a major role in
mediation of membrane fusion by the virus. As discussed in Chapter 1, it is apparent
that there is variation in the MVV genome as shown by the appearance of
neutralisation escape mutants. Variation in env may be important in survival and
persistence of the virus in the host. However, functional epitopes are generally
conserved.
The reason strain EV1 of MVV was chosen for use in this project was that
the other MVV strains were isolated outside the UK and containment requirements
pose difficulties for their use to establish experimental infections or to challenge
animals in the UK. MVV strain EV1 was originally isolated from the peripheral
blood of a sheep displaying symptoms of pneumonia and arthritis. After brief
passage in sheep skin fibroblasts, the virus was used to infect choroid plexus (SCP)
cells and stocks of virus were aliquoted and stored at -70°C.
Much of EV1 had already been sequenced from cDNA clones prepared from
EV1 infected SCP cells when I began this project, but no clone spanning the whole
of gp46 had been found despite extensive screening of the lambda gtlO library which
had yielded the other EV 1 clones.
The sequence of MVV strain 1514, an Icelandic isolate, had been ascertained
but only after extensive in vitro passaging. LV1, a strain derived from a sheep
experimentally infected with 1514 had also been sequenced (Braun et al., 1987).




2.2.1: Screening of an EV1 lambda- gtlO library for EV1 env (gp46)
Attempts were made to obtain a clone of MVV-EV1 gp46 from a library
made from cDNA from EV1 infected WSCP (Sheep choroid plexus cells) ligated
into lambda- gtlO (as described in our paper, Sargan et al., 1991). An 1180 base
Ddel fragment of the MVV strain 1514 genome, positions 7152-8332, was obtained
from a genomic clone of MVV-1514, pVisJC8.5, (Molineaux and Clements, 1983)
by sequential Sacl/Hindlll and Ddel digestions and gel purification and phenol
extraction. Full length 1514 insert was used to probe for MVV specific plaques
whilst the 1180bp. fragment was used to identify MVV gp46 specific clones.
2.2.2: Cloning of MVV EV1 env (gp46) via Polymerase Chain Reaction (PCR)
Extrachromosomal DNA purified from EV1 infected cells by the method of
Hirt (1987) was used as template for amplification of MVV-specific DNA. Partially
redundant primers, HOD and 141D, were used to amplify DNA encoding EV1
gp46.
140D- 5'- GAA TTC TCA ATC ATG GGC ATC TGT TCT C -3'
A
T
14ID- 5'- GAA TTC ATG GGI ATA GGI TTG GTI ATA GT G -3'
C
The PCR reaction conditions were as follows; 67mM Tris-Cl pH8.8, 16.6mM
Ammonium sulphate, 6.7mM Magnesium chloride, lOmM 2-mercaptoethanol,
6.7(iM EDTA, 25^M dATP, 25^iM dCTP, 25^tM dGTP, 25[lM dTTP, 0.17|lg/nl
BSA, and 1 unit Taq polymerase made up to lOQpl with sterile distilled water and
overlaid with paraffin oil. A Techne Programmable Dri-block (PHC-1) was
programmed to provide 35 cycles of 0.6 minutes melting at 95°C, 1 minute
annealing at 45°C and 5 minutes extension at 70°C, and a 5 minute final extension at
70°C.
lOpl samples of each PCR reaction were analysed by electrophoresis. The
gel was Southern blotted onto nitrocellulose and probed with 32P labelled pVisJC8.5
insert (Appendix III).
36
2.2.3: Preparation of PCR product for ligation
gp46 PCR product was phenol extracted and ethanol precipitated. A portion
of the product was digested with EcoRI in the conditions recommended by the
manufacturer and then gel purified by excising a band of the predicted size from an
LGT agarose gel following electrophoresis.
The remainder of the gp46 PCR product was gel purified without restriction.
A band of approximately lkb was excised. The DNA in LGT was made up to a
volume of 159jil with SDW, melted by heating to 60°C, then kept liquid at 37°C.
22(0.1 buffer E14 (lOmM Tris-Cl(pH7.5), ImM MgC12, 7mM B-mercaptoethanol),
37(0.1 3mM dNTPs and 2|il klenow polymerase (4U/(ll) was added and incubated at
37°C for 45 minutes. DNA was extracted and the agarose removed using 60°C
phenol/chloroform/isoamyl alcohol followed by ethanol precipitation. The
precipitate was redissolved in 10 |Ol of SDW, heated to 60°C for 2 minutes and
cooled to 37°C before adding 5|il of 10 x reaction exchange buffer (0.5M Tris-Cl
(pH 7.6), 0.1M MgCl2, 50mM dithiothreitol, ImM spermidine HC1, ImM EDTA
(pH 8.0)), 5(0.1 10|oM ATP, 3(0.1 T4 polynucleotide kinase and 27(0.1 SDW.
Concentrations were estimated by electrophoresis of sample dilutions on a
1% agarose gel containing 0.5 (ig/ml EthBr.
2.2.4: Ligation of gp46 PCR product into pTZ19R
Plasmid was prepared for ligation by digestion with HincII (as manufacturers
instructions) and treatment with Calf Intestinal Phosphatase (CIP). to remove the 5'
terminal phosphate and prevent recircularisation of the plasmid. Linear plasmid was
gel-purified and recovered by Geneclean.
Ligation reactions were set up at molar ratios of approximately 0:1, 4:1, and
10:1, of insert:vector (klenow/kinase treated gp46 PCR product: Hindl/CIP-treated
pTZ19R). 200ng of pTZ19R was used for each reaction. Vector, insert and SDW
were heated to 60°C for 2 minutes. After cooling briefly on ice, ligase buffer and
enzyme were added. The ligation reactions were incubated overnight at 14°C.
Half of each ligation was used to transform competent E.coli JM101.
Transformants were selected by plating onto LB agar containing Ampicillin
(150|ag/ml), X-Gal, and IPTG (Appendix I). Colonies were picked and inoculated
onto a fresh X-Gal/IPTG/Amp plate and into Universals containing 5ml
LB/150(ig/ml Amp. and incubated overnight at 37°C. Plasmid mini-preps were
prepared as described in Appendix II. Precipitated DNA from 1.5ml of culture was
resuspended in 8.5(tl TE/50|lg/ml RNase A, ljil E13 buffer (6mM Tris-Cl(pH7.5),
6mM NaCl, 6mM MgC^, 6mM B-mercaptoethanol, 0.02% w:v BSA), and 0.5(0.1
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Kpnl (8U/|il) and incubated at 37°C for 3 hours 45 minutes. 15jil samples were
electrophoresed.
New plasmid mini-preps were made from the possible positives, (i.e. those
plasmids which were larger than pTZ19R when linearised with Kpnl), and digested
with Hindlll followed by Xbal. The restriction digests were electrophoresed
alongside super-coiled pTZ19R, linear pTZ19R and gp46 PCR product.
2.2.5: Preparation of single-stranded pTZ-derivatives
Single-stranded DNA was prepared, (as described in Appendix IV), from
four different clones, pCC19.12, pCC19.13, pCC19.15 and pCC19.25, consisting of
the gp46 PCR product inserted into pTZ19R .
2.2.6: Inversion of gp46 insert
pCC 19.25 was digested with Hindlll and Xbal. The resultant lkb restriction
fragment was gel purified and ligated into Hindlll/Xbal-cut, CIP-treated pTZ18R.
Transformants containing plasmid derived from pTZ18R with gp46 insert were
selected, (named pCC18.n), and single stranded plasmid DNA was prepared for
sequencing (Appendix IV).
2.2.7: Subcloning from gp46 clone for sequencing
pCC18.10 and pCC19.15 were digested with EcoRI producing two fragments
of about 500bp from the gp46 insert. The 500bp material was gel purified and
ligated into EcoRI cut, CIP-treated pTZ18R. Plasmid minipreps were made from
overnight cultures of transformants selected on LB Amp/X-Gal/IPTG agar, and
digested with EcoRI to characterise the insert. Both single stranded and double
stranded DNA was prepared for sequencing of the plasmids containing a 500bp gp46
insert (Appendix IV).
2.2.8: Sequencing
DNA sequencing was performed by the dideoxy chain termination method of Sanger
et al., (1977), using a commercial kit (USB Biochemicals). Double stranded as well
as single stranded DNA sequencing allowed the sequence of both strands of gp46 to
be determined and multiple runs allowed the elimination of ambiguities.
The University of Wisconsin Genetics Computing Group (UWGCG) package





2.3.1: Cloning and sequencing of gp46
PCR with primers MOD and MID using a template of DNA prepared from
EV1 infected sheep skin cell fibroblasts amplified a product of approximately lkb
(Figure 2.1). When DNA prepared from uninfected sheep cells was used as PCR
template for primers MOD and 14ID no product was made. As a positive control
primers derived from the sequence of an EV1 gag clone were used. These amplified
a product of 635 bases. On southern blots of the PCR products 32P labelled insert
from pVisJC8.5 (SstI fragment, nucleotides 562-9132 of Visna-1514) hybridised
with the EV 1 gag and gp46 PCR products .
Restriction digestion of the PCR product revealed an EcoRI cleavage site
approximately in the middle of MW-EW l-gp46 which was not present in MVV-
\5l4-gp46. This meant that the planned ligation of EcoRI-treated PCR product into
EcoRI-cut pTZ19R would be unsuitable. Therefore the PCR product was treated
with Klenow polymerase then T4 polynucleotide kinase to ensure blunt and
phosphorylated ends, and was blunt-end ligated into the HincII site of pTZ19R.
Transformants were selected and plasmid minipreps were made. Six were larger
than pTZ19R alone when linearised with KpnI. Plasmid DNA from these 6 clones
was digested with Hindlll and Xbal to excise any insert by cutting either side of the
HincII site within the pUC19 multilinker. Four clones, namely CC19.12, CC19.13,
CC19.15 and CC19.26, contained plasmids with inserts of the required size.
Single stranded plasmid DNA was prepared using helper phage M13K07.
Sequencing of the single stranded plasmids using the reverse sequencing primer
showed that each of the four plasmids contained the insert in the same orientation.
The sequence obtained corresponded to pTZ19R multilinker, primer MOD then
sequence complementary to the 3' end of gp46 (as previously sequenced by DRS).
In order to enable single stranded sequencing from either end it was
neccessary to turn the insert round relative to the Ml3 packaging signal. This was
done by cutting the insert out of pTZ19R using Xbal and Hindlll and religating it
into Xbal/Hindlll cut pTZ18R. Again, transformants were selected. Three
plasmids, pCC18.7, pCC18.8 and pCC18.9, were found which contained an insert of
1Kb. Single stranded plasmid DNA was prepared and sequenced using the reverse
sequencing primer. This produced sequence corresponding to the 5' end of gp46 as
shown by comparison with the published sequence of MVV 1514.
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Figure 2.1: Results of PCR to amplify EV1 gp46
i) PCR products separated on a 1% agarose mini-gel
ii) Southern blot of the same gel probed with pVisJC8.5
A : EVl-gp46 primers with sheep DNA template (negative control)
B : EVl-gag primers with EV1 HIRT DNA template
(positive control)
C -E: EVl-gp46 primers with EV1 HIRT DNA template
(Decreasing amount of primer 14ID with constant amount of MOD)
C=1.2|iM MOD, 4.5(lM 141D
D=1.2|iM MOD, 1.35|lM 141D
E=1.2(iM MOD, 0.45(iM 141D
Figure 2.2: Diagrammatic representation of clones encoding EV1 gp46
Diagram of the plasmids constructed to clone and sequence EV1 gp46.
Sequencing using the reverse or universal primers (USB) enabled the directionality of
the inserts to be determined.
The insert of lkb was too large for complete sequencing from either end so
the central EcoRI site was utilised to make plasmids with half length inserts.
pCC18.9 was digested with EcoRI. The two 500bp restriction fragments, which
could not be seperated by electrophoresis, were ligated with EcoRI-cut, CIP-treated
pTZ19R or pTZ18R. Transformants were selected. Plasmids were prepared and
those with inserts of 500bp were used for double stranded sequencing. Using either
the reverse or universal sequencing primers, sequence from either end of the insert
was obtained.
Restriction maps of some of the plasmids constructed for sequencing of EV1
gp46 are shown in Figure 2.2. Multiple sequencing reactions were done to enable
the sequence of the entire gp46 coding region to be determined (Figure 2.3).
A cDNA clone pVlLTR (IB and DRS) overlapped the gp46 coding sequence
from the EcoRI site to the 3' end. The sequence obtained was confirmed by the
sequence of pVlLTR therefore I concentrated on sequencing of the 5' half of gp46.
The sequences obtained were aligned using the the GCG "Bestfit" program.
Where ambiguities occurred between sequences from different reactions, sufficient
additional runs were performed to obtain a correct sequence. Finally the sequences
were joined up using GCG "Assemble" to complete the sequence of EV1 gp46
(Figure 2.4).
Although the sequence through the EcoRI site in gp46 was not confirmed, the
translation phase was conserved, and sequence alignment with sequence from other
strains of MVV backs up the sequence shown in Figure 2.4. Therefore, this can be
considered to be a faithful representation of the sequence encoding MVV EV1 gp46.
2.3.2: Sequence Comparison between gp46 of EV1 and other MVV isolates
The EV1 gp46 sequence was compared with the other available MVV
sequences, visna-1514 (Molineaux and Clements, 1983) and SAOMVV ( Querat et
al, 1990), using the GCG "Bestfit" and "Lineup" programs (Figure 2.5). Percentage
similarity between them was calculated: EV1 and 1514 were 81.6 % identical, EV1
and SAOMVV were 82.2 % identical, and 1514 and SAOMVV were 81.3 %
identical.
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Figure 2.3: Diagrammatic representation of sequencing results
The arrows in the diagram represent sequence obtained and show that the
sequence for the whole of the region encoding EV1 gp46 was the result of at least
three independent sequencing reactions.
7Qoi EcoRI7931 8889
8000 8200 8400 8600 8800








Overlap with pV 1LTR
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Figure 2.4: Nucleotide sequence and amino acid translation of MVV-EY1 gp46
The first four nucleotides, and the initial amino acid, cysteine, are derived
from the 5' PCR primer. In the completed sequence of EV1 env the protease
recognition sequence ArgLysLysArg lies immediately upstream of the first amino























































The EV1 DNA sequence was translated and the predicted amino acid
sequence was compared with other MVV isolates. EV1 and 1514 were 79.5 %
identical (88% similarity), EV1 and SAOMVV were 79.9 % identical, and 1514 and
SAOMVV were 79.8 % identical. The similarity between these isolates suggests
that each may be equally diverged from a common ancestor. Comparison of the
sequences using the GCG "Lineup" program, allowed conserved regions to be
visualised (Figure 2.6).
Translation of the EV1 sequence revealed five potential N-linked
glycosylation sites in gp46 (as identified by the motif N X S/T) all occuring in the
region thought to lie to the external side of the membrane. These occur at 42-44,
110-112, 117-119, and 133-135 and are conserved in all three MVV isolates except
that 1514 has one extra potential site at 167-169. The conservation of sequence at
the four sites listed suggests that glycosylation at these sites is necessary for the
function of gp46. Alterations in glycosylation may alter the structure of the
glycoprotein and may alter its antigenicity.
There are seven conserved cysteines. These are found at residues 90, 97,
118, 190, 196, 201, and 312. Conservation of these residues may be important in
maintaining the required secondary structure of the glycoprotein. Conversely
additional cysteines at non-conserved sites may alter the protein structure and
therefore alter the antigenicity of the protein.
The amino-terminal end of gp46, which is predicted to be involved in
mediating cell fusion, is well conserved with only two amino acid changes within the
first 50 bases. Indeed in the first 106 amino acids there are only 8 differences
between these three strains and each is a conservative change in that the charge and
polarity of the amino acid stays the same. Within the nucleotide sequence encoding
these amino acids there are 54 differences between the three sequences. The
majority of these changes are at the third base of the codon and do not alter the
amino acid sequence which suggests that there is positive selection for conservation
of the amino acid sequence.
The sequence 115-131, (DNCTWQQWEEEIEQHE), known as the Kennedy
motif, and the sequence 87-100, (ELDCWHYQHYCVTS), the immunodominant
region, are the same for all three isolates.
The sequence 177-195, predicted to be trans-membrane in the native protein,
is similar for all three strains. Where there are changes they are semi-conservative in
that all the changes are from one hydrophobic amino acid to another. The exception
is at aa 183 which is cysteine in SAOMVV and glycine in 1514 and EV1. Both
cysteine and glycine are uncharged polar amino acids so this is also a semi-
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Figure 2.5: Comparison of MVV gp46 nucleic acid sequences .
The EV1 gp46 sequence was aligned with two other MVV gp46 sequences
using the GCG "Lineup" program. A capital letter is shown in the consensus
sequence where all three bases match, a small letter is shown where two of the three
strains have that base, an x is shown where the bases are different for each MVV
strain.
1 50
Consensus xxxxGGGATA GGcTTGGTxA TaGTGCTxGC tATCATGGCa ATAATaGCTG
Saomvv ....GGGATA GGATTGGTCA TAGTGCTTGC TATCATGGCT ATAATAGCTG
1514 GGGATA GGCTTGGTTA TTGTGCTAGC CATCATGGCA ATAATCGCTG
EV1 ATGTGGGATA GGCTTGGTGA TAGTGCTCGC TATCATGGCA ATAATAGCTG
51 100
Consensus CTGCAGGAGC TGGtCTCGGt GTtGCaAAtG CCGTGCAGCA aTCCTAtACc
Saomvv CTGCAGGAGC TGGACTCGGC GTTGCTAATG CCGTGCAGCA ATCCTACACC
1514 CTGCAGGAGC TGGTCTCGGT GTCGCAAACG CCGTGCAGCA ATCCTATACC
EV1 CTGCAGGAGC TGGTCTCGGT GTTGCAAATG CCGTGCAGCA GTCCTATACA
101 150
Consensus AGGACGgcTG TcCAGTCTCT TGCTAACGCA ACTGCTGCtC AGCAGaAt GT
Saomvv AGGACGGCTG TTCAGTCTCT TGCTAACGCA ACTGCTGCTC AGCAGAATGT
1514 AGGACGGCTG TCCAGTCTCT TGCTAACGCA ACTGCTGCCC AGCAGGAAGT
EV1 AGGACGCTTG TCCAGTCTCT TGCTAACGCA ACTGCTGCTC AGCAGAATGT
151 200
Consensus GTTaGAAGCA aCtTATGCCA TGGTxCAGCA TgTaGCcAAA GGagTAAGAA
Saomvv GTTAGAAGCA ACTTATGCCA TGGTTCAGCA TGTGGCAAAA GGGGTAAGAA
1514 GTTGGAAGCA TCGTATGCCA TGGTACAGCA TATAGCCAAA GGAATAAGAA
EV1 GTTAGAAGCA ACTTATGCCA TGGTGCAGCA TGTAGCCAAA GGAGTAAGAA
201 250
Consensus TatTAGAGGC AaGAGTxGCt cGaGTgGAAG cccTgGTaGA TaGaATGATG
Saomvv TATTAGAGGC ACGAGTAGCT CGAGTAGAAG CTATAGTCGA TAGAATGATG
1514 TCCTAGAGGC AAGAGTGGCT AGGGTGGAAG CCCTGGTAGA TTGAATGATG
EV1 TATTAGAGGC AAGAGTTGCC CGAGTGGAAG TCCTGGTAGA TAGGATGATG
251 300
Consensus gTaTAtCAxG AATTgGATTG tTGGCATTAT CAaCACTAtT GTGTAACCTC
Saomvv CTCTATCATG AATTGGATTG TTGGCATTAT CAACACTATT GTGTAACCTC
1514 GTATACCAAG AATTGGATTG CTGGCATTAT CAACACTACT GTGTAACCTC






































































































Consensus CAgTgGTGAT AGAAGcACCx GTGGAccTgG AGGAAAAACa AagAgaAgAa
Saomvv CACTAGTGAT AGAAGCACCC GTGGACCTGG AGGAAAAACA AAGAGAAGAA
1514 CAGTGGTGAT AGAAGCACCG GTGGAATTGG AGGAAAAACA AAAAAGAAAC
EV1 CAGTGGTGAT AGAAGAACCA GTGGACCTCG AGGAAAAACC AGGAGAAGAA
701 750
Consensus agGGATGGTt caAaTGGCTx cGaAaaCTTA gaGCAcGAGA aAAGAACATC
Saomvv AGGGATGGTT CCAGTGGCTC AGAAAACTTA GAGCACGAGA AAAGAACATC
1514 GGGGATGGTA CAAATGGCTG CGCAAGCTTA GAGCACGAGA GAAGAACATC
EV1 AAGGATGGTT TAAATGGCTT CGAAGAC T TA AGGCAAGAGA AAAGAACATC
751 800
Consensus CCxtCGCAgT TTTAtCCAGA TATGGAGaGC AACxtgGcaG GCxTGGAAAA
Saomvv CCCTCGCAGT TTTATCCAGA TATGGAGGGC AACTGTGCAG GCTTGGAAAA
1514 CCATCGCAGT TTTATCCAGA TATGGAGAGC AACATGGTGG GCATGGAAAA
EV1 CCGGCGCACT TTTACCCAGA TATGGAGAGC AACGTGGCAG GCCTGGAAAA
801 850
Consensus cCTCACCtTG GaggaAxagx T GGAgGAxAA tcCtaTATAT gActCTaCTa
Saomvv CCTCACCCTG GGGGAAGGGA T GGAAGAAAA TCCTATATAT GACTCTACTG
1514 CCTCACCTTG GAGACACAAC TGGAGGACAA TGCCCTATAT AACCCTGCTA
EV1 ACTCACCTTG GAAGAAAAGT TGGAGGAGAA GCCTATATAT GAGTCTACTA
851 900
Consensus CCxcTAcTgg cgxTacaxca aTGGaTGGAA GAgAc TGGAT GGAaTGGaGa
Saomvv CCGCTACTAA CACTGCAAAT ATGGATGGAA GAAACTGGAT GGAATGGAGA
1514 CCCATATTGG TGATATGGCA ATGGATGGAA GAGAATGGAT GGAATGGAGA
EV1 CCTCTACTGG CGGTACATCA GTGGCTGGAA GAGACTGGAT GGATTGGCGG
901 950
Consensus gAAtcaGcxC AAaAAgAAAA AAGAAAGGGT GGACTGTCAG GaCAGAGAAc
Saomvv TAAGAGGTGC AAGAAGAAAA AAGAAAGGGT GGACTGTCAG GACAGAGAAA
1514 GAATCAGCAC AAAAAGAAAA AAGAAAGGGT GGACTGTCAG GACAGAGAAC
EV1 GAATCAGCTC AAAAATAAAA AAGAAAGGGT GGACTGTCAG GGCAGAGAAC
951 991
Consensus axATGCCtac caTxGAgAAT GAcTATGTAG AgxTgaagtA g
Saomvv GCATGCCTGC CATAGAGAAT GAGTATGTAG AGCTGAGCTA G
1514 AAATGCCTAC CCTGGAAAAT GACTATGTAG AGTTATAGGA A
EV1 AGATGCCCAT GATTGAGAAT GACTATGTAG AAATGAAGTA G
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Figure 2.6: Comparison of MVV gp46 amino acid sequences.
The GCG "Lineup" program was used to align the gp46 amino acid sequence
of MVV EV1 with those of strains 1514 and SAOMVV. A capital letter is shown in
the consensus sequence where all three amino acids match, a small letter is shown
where two of the three strains have that amino acid, an x is shown where the amino
acid is different for each MVV strain.
0 49
Consensus .GIGLVIVLA IMAIIAAAGA GLGVANAVQQ SYTRTaVQSL ANATAAQQnV
Saomvv .GIGLVIVLA IMAIIAAAGA GLGVANAVQQ SYTRTAVQSL ANATAAQQNV
1514 .GIGLVIVLA IMAIIAAAGA GLGVANAVQQ SYTRTAVQSL ANATAAQQEV
EV1 .GIGLVIVLA IMAIIAAAGA GLGVANAVQQ SYTRTLVQSL ANATAAQQNV
50 99
Consensus LEAtYAMVQH vAKGvRILEA RVARVEalVD rMMvYqELDC WHYQHYCVTS
Saomvv LEATYAMVQH VAKGVRILEA RVARVEAIVD RMMLYHELDC WHYQHYCVTS
1514 LEASYAMVQH IAKGIRILEA RVARVEALVD xMMVYQELDC WHYQHYCVTS
EV1 LEATYAMVQH VAKGVRILEA RVARVEVLVD RMMVYQELDC WHYQHYCVTS
100 149
Consensus TrsEVAxYVN WTRykDNCTW QQWEEEIEQH EaNLSlLLrE AALQVhIAQR
Saomvv TRTEVAQYVN WTRYKDNCTW QQWEEEIEQH EANLSLLLKE AALQVQIAQR
1514 TRSEVANYVN WTRFKDNCTW QQWEEEIEQH EGNLSLLLRE AALQVHIAQR
EV1 TKSEVAKYVN WTRYRDNCTW QQWEEEIEQH EANLSQLLRE AALQVHIAQR
150 199
Consensus DAqRIPDvWk AlQeAFdWsg WFsWLKYIPW IvmglvGliC FRilMCVism
Saomvv DAQRIPDVWK ALQEAFDWSG WFSWLKYIPW IWCIVGVIC FRLLMCVITM
1514 DARRIPDAWK AIQEAFNWSS WFSWLKYIPW IIMGIVGLMC FRILMCVISM


































In contrast, the carboxy-terminal region of gp46, encoding the cytoplasmic
tail of the gp46 protein, is very variable; the longest run of amino-acids conserved in
all three strains in this region is only seven residues, and at many positions each of
the sequences have different amino acids. This is the region of the MVV genome
where the env and rev genes overlap but are translated in different reading frames.
Figure 2.7 shows a secondary structure prediction for gp46. Superimposed
on the structural backbone are hydrophobic and hydrophilic domains. The profile
shows two particularly hydrophobic areas; one at the extreme N-terminal of the
protein, the other covering the probable membrane spanning region.
In the amino terminal half of gp46 the majority of sequence changes between
the three isolates substitute one amino acid for another of similar charge or polarity.
This together with the conserved cysteine residues and potential glycosylation sites,
suggests conservation of the secondary structure of the external part of the native
protein, whilst the carboxy terminal region, predicted to lie to the cytoplasmic side
of the membrane, is much more variable.
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Figure 2.7: Predicted secondary structure of gp46
The secondary structure of Evl gp46 was predicted using the UWGCG programs
"peptidestructure" and "plotstructure". Alpha helices are shown as tight zig-zags,
whilst beta-pleated sheets are shown as wide zig-zags. Predicted hydrophobic










It was decided to attempt to amplify EV1 gp46 by PCR in order to clone it.
A sequence from the 3' end of gp46 in pVlLTR was chosen for the complementary
PCR primer. At this time the only known sequence for the 5' end of gp46 was from
the 1514 MVV strain. To give the best chance of the primer annealing with the EV1
gene the primer was chosen from the sequence of 1514 but including dITP at some
of the third base positions to allow for codon ambiguities. A mixture of dATP,
dCTP, dGTP or dTTP was used for the 3' end of the primer where the use of dITP is
not recommended. An EcoRI recognition sequence was added at the 5' and of each
primer in the hope of amplifying a PCR product with EcoRI ends to make cloning
easier. The primers amplified a product of the expected size from EV1 Hirt DNA
template and this was shown to be MVV specific by blotting with a probe derived
from a full-length MVV-1514 clone. However the yield from the PCR was poor.
This may have been partly due to poor primer design, however the choice of primers
was restricted by the need to be as close as possible to the ends of the gp46 coding
region. Several books published since the time this work was done suggest typical
primers should be 18-28 nucleotides long, 50-60% G+C, and with a balanced Tms
for a given primer pair.
3' PCR primer
140D- 5'- GAA TTC TCA ATC ATG GGC ATC TGT TCT C -3'
16 A/T, 12 G/C, Tms approx. 80°C
5' PCR primer A
T
14ID- 5'- GAA TTC ATG GGI ATA GGI TTG GTI ATA GT G -3'
C
14 or 15 A/T, 3 I, 10 or 11 C/G, Tms approx. 70-72°C
This suggests the percentage of G and C nucleotides was low thus decreasing the
annealing efficiency of the primers. However in the initial rounds of amplification
the extra bases forming the EcoRI recognition sites at the 5' end would not be
involved in pairing and therefore may be discounted in calculating the Tms.
There did not appear to be amplification of any non-specific products so it
may have been possible to increase the yield of gp46 PCR product by reducing the
annealing temperature and/or by increasing the number of cycles.
Nevertheless the PCR did amplify sufficient amounts of the required
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fragment to enable cloning. EV1, unlike 1514, was found to have an EcoRI site
near the middle of gp46 which meant that the terminal EcoRI sites which had been
added could not be utilised for cloning the entire product and instead, blunt-ended
PCR product was ligated into pTZ19R.
2.4.2: Sequencing
As Taq polymerase has no editing function there is always a possibility that PCR
amplification will introduce base changes. The error rate of Taq polymerase is
affected by a number of factors including enzyme, substrate and dNTP
concentrations (Innis et al., 1988). The estimates for the error rate vary from 1 in
300 (Meyerhans et al., 1989) to 1 in 1500 (Perrin and Gilliland, 1990) to 1 in 9000
for single base pair substitutions and 1 in 41000 for frameshift mutations (Tindall
and Kunkel, 1988). Although several clones were isolated and sequenced these were
all obtained from the same ligation and transformation. The transformation protocol
allows a period of growth in LB prior to plating for single colonies on selective agar
but this period is insufficient to allow more than one cell division and therefore the 4
clones are unlikely to have been the result of a single ligation/transformation event.
Although each of the four clones contained insert in the same orientation this is not
sufficient to confirm or deny the above suggestion.
A single PCR reaction may also by chance amplify one variant preferentially
from another. As the error rate for reverse transcriptase has been estimated at
approx. 10-7 there are likely to be some variants within any population of MVV, so
the particular sequence amplified and cloned will always represent only a
quasispecies within a population except if a full-length infectious clone is being
used.
The high rate of variation is due to the high error rate of reverse transcriptase which
lacks a proof-reading activity. However the difference in mutation/variation rate
between the different genes shows other factors must also be important. Studies by
Hahn et al., (1985), on HIV, showed 10'2-lO3 changes per base per year for env but
tenfold less for gag.
2.4.3: Sequence comparisons
If reverse transcriptase is considered to introduce base changes at random
throughout the retroviral genome then sequences which remain conserved between
different strains are likely to be maintained by functional constraints. Meanwhile
other areas may appear hypervariable if there are no functional constraints on them.
Indeed there may be positive advantages for the virus in evading the immune system
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by introducing changes e.g. Braun et al., (1987), described sequence differences
between 1514 and a sequential isolate LV1-1 which was resistant to neutralisation
antibodies directed against strain 1514. This may be one reason why env is the least
homologous gene between MVV isolates (Querat et al., 1987).
It has been shown that passage of plaque purified 1514 produced
neutralisation resistant variants in absence of selective antibody (Staskus et al.,
1991). Variants had different sequence to 1514 and the changes were not spread
evenly throughout the genome. This shows that even in the absence of a selective
immune response env is the region of the genome most permissive for variation
Sequence comparisons between the gp46 sequence of the three different
strains of MVV revealed regions of relatively conserved or of variable sequences.
This is expected to be related to both the error rate of RT and negative selection of
any mutations which result in loss of infectivity/replication ability of the virus. Thus
some regions are conserved probably because a particular sequence or structure is
required for infection/replication.
2.4.4: Prediction of functional regions of gp46
Structure of gp46: Conserved cysteines and potential glycosylation sites
suggest some requirement for maintenance of a particular secondary structure. This
may be required for interaction with other gp46 molecules to form functional trimers
(or tetramers).
Fusion: The extreme amino terminal end of gp46 was first identified as a
fusion peptide sequence in sequence comparison studies (Gallaher, 1987). The high
degree of conservation at the amino terminal end of the protein is as might be
expected for a predicted functional region. MVV does not include the Phe-X-Gly
motif found in the paramyxovirus fusion domains and also in SIV and HIV, but it
does exhibit the characteristic highly hydrophobic amino-terminal region typical of
other fusion-mediating viral envelope proteins. The amino acid sequence 12-29
within the N-terminal region has some homology with the predicted fusogenic
epitope of ortho- and paramyxoviruses.
Immunosuppression: Ruegg et al., (1990) identified a sequence within the
MVV transmembrane which had (limited) sequence homology to the region of HIV
which had been identified as having immunosuppressive properties. This in turn had
been identified by sequence similarity with an immunosuppressive peptide
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conserved in the transmembrane protein, pl5E, of the oncornavirus subgroup of
retroviruses. The peptide 64-78 (GvRILEARVARVEal) has been reported to be
immunosuppressive. When conjugated to carrier protein the peptide specifically
inhibited T-cell proliferation at micromolar concentrations. This peptide as well as
those of HIV and the oncornaviruses appear to exert their immunosuppressive effects
by inhibition of protein kinase C (Ruegg et al., 1990, Gottlieb et al., 1989). As
shown by the small letters in the sequence above there are changes between MVV
isolates at either end of this peptide but the central 11 residues are conserved. This
suggests the sequence may be functional even though immunosuppression is not
generally considered to be an outcome of MVV. It may be that the peptide is
effective at limited immunosuppression and may help MVV to persist. The peptide
may be more potent in its native form as part of the TM gp, so lower concentrations
may be effective in vivo than measured in vitro using synthetic peptides. However
there appears to be no difference between the mitogen stimulation or mixed
lymphocyte responses of peripheral blood leukocytes of experimentally MVV
infected compared to mock infected sheep (Griffin et al., 1978) suggesting that
MVV-infected sheep are not immunosuppressed. It may be that any
immunosuppressive effects of gp46 act only at a local level, or that as part of gp46
the peptide is not presented in such a way as to be immunosuppressive.
Contact with the surface envelope glycoprotein, gpllO: The 11-base
sequence ELDCWHYQHYCVTS, (aa 87-100) was conserved for all three MVV
isolates. This sequence has been proposed as the immunodominant region of MVV
gp46 by analogy with a similar sequence in the TM glycoprotein of HIV and of other
retroviruses (Schulz et al., 1992). Di-sulphide bonding between the two cysteines is
thought to form a finger or knob-like structure which interacts with a pocket-like
structure in the external membrane glycoprotein (by analogy with HIV). This region
was identified as a gpl20 contact region because it binds a monoclonal antibody
which is an anti-idiotypic antibody against another monoclonal which reacts with the
carboxyterminal end of gpl20 (Schulz et al., 1991). Mutations in this region of
gpl20 abrogate its binding to gp41, (Helseth et al., 1991).
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CHAPTER 3: Expression of recombinant go46 in veast
3.1: INTRODUCTION
Investigations into the structure, function and antigenicity of MVV envelope
glycoproteins has been extremely limited because of the difficulty in purifying
sufficient yields from viral preparations. Stanley et al., (1987) used lectin based
affinity chromotography to prepare gpl35 from MVV-infected cells, but there are no
reports of purification of gp46 from infected cells and because it is a transmembrane
protein it would be extremely difficult to separate it from other membrane
components. As well as being difficult, preparation from large-scale virus cultures
would include variants introduced during virus culture whereas a recombinant
system will express a defined product.
The yeast Ty-VLP expression system was chosen as it has previously been
reported to produce high yields of recombinant protein in a non-denatured
immunogenic form. Fragments of HIV-1 gp41 and HIV-2 gp36 (Gilmour et al.,
1989 and 1990), and fragments of HIV-1 gpl20 (Adams et al., 1987) are among the
proteins which have been expressed in this system.
The Ty element is a yeast retrotransposon. It consists of long terminal
repeats (LTRs) at either end, and two genes TyA and TyB analogous to retroviral
gag and pol genes (Kingsman et al., 1981). It encodes proteins that self-assemble in
the cytoplasm of yeast cells into virus-like particles (VLPs) containing Ty RNA,
reverse transcriptase, a protease and probably integrase. A truncated form of the Ty
retrotransposon of yeast can be utilised as an expression system for recombinant
protein (Adams et al., 1987). The TyA gene encodes the protein pi which in the
complete Ty VLP is the precursor of the four structural proteins constituting the
capsid of the VLP. However pi alone can self-assemble in the yeast cytoplasm to
form virus-like particles. These are approximately 60nm in diameter and comprised
of about 300 pi monomers. Another coding sequence fused in frame to the TyA
encodes a hybrid pi fusion protein that may assemble into hybrid Ty-VLPs. The
particulate nature of the product enables purification by centrifugation on sucrose
gradients. In addition the polyvalency of the product and the immunogenic nature of
pi accounts for it being recommended as a good recombinant antigen. The system
may be further modified by including an Xa protease recognition sequence to allow
proteolytic cleavage of the protein from pi (Braddock, et al., 1989). Some but not
all of the recombinant proteins expressed in the Ty-VLP system have been shown to
be glycosylated (Carey, 1992), although glycosylation is unlikely to be normal.
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Plasmids pOGS40 and pMA5620 were obtained from British Biotechnology,
Oxford. Both are E.coli/yeast shuttle vectors encoding 381 codons of TyA followed
by a BamHI linker, stop codons in each of the three reading frames, and a
transcription terminator. pMA5620 expresses pi from the constitutive yeast
phosphoglycerate kinase (PGK) promoter (Adams et al., 1987), whilst pOGS40
expresses pi from the hybrid PGK/GAL promoter which is galactose (or IPTG)
inducible (Gilmour et al., 1989).
Expression from the pOGS40 PGK-GAL promoter is dependent on the
relative levels of (host-encoded) GAL4 and GAL80 proteins. GAL4 activates
expression from the GAL promoter by binding to a specific DNA site, whilst its
antagonist, GAL80, blocks activation by binding to GAL4 and/or its DNA binding
site. Excess GAL4 over GAL80 is thus required to promote expression. The helper
plasmid pUG41S expresses GAL4 protein under the control of the GAL1 promoter
which is galactose inducible and also activated by GAL4 (positive feedback).
Therefore co-transformation with pUG41S and pOGS40 should increase the level of
expression from the PGK-GAL promoter by overcoming the limiting levels of
GAL4, whilst maintaining the galactose inducibility of expression (Schultz et al.,
1987).
All the above vectors are selectable by ampicillin resistance in E.coli.
pOGS40 is selectable in S. cerevisiae by transformation of leu" strains to leucine
independence, whilst pMA5620 transforms trp" S.cerevisiae to tryptophan
independence, and pUGS 41 transforms to uracil independence. S.cerevisiae co-
transformed with pUG41S and pOGS40 can be selected by their uracil and leucine
independence. The yeast vectors are based on the 2[im plasmid which is normally
present at 100-200 copies per yeast cell.
Whereas I had to design PCR primers to specifically amplify the gene
fragment in the correct reading frame, a family of pOGS vectors are now available
which differ in the reading frame of the BamHI cloning site at amino acid 381.
Similarly vectors are also now available which contain a factor Xa cleavage site
immediately upstream of the BamHI cloning site whereas I added the protease





PCR reactions were set up using approximately lng plasmid pCC18.9 as
template for primers 095G and 096G, or 096G and 097G, (shown in section 3.3.2).
0.3(ig or 0.6|ig of each primer, 10|ll lOx PCR buffer, 10|il 300pM dNTPs, and lOpl
200|ig/ml BSA was used for each reaction and was made up to 100|il with SDW. 35
cycles of melting at 95°C for 0.6 min, annealing at 45°C for 1.0 minute, and
extending at 70°C for 4.0 min were completed with a final extension at 70°C for 5.0
min.
The 990bp product amplified by primers 097G and 096G was designated
naTF (Transmembrane protein , Full length), whilst the 500bp product amplified by
primers 095G and 096G was designated naTH (Transmembrane protein, Half-
length).
3.2.2: Ligation of naTH and naTF (PCR products) into plasmid vectors
A series of reactions were set up to try to ligate BamHI digested PCR
products into pOGS40 or pMA5620 without success. It was therefore decided to
ligate in the first place into pTZ18R in order to increase the amount of available
product to insert into the larger vectors.
In order to make more product, the PCRs were repeated. After 30 cycles of
PCR as described above, a further 0.5(0.1 of each primer, 2(il dNTPs and O.lp.1 of Taq
polymerase was added to each reaction tube. Three more PCR cycles as before were
followed by a final extension of ten min at 70°C. The aim was to try to increase the
amount of PCR product with completed ends. The PCR products, naTH or naTF,
were phenol extracted, ethanol precipitated and resuspended in 50|il of water.
A sample of each PCR product was treated with Klenow and T4
polynucleotide kinase to ensure blunt ends. The remainder was digested with
BamHI. All four products were gel purified and recovered from low gelling
temperature (LGT) agarose using Geneclean (as manufacturers instructions). The
blunt-ended or BamHI treated PCR products were ligated into HincII or BamHI cut
CLP treated pTZ18. DNA was from each ligation reaction was phenol/chloroform
extracted, ethanol precipitated (Appendix II) and resuspended in 30(0.1 of SDW. 10(il
was used to transform competent E. coli strain JM83 (Appendix I).
Transformed bacteria were selected on LB/Amp/X-Gal/IPTG agar (Appendix
I). Plasmid mini-preps were prepared from overnight cultures of transformants
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which had been inoculated into 6ml LB, 150|ig/ml Amp (Appendix II). Samples of
super-coiled plasmid were electrophoresed. Plasmids larger than pTZ18R were
digested with BamHI and analysed by electrophoresis.
Two clones were selected; pF102.7 consisting of naTF in pTZ18R and
pH103.11 containing naTH insert in pTZ18R. Plasmid was prepared from 25ml
overnight cultures, resuspended in TE/RNase, restriction digested with BamHI and
electrophoresed in 1% LGT agarose. Bands of ~500bp and -lKbp, corresponding to
inserts naTH (5am///) and naTF(flam///) respectively, were excised and the DNA
extracted by Geneclean (as manufacturers instructions).
Ligation reactions were set up using BamHI restricted, CIP treated pOGS40
or pMA5620 vector and naTH{BamHI) or naTH (BamHI) insert at molar ratios of
insert : vector of approximately 1:1, 5:1, 10:1, and 15:1. Vector, insert and SDW
were added and the mixture was heated to 65°C, then snap cooled on ice before
addition of ligase buffer and enzyme. The ligation reactions were incubated
overnight at room temperature. 3|ll or 7(J.l of each ligation was used to transform
competent E.coli JM83. Transformants were selected by plating onto LB
agar/150pg/ml Amp. Colonies which had grown up overnight incubated at 37°C
were picked onto duplicate LB agar/150pg/ml Amp. plates and screened by colony
hybridisation on Nylon filters probed with 32P labelled gp46INS (Appendix III).
Blot positive clones were inoculated into 6ml of LB/150|lg/ml Amp. Plasmid
mini-preps were made, resuspended in TE/RNase, and the desired clones were
identified by electrophoresis of plasmid samples digested with BamHI, PstI or EcoRI
alongside digested pOGS40 or pMA5620.
3.2.3: Verification of vectors for expression of EV1 gp46 in yeast
Large scale plasmid preparations (Appendix II) were made of the three
clones selected to use for transformation of yeast.
2|ig of each of the three plasmids was digested with BamHI, PstI or EcoRI in
a total volume of 20(0.1. 4p.l of each digest was electrophoresed alongside control
digests of pMA5620 or pOGS40. The gels were Southern blotted onto nitrocellulose
and probed with 32P labelled gp46INS (Appendix III).
The plasmids were sequenced (Appendix IV) across the TyA:gp46 junction
using ~0.5pmole of primer 098G (sequence: CAG GAG AAA TCC GAG TG ) to
anneal to -lpmole (~6pg) of double-stranded plasmid template.
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Expression of EV1 gp46 in veast
3.2.4: Transformation of Yeast with Expression Vectors
Protease deficient yeast, strain BJ2168 (a, leu2=, trpl-, ura3-52, prbl-1122,
pep4-3, pcrl-407, gal2) was transformed with pEVlTH.O by a Lithium acetate
transformation method (Appendix V). Transformants, designated BTH.O, were
grown up on SC-Glc agar plus tryptophan and uracil. BTH.O cells were again made
competent (Lithium acetate method) and transformed with pUGS41 to become uracil
and leucine independent. Doubly transformed cells were designated BTH.U.
Subsequently BJ2168 was transformed by a spheroplast method. (Appendix
V). Briefly, the yeast cell wall was digested off using the enzyme glusulase and 5|ig
or 10|ig of plasmid DNA was added, with or without lOpg salmon sperm DNA as
carrier. Cells which had taken up the plasmid DNA were selected by growth in
regeneration agar plus tryptophan and uracil for singly transformed cells or plus
tryptophan only for double transformants. BJ2168 transformed with the pMA5620
derivative pEVlTF.A were designated BTF.A. Similarly cells transformed with the
pOGS40 derivative pEVlTF.O were designated BTF.O. Double transformants with
both pEVlTF.O and pUGS41 were designated BTF.U.
Four colonies of each type of transformant, i.e. BTF.A, BTF.O and BTF.U,
were taken from the regeneration plates and streaked onto SC-glc agar plates with
appropriate amino acid(s) added.
3.2.5: Preparation of yeast crude cell extract
A single colony from each streaked plate was used to inoculate 50ml of SC-
glc medium plus amino acid(s), and incubated at 30°C with shaking. After 45 h The
OD600 of each culture was measured to estimate cell density using the relationship
that OD600 1.0 is equivalent to approximately 3xl07 cells/ml. Stocks were stored
down by taking 1ml aliquots, adding an equal volume of 40% glycerol in SC-glc and
freezing at -20°C for 1 hour then at -70°C.
To prepare crude cell extract approximately 5xl08 cells were spun down
(1500rpm for 5 min) and resuspended in 1ml TEN (Appendix V). lg of acid washed
glass beads was added and the cells were disrupted by whirlimixing for three one
minute periods with one minute cooling on ice in between. Samples were analysed
by SDS PAGE and Western blotting (Appendix VI).
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3.2.6: Comparison of protein production from double or single transformed
yeast
Single colonies of BTF.O.6.1 and BTF.U.8.2 were inoculated into 100ml of
SC-glc plus uracil and tryptophan or SC-glc plus tryptophan, respectively, and
grown at 30°C with shaking. After 2 days aliquots of approximately 5xl08 cells
were resuspended in 50ml SC-glc/gal plus amino acid(s), and incubated at 30°C with
shaking. After various times the OD600 was measured, and crude cell extract was
prepared. Samples were analysed by SDS- PAGE and Western blotting (Appendix
VI).
3.2.7: Large scale preparations of pl-fusion protein
Large scale preparations of pl-fusion proteins from BTH.U or BTF.U were
made. Incubations were at 30°C with shaking and media contained added tryptophan
at 40mg/l. One glycerol stock was inoculated into 100ml of SC-glc and incubated
until the cell density had reached 2-4xl07 cells/ml. The culture was divided into two
21 flasks containing 11 of pre-warmed SC-glc. After 24 h incubation the cells were
harvested in 250ml Beckman bottles in a J2-21 rotor at 5000 rpm for 5min at 4°C.
The cells were washed three times with SDW and once with TEN. To the cell pellet
an equal volume of TEN plus protease inhibitors and of acid-washed glass beads was
added. The mixture was vortexed for at least ten 30 second periods interspersed with
cooling on ice then centrifuged for 5 min at 3000 rpm, 4°C. The supernatant was
retained. 4ml of buffer (TEN plus protease inhibitors) was added to the pellet.
Vortexing and centrifugation was repeated and the supernatant was retained. 3ml of
buffer was added to the pellet and the mixture was vortexed a further four times,
centrifuged and the supernatant retained once more. Cell breakage was evaluated by
adding a drop of the cell pellet to a drop of water and looking for lysed cells by
phase'contrast microscopy. If lysis was less than 70%, further rounds of vortexing
etc. were continued. Pooled supernatants were centrifuged at 9K for 20 min to pellet
cell debris and whole cells. The supernatant was transferred to a Beckman SW40
tube, underlaid with 2ml 60% sucrose in TEN, and centrifuged for 1 hour at 30K in a
Beckman ultracentrifuge (SW40 rotor). The sucrose cushion and the layer
immediately above were collected and dialysed overnight against TEN. The
dialysate was microcentrifuged for 15 min at 4°C and the supernatant was carefully
loaded on top of a 15-45% sucrose gradient (prepared as 10ml layers of 15%, 25%,
35%, and 45% sucrose in TEN, left at 4°C overnight, and underlaid with 3ml of 60%
sucrose just before use). After 3 h centrifugation at 25K, 4°C, the gradient was
harvested into 2 ml fractions. Fractions containing pl:fusion VLPs were identified
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by running 5pl aliquots on SDS-PAGE, and were pooled and dialysed against PBS
before use or storage at -20°C.
3.2.8: Preparation of yeast for electron microscopy (Adapted from the method of
Byers and Goetsch, 1975)
One glycerol stock of BTF.U.8.2 was inoculated into 100ml of SC-glc plus
trp and incubated at 30°C with shaking for 20 h until until an OD600 of 0.7 was
reached. 30ml was added to 100ml SC-gal plus trp. and 20ml was added to 100ml of
SC-glc plus trp. After 6 h and 22 h 25ml of culture was harvested at 4°C,
resuspended in 5 ml cacodylate buffer (3% gluteraldehyde, 0.1M cacodylate pH6.8,
5mM CaC^) and incubated at room temperature for 30 min. Cells were pelleted,
resuspended in 10ml cacodylate buffer and mixed overnight at 4°C on a rotator.
Cells were washed twice with 10ml pre-treatment buffer (0.1M mercaptoethanol,
0.02M EDTA, 0.2M Tris-Cl pH8.1) and resuspended in 5ml citrate-phosphate buffer
( 0.04M citric acid, 0.06M Na2HPC>4, pH to 5.8 with NaOH) containing 250(0.1 of
glusulase. Following 1 h incubation at 30°C, spheroplasts were washed twice in 10
ml citrate-phosphate buffer and finally resuspended in 5ml citrate-phosphate buffer.
Cells were treated for 60 min in 2% osmium tetroxide, rinsed with water then treated
with 2% aqueous uranyl acetate at 20°C for 60 min. The cells were then dehydrated
and embedded in resin. Blocks were sectioned using a microtome and the sections
were fixed to grids for viewing by EM.
Cultures of untransformed BJ2168 were also grown up in a similar manner
(except leu, trp and ura was added to media) and cells were prepared for EM.
3.2.9: Negative staining of VLPs for EM
A drop of VLP preparation, at a concentration of ~300pg/ml was placed on
an EM grid and left for 15 seconds. The edge of a piece of Whatman 1 paper was
used to draw off most of the liquid. The grid was washed three or more times by
adding a drop of SDW to the grid then drawing the water off with paper. A drop of
2% uranyl acetate in SDW, (filtered through a 0.22 pm filter and stored in the dark at
-20°C and microcentrifuged for 5 min immediately prior to use), was added to the
grid and then most of the liquid was drawn off. The grid was placed on filter paper
to dry, then stored at room temperature prior to EM.
3.2.10: Transformation of yeast strain MC5
Diploid yeast strain MC5 (homozygous prb-1, prc-1, pep-4, trp-1, leu-2, ura-
3) was transformed with plasmids pTF.O, pTF.O and pUG41S, or pTH.O and
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pUG41S for expression of pl-fusion proteins. Transformation was by the
spheroplast method, using 5|ig or 10(ig of each plasmid with or without 10(lg of
salmon sperm DNA as carrier. Transformed yeast were selected initially in
regeneration agar with tryptophan (single transformants) or tryptophan and uracil
(double transformants) (Appendix V). After several days incubation at 30°C
colonies were picked and streaked onto SC-glc agar plus amino acid(s).
MC5 transformants were validated for production of pi or pl-fusion protein
by running samples of crude lysate on SDS-PAGE. Nomenclature was assigned to
the MC5 transformants in a similar way to the BJ2168 transformants e.g., cells
transformed with TF.O were designated MTF.O, cells transformed with pTF.O and
pUGS41 were designated MTF.U.
3.2.11: Growth curves of induced MC5 transformants
A colony from an SC-glc streaked plate was inoculated into 50ml SC-glc
plus trp or trp/uracil and incubated for 48 h at 30°C with shaking. The ODgoo was
measured and approximately 3 x 108 cells were pelleted and resuspended in 50ml
SC-gal plus trp or trp/uracil. Incubation at 30°C with shaking continued and the
OD600 of each culture was measured at intervals over 28 h.
3.2.12: Large scale preparation of pl-fusion protein from MEV1TF.U
pl:TF was prepared from 81 of induced MTF.U using the method described
above.
3.2.13: Factor Xa protease digestion of pl:TF
Factor Xa protease was added at ratios of 1:10, 1:20, 1:40 and 1:80 w:w
enzyme:total protein in buffer to give a final concentration when added to the
substrate of lOmM CaCl2, lOOmM Tris pH7.5, 0.05% CHAPS, 0.05% DOC.
Samples were taken after 1, 2, 4, 8, and 21 h incubation at 25°C. 10(0.1 of each was
run on SDS PAGE and detected by silver stain.
Subsequently pl:TF was digested at a ratio of 1:25 Factor Xa protease:total
protein at 25°C for 16-24 h.
3.2.14: Production of polyclonal rabbit serum against pi or pl:TF
Rabbit R194 was immunised i/m with ~100|ig of pi protein in complete
Freunds adjuvant (CFA) and boosted after 2 weeks with 100(lg of pi in incomplete
Freunds adjuvant (IFA). Rabbit R193 was immunised i/m with material derived from
induced BTF.U containing ~ 100|ig of pl:TF (~250|ig total protein) in CFA and
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boosted after 2 weeks with the same preparation in IFA. 5ml of blood was taken
from each rabbit 2 weeks after the boost.
Pre-immune and post-inoculation sera were reacted, at 1:500 dilution, against
Western blots of pi, pi :TF and Factor Xa digested pl:TF. (l|ig of antigen per track
of a 10% acrylamide reducing gel, blotted onto nitrocellulose) (Appendix VI)
3.2.15: pltSepharose column
6mg of pi was dialysed against four changes of 0.1M Sodium Bicarbonate
pH9, 0.5M NaCl. 0.7g of Cyanogen bromide activated Sepharose 4B was swollen in
ImM HC1 in a sintered glass funnel, pi protein was added to the Sepharose and
mixed on a rotator overnight at 4°C. The coupled Sepharose was recovered by
centrifugation at lOOOrpm for 5 min. The protein concentration of the supernatant
was measured by Biorad protein assay to check coupling efficiency. The Sepharose
was rotated in 1M ethanolamine for 3 h, then washed with BBS and allowed to settle
in a 1cm diameter column. The column was pre-eluted with 0.1M glycine pH2.7
then equilibrated with BBS. 1ml of serum (pH7-8) was loaded and the flow through
collected and loaded through the column once more. 0.5ml fractions were collected.
The column was washed with BBS and fraction collection was continued until the
effluent was clear. The column was washed extensively before antibodies bound to
the column were eluted with 10ml 0.1M glycine pH2.7. 0.5ml fractions were
collected into tubes containing 30(ll 2M Tris pH9 to neutralise the glycine. The
OD280 of each fraction was measured. Peak fractions were pooled and dialysed into
PBS. The column was washed extensively with BBS before reuse.
Activity of the sera, pooled fractions and column flow-through was measured
by ELISA, (Appendix VII), against plates coated with 70|ll per well of 10p.g/ml pi
or 10(ig/ml pl:TF (~25|ig/ml total protein). The same samples were also reacted
against pi, pl:TF, pl:TF digest and BJ2168 crude lysate on Western blots.
3.2.16: Western blots with sera from MVV infected or uninfected sheep
Sera from sheep infected with MVV or from uninfected sheep were reacted




3.3.1: Construction of plasmids for expression of recombinant EV1 gp46 in the
veast Tv-VLP system
The aim of this work was to express recombinant EV1 transmembrane
glycoprotein in yeast as a fusion protein with pi. A 43kDa polypeptide fused to pi
has been expressed without disrupting VLP formation (Bums et al., 1992) so the size
of gp46 was not expected to present a problem, but due to the possibility that the
hydrophobic nature of gp46 might have interfered with assembly into VLPs two
different products were made; one to encode full length EVl-gp46, bases 1-990,
(TF), the other to encode the external domains of gp46, bases 1-530, (TH). Inserts
suitable for ligation into pOGS40 or pMA5620 were modified from the EV1 gp46
clones in pTZ using PCR. As shown below additional bases were included in the
PCR primers in order to add BamHI recognition sites at either end of the coding
sequences to make cloning into theses plasmids easier and an Xa protease cleavage
site was added at the 5' end to enable cleavage of the fusion protein product from pi.
3.3.2: PCR primers for expression of Vl-gp46 in the Ty system
096G- (5' primer)
G GGA TCC ATA GAA GGT AGA TGT GGG ATA GGC TTG GTG ATA GT
[ BamHI ][ Factor Xa ][ 5' gp46 ]
097G- (3' primer for full length construct, TF) :
GGA TCC TCA ATT CTC AAT CAT GGG CAT CTG
[ BamHI ][Stop][Complementary to gp46 bases 970-950]
095G- (3' primer for external half of EVl-gp46 construct, TH):
G GGA TCC TCA TTT CAA CCA TGC GAA CCA TCC TGC
[ BamHI ][Stop][ Complementary to gp46 bases 529-506 ]
Using pCC18.9 as template primers 096G and 097G amplified a product,
(TFna), of about lkb representing 1-990 of the gp46 insert described in Chapter 2.
Primers 096G and 095G amplified bases 1-530 of the gp46 insert, (THna). Initial
attempts to ligate BamHI treated PCR products directly into the BamHI site of either
plasmid proved unsuccessful. The PCRs only produced a low yield perhaps because
the additional bases on the PCR primers made them sub-optimal. Ligation into the
yeast expression plasmids was predicted to be less efficient than into pTZ18R or
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pTZ19R because of the larger size, so to increase the yield of naTH and naTF it was
decided to first ligate the PCR products into pTZ18R. Additional primers were
added for the final few PCR cycles to try to maximise the amount of product with
completed ends for ligation. Two clones were selected; pF102.7 and pH103.11
consisting of TF and TH PCR products, respectively, blunt-end ligated into the
HincII site of pTZ18R. BamHI was used to retrieve the inserts from these plasmids,
and the gel purified inserts were then ligated into BamHI cut, CIP-treated pOGS40
or pMA5620. Cloning the PCR products via pTZ18R not only enabled a larger
amount of insert DNA to be prepared for ligation into pMA5620 or pOGS40 but also
fortuitously circumvented a problem that had not been recognised at the time,
namely that restriction enzymes do not cut efficiently at sites very close to the ends
of PCR products.
Recombinant Ty vectors were selected initially by colony hybridisation.
Plasmid mini-preps were made from blot positive clones and restriction digested to
check the size and directionality of the insert in any positive clones (Figure 3.1).
There was quite a high rate of carry over of pTZ18R plasmids demonstrating the
inefficiency of gel purification of the inserts. Any pTZ18R in the ligation reaction
was not CIP treated and would therefore readily religate and also more easily
transfect competent cells than the larger plasmids (Hanahan, 1983). As shown in the
predicted restriction maps of the plasmids (Figure 3Ad)BamHI digestion could be
used to confirm the size of the insert, EcoRI digestion allowed pOGS40 and
pMA5620 plasmids to be distinguished, and PstI digestion determined the
orientation of the insert.
Three plasmids were selected for expression in yeast ;. plasmid pTF.O
(insert encoding MVV-EV1 transmembrane protein (full-length) in pQGS40),
plasmid pTF.A (full-length insert in pMA5620), and plasmid pTH.O (half-length
insert in pQGS40).
Restriction digests of these plasmids and Southern blots probed with
gp46INS (Figure 3.1), agreed with the predicted results and verified the choice of
plasmid. Double stranded sequencing through the TyA:TH or TyA:TF junction
region of each of the three correctly orientated constructs confirmed the BamHI and
Xa protease recognition sequences were intact and that the insert was in the same
reading frame as the pi encoding sequence (Figure 3.2).
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Figure 3.1: Restriction fragment analysis of Ty-based expression constructs.
Plasmid DNA extracted from clones 2C6 (pTH.O ), 2C2 (pTF.A), and 7A5
(pTF.O) were digested with BamHI, PstI or EcoRI, and were electrophoresed
alongside restriction digested control plasmid in order to confirm the size and
directionality of the insert. As a further check Southern blots were made and
hybridised with gp46INS (the insert from pCC18.9 described in Chapter 2). PCR
products naTH and naTF were included as positive controls.
The predicted restrictrion fragment sizes are shown below. Those shown in
bold type would contain gp46 sequence and therefore should hybridise with the
gp46INS probe. Fragments shown in bold with a * only contain 50 or 66 bases of
gp46 and therefore would be expected to hybridise only weakly, if at all.
Predicted restriction fragment sizes of Ty constructs





Restriction fragment size (kb)
6.55,2.87 5.02,2.55,1.1,0.75
6.55,2.87 6.12,2.55,0.75
pOGS40+ TH insert 9.42, 0.5
(correct orientation)










pOGS40 + TF insert 9.42, 0.97
(correct orientation)










pMA5620 + TF insert 9.42, 0.97
(correct orientation)










d) shows plasmid maps of the constructs.
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a). pTH.O (p()GS40:THinsert)
i) Electrophoresis of restriction fragments ii) Southern blot of i)
b). pTF.A (pMA5620:TFinsert)
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Figure 3.2: Sequence of Vl-gp46/Ty constructs through the insert site.
Xa protease
TyA BamHI recognition EVl-gp46 coding sequence
. . . ACCCAAGCCGGATCCATAGAAGGTAGATGTGGGATAGGCTTGGTGATAGTGCTCGCTATCAATG. .
5' primer for TH and TF
3.3.3: Transformation of veast and expression of d! fusion proteins.
The first of the expression plasmids constructed was pTH.O. This was used
to transform Saccharomyces cerevisiae strain BJ2168 and create clone BTH.O.
BTH.O was transformed with helper plasmid pUG41S to create clone BTH.U. The
same S. cerevisiae strain was transformed with pTF.O, or pTF.A, but by a
spheroplast transformation method. Selection of transformants was by growth in
regeneration agar with tryptophan (trp) and uracil (ura) added, but not leucine, and
transformed clones were named BTF.O and BTF.A respectively. Double
transformants with both pTF.O and pUGS41, (called BTF.U), were made and
selected by transformation to leucine and uracil independence in regeneration agar
plus tryptophan.
3.3.4: Results of spheroplast transformation
Spheroplast transformation with pTF.A resulted in numerous very small colonies.
The size was at first thought to be due to competition by too many colonies.
Transformation with pTF.O resulted in hundreds of colonies whilst double
transformation with TF.O and pUGS41 together was less efficient producing 10-44
colonies per plate.
As illustrated in Figure 3.3, when streaked onto SC-glc agar plates with
appropriate amino acid(s) added, the BTF.O and BTF.U transformants had grown up
to give single colonies of about 2mm diameter in 2 days, whilst the BTF.A colonies
were still barely visible.
The pMA5620 derived construct, pTF.A had a constitutive promoter whilst
the pOGS40 derived construct had a promoter inducible by galactose, so the fact
that the BTF.A yeast clones did not grow well suggested immediately that
expression of the pl:TF fusion protein might be toxic to the yeast. This was backed
up by observation of BTF.O and BTF.U cells after galactose induction in liquid
medium. Examination of the cells under a phase contrast microscope showed that
initially normal budding cells were visible in the cultures but several hours after
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Figure 3.3: Growth of transformed yeast strains on solid medium
Single colonies of yeast BJ2168 transformed with vectors for the expression of
pl:gp46 (TF), as shown below, were streaked out onto SC-glc agar plus appropriate
amino acids and incubated at 30°C for 44 hours.
The photographs illustrate the variation in growth rate between the different
transformed clones.
a) BTF.O 5.1 (transformed with pTF.O)
b) BTF.U 8.1 (transformed with pTF.O and pUGS41)
c) BTF.A 1.2 (transformed with pTF.A)
d) BTF.O 6.1 (transformed with pTF.O)
e) BTF.U 8.2 (transformed with pTF.O and pUGS41)
f) BTF.A 2.1 (transformed with pTF.A)
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transfer to galactose-containing medium there were many swollen cells which
appeared large and dark by phase contrast. The proportion of 'bloated' cells
appeared to be greater in the double transformants; 12 hours after induction BTF.U
cultures contained many large cells and a few phase bright dead cells, and after 24
hours very many large cells were visible but there were also very many dead and
clumped cells, whilst BTF.O cultures had fewer "sick" cells. Budding cells were
still present at 24 hours although some aberrantly shaped cells (oval or balloon
shaped) were also present at this time. BTF.U was also slower growing than BTF.O
in liquid culture; inocula of 107 cells/ml into SC-gal reached 3.3xl07 cells/ml for
BTF.O and 2.4x107 cells/ml for BTF.U. Cultures of four different clones of each all
produced very similar results.
3.3.5: Analysis of pl:fusion protein production
Crude whole cell extracts, made by breaking the cells open using glass beads,
were analysed by SDS-PAGE (Figure 3.4). Samples from wild-type BJ2168, BP1.A
(pMA5620 transformed BJ2168), and a transformant which produces pl:p25gag
(gifted by H.T.Reyburn) were run alongside as controls. One gel was stained with
Coomassie, the other was blotted onto nitrocellulose. The blot was reacted with
anti-pl polyclonal rabbit serum. By comparison with extract from pMA5620
transformed cells, samples from each transformant show an upwards shift in size
compatible with the predicted sizes of the pi fusion products pl:TF (81KDa) and
pl:TH (63KDa) as compared with pi alone (43KDa). (Note that pi migrates with
an apparent molecular weight of 55-60kDa in this gel system. This is consistent
with previous data (Adams et al., 1987)). On Coomassie stained gels of the same
preps no clear band corresponding to the fusion product is visible. This indicates
that the recombinant protein is not produced at high yield. The blots show that pi
protein was produced endogenously by untransformed yeast and that in the
transformed yeast strains pi was present pre-induction but at low levels.
None of the strains of BTF.A produced any detectable pl-fusion protein, but
produced only pi, equivalent to that made by wild-type untransformed BJ2168
(Figure 3.5). As the BTF.A strains did not grow well on agar it is likely that they
also did not grow well in liquid medium . It may have been that the cells which did
grow had lost the insert from the plasmid which would account for detection of only
wild-type pi. (This could have been checked either by trying to recover plasmid
from the yeast or more simply by Southern blotting of DNA from the yeast).
Another explanation could be that a stop codon had been introduced near the start of
the gp46 coding region.
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Figure 3.4: Analysis of cell extracts from transformed yeast strains
a) Coomassie-stained SDS-PAGE gel
5(il samples of crude yeast lysate were analysed by SDS-PAGE.
b) Western blot
lOjJ.1 samples of crude cell lysate were run on a 1% polyacrylamide SDS-PAGE
gel which was blotted onto nitrocellulose. The blot was reacted with polyclonal anti-
pi rabbit antiserum followed by goat anti-rabbit AP conjugate.
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Figure 3.5: Analysis of BTF.A yeast strains
a) Coomassie-stained SDS-PAGE gel
5(il samples of crude yeast lysate were analysed by SDS-PAGE.
b) Western blot
10(il samples of crude cell lysate were run on a 1% polyacrylamide SDS-PAGE
gel which was blotted onto nitrocellulose. The blot was reacted with polyclonal anti-





3.3.6: Comparison of protein production between BTF.O and BTF.U
BTF.O and BTF.U cells grown up in SC-glc media and transferred into SC-
gal plus amino acid(s). After various incubation times crude cell extract was
prepared and analysed by SDS-PAGE (not shown) and by Western blotting (Figure
3.6). The Coomassie stained gels show that the loading was approximately equal on
both gels. However, the blot of BTF.O is clearly less dark than the blot of the
doubly transformed BTF.U, indicating that the yield of recombinant protein was
greater in the latter strain. The amount of pl:TF appears to peak at about 12 hours
after induction in strain BTF.O but peaked earlier in strain BTF.U. On the Western
blots of BTF.U reactivity was saturated after 8 hours, so the concentrations can not
be compared in this way. There is no evidence of a reduction in the amount of
pl:TF at 24 hours or beyond which would indicate spontaneous breakdown of the
product, however, 18 hours was chosen as the optimal time for harvesting induced
cultures because less dead and dying cells were seen at this time compared to at 24
hours.
Little or no pl:TF was produced pre-induction in BTF.O but it was produced
in uninduced BTF.U suggesting that the gal4 promoter on the pUGS41 promoter is
leaky.
3.3.7: Large scale preparation of pl:TF from BTF.U
Production was scaled up in order to purify recombinant protein. Briefly, 11
galactose-induced cultures were harvested and the cells lysed with glass beads. Cell
debris was pelleted and the supernatant was centrifuged onto a 60% sucrose cushion.
The VLP containing fraction spanning the interface with the sucrose cushion was
collected, dialysed to remove the sucrose and then centrifuged through a 15-45%
sucrose gradient.
Collection of gradient fractions and analysis by SDS-PAGE (Figure 3.7)
showed that the pl:fusion protein did not band tightly in the gradient but was spread
over most fractions. Most pl:fusion proteins do not band tightly and different
pl:fusion proteins tend to band at different densities in the gradient. The amount
and the purity of the protein obtained varied between individual large scale preps. A
number of factors could have played a part in this e.g. the percentage cell lysis
acheived can significantly affected the yield. The state of the sucrose gradient would
also have been important in separating contaminant proteins away from the fusion
protein. However the use of a stepped gradient rather than a semi-continuous one
made little difference to the spread of pl:TF across many fractions (results not
shown).
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Figure 3.6: Comparison of P1:TF fusion protein production between BTF.O
and BTF.U
To show the effect of co-transformation of pTF.O with or without pUG41S
Western blots were made of crude extracts from samples taken at intervals following
galactose induction of pl:TF expression in transformed yeast strains BTF.O and
BTF.U.
Samples were subjected to (10% polyacrylamide) SDS-PAGE and blotted onto
nitrocellulose. The blot was reacted with polyclonal anti-plrabbit antiserum
(1:2000) followed by goat anti-rabbit IgG:AP conjugate (1:1000).
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Induction time (hours) <
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Figure 3.7: Fractions from sucrose gradient purification of pl:TF fusion
protein
a) Coomassie-stained SDS-PAGE gel
20|il of samples of fractions from sucrose density gradient centrifugation were
analysed by (10% polyacrylamide) SDS-PAGE. 1ml fractions were collected
numbered beginning from the top of the gradient.
b) Western blot
Duplicate gels to the ones shown in a), above, were blotted onto nitrocellulose.
The blot was reacted with polyclonal anti-plrabbit antiserum (1:2000) followed by
goat anti-rabbit IgG:AP conjugate (1:1000).
(Note that the lanes in the western blot are shown back-to-front relative to the
Coomassie stained gel).
c) Final product of large scale preparations of pi and pl:TF
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c) Final products of pi and pl:TF large scale preps.
Coomassie stained SDS-PAGE gel.
BPl.A BTF.U
pl:TF was never obtained at high yield in any of the fractions and as a
consequence the relative amount of contaminating proteins was very high. Other pi
fusion proteins produced in this laboratory at much higher yield tended to contain
almost as much contaminant protein in real terms but far less relative to the amount
of pi fusion product. The pi preparation from BP1.A, (BJ2168 transformed with
pMA5620), also contained contaminating proteins. A major contaminating band in
the pl:TF preparation at ~43kDa may represent endogenous VLPs, but as the same
band is not present in the pi preparation this band may instead be a protein which
associates with pl:TF.
The western blot (Figure 3.7b) reacted with anti-pl serum suggests pi at
many molecular weights. This may be due to induction of antibodies to
contaminating yeast proteins in the pi preparation used for immunisation.
Proteolysis or instability of the fusion protein cannot be ruled out, although protease
inhibitors were included during the preparation to try to limit proteolysis.
A large scale VLP preparation from 101 of induced BTF.U gave a total yield
of approximately 5mg protein of which less than 20% was pl:TF, the rest being
contaminant yeast proteins. Large scale preparation of pl:TH gave a similar yield
and purity. In contrast strain BP l.A yielded over lOmg of pi per litre.
As the yield of pl:TH was not noticeably better than the yield of pl:TF it
was decided to use the latter for the subsequent studies.
3.3.8: Visualisation of VLPs by electron microscopy
Electron micoscopy of the pl:TF product confirmed the formation of virus¬
like particles. (Figure 3.8) These were much more heterogeneous than VLPs formed
by pi alone.
Electron micrographs of whole yeast cells expressing pi protein often show
the cytoplasm to be absolutely full of VLPs. By contrast it was very hard to find
anything resembling VLPs in the yeast cells expressing p 1 :TF. Many of the cells
had vacuoles in their cytoplasm, a condition which is often seen in unhealthy cells.
Particles in the vacuoles had the appearance of VLPs but untransformed BJ2168
grown in galactose for a similar length of time contained similar particles in their
vacuoles. The only things resembling VLPs in induced BTF.U cells but not in
uninduced or untransformed controls are arrowed in Figure 3.8. These appear in the
cytoplasm and seem to be of a similar size and structure to the purified particles seen
in Figure 3.7, and to published EMs of yeast cells expressing hybrid VLPs. These
putative VLPs were visible in only a few BTF.U cells, and very few were present in
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Figure 3.8: Electron micrograph of pl:TF preparation
A sample of the product of a large scale preparation of pl:TF was negatively
stained with uranyl acetate in order to visualise VLPs by electron microscopy.
Magnification: x 60 000
Figure 3.9: Electron micrographs of yeast cells
a) BTF.U cell prepared for EM after 22 hours culture in (SC-gal plus trp).
Possible pl:TF VLPs are shown by an arrow.
Magnification: x 60,000





each cell. In contrast, the cytoplasm of transformed yeast expressing pi as a fusion
with visna-EVl gag protein, was packed with VLPs when examined by EM and
pl:gag protein could be purified from them at a yield of 2 mg from 11 of cells
(Personal communication H. T. Reyburn).
The scarcity of VLPs in induced BTF.U cells may explain why the yields of
pl:TF acheived from large scale preparations were so low despite the fact that the
cells were expressing pl:TF as detected by analysis of crude lysate. Consideration
of Figures 3.8 and 3.9 demonstrates the efficiency of the large scale preparation
method to purify the small number of VLPs present.
3.3.9: Transformation ofS. cerevisiae strain MC5
MC5 is a homozygous diploid strain (prb-1, prc-1, pep-4, trp-1, leu-2, ura-3)
of S.cerevisiae. It was hoped that the larger diploid cells might be able to withstand
the apparent toxicity of the recombinant proteins better than strain BJ2168 and
therefore improve the yield of protein.
The spheroplast transformation method was used to transform MC5 yeast
with pOGS40, pOGS40 and pUGS41 together, pTF.O, pTF.O and pUGS41 together,
or with pTH.O. Transformed strains were named MPl.O, MP1.U, MTF.O, MTF.U
and MTH.O, respectively. Western blotting of crude lysates (Figure 3.10) confirmed
that recombinant proteins were being produced. Coomassie-stained SDS-PAGE gels
again indicated the level of production to be low, even though the MC5 transformant
cells did look more healthy following induction than their BJ2168 counterparts.
Cell division of the MC5 transformants following galactose induction was
monitored by measuring the OD600 of culture at intervals following transfer of the
cells into SC-gal (Figure 3.11). As the strain cannot utilise galactose, growth would
be expected to slow down once the amount of glucose available became limiting. In
the strains producing pi the OD600 at least doubled before levelling off after about
24 hours. The ODgoo of the cultures expressing recombinant gp46 did not even
double and levelled off rapidly following induction. The strain potentially producing
the most pl:TF, i.e. MTF.U stopped growing most quickly.
From these growth curves, and taking into account the low yields of
recombinant proteins produced compared to the yield of pi, it may be concluded that
full-length MVV EV1 transmembrane protein (TF) is toxic to yeast cells and that the
half-length product (TH) is also toxic but to a slightly lesser extent.
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Figure 3.10: Analysis of cell extracts from transformed MC5 strains
a) Coomassie stained SDS-PAGE gel
4jil samples of crude cell lysate from MC5 transformants grown in SC-glc
(uninduced) or in SC-gal (induced) were analysed by SDS-PAGE.
b) Western blot
A western blot of samples of crude extracts, as above, was developed with
1:2000 dilution of rabbit anti-pl serum and and 1:2000 dilution of goat anti-rabbit
alkaline phosphatase conjugate.
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Figure 3.11: Growth curves of MC5 transformants in galactose containing
medium.
Log phase cultures of transformed MC5 yeast strains in SC-glc medium were
used to inoculate SC-gal medium to give an initial concentration of approximately
1.7 x 107 cells /ml. The growth of each strain was followed by measuring the OD600
at intervals over the 28 hours following transfer to SC-gal medium.
Time (hours) from shift into SC-gal
3.3.10: Factor Xa digestion of pi:TF
Initial experiments suggested many sheep sera tested on western blots reacted
with pi and with pl:TF therefore it was desirable to separate the TF component from
pi in order to screen sera from MVV-infected sheep against recombinant gp46.
(However, in retrospect, the amounts of antigen used in these blots was too high and
may have resulted in false positives).
pl:TF was incubated with the protease Factor Xa at various ratios of enzyme
to substrate for various incubation times. Western blots of digested pl:TF developed
with anti-pl sera (Figure 3.12) showed a size shift back to that of pi, indicating that
pl:TF was being cleaved. The amount of pl:TF detected decreased whilst pi
increased with higher concentrations of Factor Xa and longer incubation times.
Cleaved TF was expected to be approximately 38kDa in size. Unfortunately,
it was not possible to identify a band corresponding to cleaved TF on a Coomassie or
silver stained gel due to the other contaminants in the pl:TF preparation. No
antibody against MVV gp46 was available to identify TF by Western blot.
However, two out of six sera from MVV-infected sheep tested did react with a
protein band of approximately the predicted size for cleaved TF (Figure 3.13); sera
ShM7 and ShM19 both reacted with a band running just ahead of the 36kDa marker
in the track of Factor Xa-digested pl:TF but not in any other track. Normal sheep
sera did not react with this band. The seropositivity of the six MVV-infected sheep
was confirmed by their reactivity with various EV1 proteins especially bands
indicative of p25 and gpl60.
Unfortunately the gel shown in Figure 3.13 had run too far to illustrate that
the polyclonal rabbit anti-pl:p25 serum reacts with MVV-EV1 p25. The serum also
reacts strongly with pi. However only a faint band representing pi is visible in the
pi and Factor Xa digested pl:TF tracks and no pl:TF band is visible in either the
digested or undigested track. This shows that the amount of antigen used for these
blots was low. This adds credence to the specificity of the putative TF band which
reacted with S30 and S31.
Ideally TF protein would have been purified, following digestion with Factor
Xa, by spinning down the VLPs leaving cleaved off recombinant protein in solution.
However, with the extremely low amount of TF present, even before digestion, it
was not possible to recover acceptable amounts.
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Figure 3.12: Factor Xa protease digestion of pl:TF
pl:TF was incubated with four different concentrations of Factor Xa.
Samples were taken after 1, 2, 4, 8, and 21 hours and analysed by SDS-PAGE (10%
acrylamide) and western blotting. Mock-digested pi and pl:TF were included as
controls.
a) Western blot
The blot was developed with 1:200 rabbit anti-pl serum and 1:1000 goat anti-
rabbit -AP conjugate.
b) Silver stained SDS-PAGE gel
The pl:TF digests shown here were incubated with Factor Xa at a ratio of
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Figure 3.13: Western blots of pi, pl:TF and EV1 developed with sheep sera.
Antigen: l:pl:TF
2: pi :TF after Factor Xa digestion
3: pi
4: EV1 antigen prepared from infected cells in vitro.
Western blots of the antigens listed above were developed with 1:100 dilution of
sheep serum and 1:2000 anti-sheep-AP conjugate, or 1:500 rabbit serum followed by
1:2000 anti-rabbit-AP conjugate.
Sheep ShM were infected with MVV. Normal sheep ShU were uninfected controls.
The rabbit had been immunised with recombinant pl:p24 (MVV gag) protein.
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3.3.11: Immunisation of rabbits with pi or pl:TF
Rabbits R194 and R193 were immunised with pi and pl:TF, respectively.
The preparations used for immunisation were from large scale preparations, as
shown in Figure 3.7c. Serum collected before and after immunisation was tested
against pi and pl:TF on Western blots (Figure 3.14) and by ELISA (Figure 3.15).
R194 sera reacted with pi on Western blots, but R193 had little reactivity
against pi or pl:TF (Figure 3.14 and Figure 3.15 where a greater amount of antigen
was used). Pre-immune sera had low levels of activity against a number of yeast
proteins. Surprisingly pre-immune R193 serum reacted against a band similar in
size to pl:TF in the BTF.U crude extract track but no similar reactivity was seen
against BJ2168 crude extract or against the pl:TF preparation. Immunisation
increased the response to several proteins including pl/pl:TF. However it was not
possible to detect any activity against the TF component of Factor Xa digested
P1:TF.
To try to enhance the detectable anti-TF activity it was attempted to remove
as much as possible of the anti-pl component of the R193 serum by binding it to a
column of pi cross-linked to Sepharose. The pi affinity-purified antibody peak
eluent contained increased activity against pi as expected; bands representing pi and
pl:TF became more prominent on Western blots (Figure 3.15). The size shift of
Factor Xa digested pl:TF on this blot showed that pl:TF had been cleaved but that
the amount of antigen present was low. The column flow-through reacted with a
number of bands of smaller size than pi in the Factor Xa digested pl:TF track.
Although it is not certain which, if any, of these bands may represent TF protein a
likely candidate is the protein running just below the 36kDa marker which may be
the same band as was recognised by sera from MVV-infected sheep, ShM7 and
ShM19 (Figure 3.13).
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Figure 3.14: Western blots of pl:TF or pi developed with serum from rabbits
immunised with pl:TF or pi
Antigen :
1: pl:TF
2: pl:TF incubated with Factor Xa for 2 hours.
3: pl:TF incubated with Factor Xa for 22 hours.
4: pi
Rabbit R193 was immunised with pl:TF. R194 was immunised with pi. BBL
anti-pl rabbit serum was a gift from British Biotechnology Limited. Western blots
of the antigens listed above were developed with serum or pre-immune serum.
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Figure 3.15: Western blots: pl:TF antiserum (R193) against pl:TF
Antigen :
1: BJ2168 (untransformed) crude extract
2: BTF.U crude extract
3: pl:TF
4: Factor Xa treated pl:TF
Rabbit R193 was immunised with pl:TF. R193 serum was passed through a
pi:Sepharose column to try to separate anti-pl activity from other activities in the
serum. Western blots of the antigens listed above were developed with flow-through
or peak antibody eluent from the pi column or with R193 whole serum or pre-
































3.3.12: ELISA of serum from pl:TF immunised rabbit
Pre-immune serum from R193 was negative in ELISAs against pi or pl:TF
(Figure 3.15). After immunisation with pl:TF R193 serum showed positive
reactivity in the ELISAs. (A negative result was taken to be near background and a
positive ELISA was taken to be a reading of greater than twice background).
The results of R193 serum, of pi column flow-through and of the antibody
peak eluted from the pi-column in ELISA, with pi as antigen, were compared.
R193 serum had a titre of 1:400-1:800 against pi and flow-through had a titre of
1:200. There was no dilution factor to take into account, therefore 50-75% of the
anti-pl activity had bound to the column, whilst 25-50% remained unbound and was
present in the column flow-through. The peak was eluted in 1ml and the anti-pl titre
was 1:800 (but some dilution had occurred as antibody was also present in non-peak
aliquots). The anti-pl activity coming out of the column was thus greater than that
going in. This suggests the column was incompletely eluted during its previous use
and so some anti-pl activity was carried forward to this elution. As the same pi
preparation was used for the pl-Sepharose column and as antigen in the ELISA the
effect of the presence of small amounts of contaminating proteins should cancel out
and not alter the conclusions above.
The results of ELISA against pl:TF showed that passing the serum through
the pi column reduced the anti-pl:TF titre by a factor of about two. Even taking
into account that 25% or more of the anti-pl activity remained in the flow-through it
does appear that there was reactivity to proteins/epitopes in the pl:TF preparation
which were not present in pi preparation. This is backed up by the difference
between the results of the pi and pl:TF ELISAs; the titre of R193 serum was about
16 times higher against pl:TF than against pi and the titre of the flow-through was
also much higher against pl:TF than against pi. It was not possible to determine
from these results whether the activity was directed against TF or against
contaminating yeast proteins, particularly as the amount of pl:TF present in the
ELISA was shown to be lower than the amount of pi used for ELISA: the anti-pl
peak titred out at 1:200-1:400 against pl:TF compared to 1:800 against pi. As the
amount of total protein used was similar the result confirms what was already clear
i.e. that the amount of contaminating proteins in the pl:TF preparation was
considerably higher than in the pi preparation.
In summary, immunisation with pl:TF had induced detectable antibodies to
pi protein, and also to components found in the pl:TF preparation but not in the pi
preparation, although specific anti-TF activity could not be determined due to the
difficulties in preparation of TF.
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Figure 3.16: Results of ELISA of R193 serum against pi or pl:TF antigen
Twofold dilutions of serum were made starting from 1:50 and added to ELISA
plates coated with 10|ig/ml pi or pl:TF. 1:4000 dilution of anti-rabbit horse radish
peroxidase was used as second antibody. After development with OPD results were
read by measuring the OD492 of each well.
The results of duplicate wells were averaged and are shown in the graphs
opposite. The results from 8 negative control wells containing buffer but no
antibody were averaged then doubled to give a figure for 2xbackground
The serum used was pre-immune serum from R193, serum collected following
immunisation of R193 with pl:TF and derivatives of the latter serum depleted of
anti-pl activity after passing through a pl-Sepharose column (flow-through), or
enriched for anti-pl activity after binding to and elution from the pi Sepharose
column (column peak).
a) Results of ELISA against pi












































3.4.1: Production of recombinant gp46 polypeptides
These studies showed that the recombinant full-length and half-length gp46
fusion proteins with pi, i.e. pl:TF and pl:TH, respectively, were expressed in
transformed yeast but that their expression was toxic to the yeast. They also showed
the necessity of using an inducible promoter for expression of toxic proteins as no
transformants expressing pl:TF from the constitutive promoter could be found.
The toxicity of the expressed proteins to the host cells is particularly clear
from the growth curve which shows an almost immediate cessation of cell division
upon induction of pl:TF at a time before much recombinant protein is detectable,
e.g. pl:TF is barely detectable on western blots of crude lysates of BTF.O cells 6
hours after induction (Figure 3.6), yet cell division has almost stopped at this time in
MTF.O (Figure 3.11). Unfortunately the two figures concern different yeast strains,
nevertheless the data suggests that expression of even small amounts of recombinant
protein has a profound effect on the cell metabolism. A similar though slightly
reduced effect upon growth was seen following induction of pl:TH expression.
Since expression of pi, which is produced at a much higher yield than either pl:TH
or pl:TF does not have as rapid an effect on cell division, diversion of host cell
enzymes and energy reserves would not account for the apparent toxicity.
The toxicity of the recombinant proteins caused great difficulty in their
purification. The yield of recombinant protein was low and there was a relatively
high level of contamination with other yeast proteins. The large scale purification
method is dependent upon the formation of VLPs. It may be that the hydrophobicity
of the TF portion makes it bind other cell proteins reducing the ability of the pi
portions to interact with other pi molecules and to form VLPs. This may also be the
mechanism by which the protein is toxic to the cell. Nevertheless given the EM
evidence that very few VLPs were present in the cells the fact that even a small
amount of recombinant protein was recoverable shows that the purification method
must be very efficient.
If the ability to form VLPs was the problem rather than the total yield of
pi recombinant protein it should be possible to purify it using an anti-pl affinity
column rather than the method reliant on VLP purification. An anti-pl affinity
column may not be so efficient for purification of recombinant VLPs as the non-pl
moiety is thought to lie to the outside of the VLP whilst the pi subunits interact with
each other on the inside of the VLP.
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pl:TH preparations also yielded very small amounts of recombinant protein
suggesting that the amino-terminal hydrophobic region, in the absence of the
transmembrane hydrophobic region is sufficient to cause this problem.
An alternative reason for a low yield of recombinant fusion protein compared
to the fusion partner alone is sometimes due to more rapid turnover of mRNA
encoding the fusion protein (Hoekema et al., 1987). There may be some influence
of codon usage on the rate of turnover of mRNA.
Asenjo et al., (1993), report an alternative purification method for yeast
proteins using purified glucanase for cell lysis instead of mechanical lysis. This
appears to reduce degradation of VLPs. Although they report that this method also
gives selective product with less contaminants they present no evidence to support
this as only Western blots probed with anti-pl antibody, but not Coomassie or
Silver stained PAGE gels, were published.
The yields of heterologous proteins can be markedly influenced by the host
strain (Kingsman et al., 1990). The best strain varies for different proteins. The
reason for using BJ2168 was that this is the strain used routinely at British
Biotechnology Ltd. (BBL) for production of hybrid VLPs. This strain has the
advantage of being protease deficient and is therefore less likely to degrade the
recombinant protein. However, BJ2168 gave a very poor yield of recombinant
protein so strain MC5 was tried, in the hope that this diploid strain might be better
able to withstand the toxicity of the expressed proteins. Unfortunately the yield from
MC5 transformants was not significantly better than for BJ 2168 transformants.
Factor Xa protease clearly cleaved the recombinant protein as shown by the
shift from pl:TF to pi on Western blots probed with anti-pl antiserum. The lack of
any defined anti-gp46 antiserum and the presence of contaminating proteins in the
preps made it impossible to be certain which band on SDS-PAGE gels or western
blots corresponded to TF. Nevertheless the reactivity of sera from some MVV-
infected sheep, and not from uninfected sheep, indicated that the recombinant gp46,
TF, was a band running just ahead of the 36 kDa marker on SDS-PAGE.
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3.4.2: Antibody responses to recombinant pl:TF
Although it has been reported that a range of hybrid VLPs have been used to
elicit antibodies against the non-Ty components in rabbits (Adams et al., 1987) we
have found that the Ty component is often immunodominant. It is possible that the
rabbits used have previously encountered yeast infections and therefore when
immunised with Ty-VLPs mount a secondary response to the pi component but only
a primary response to the recombinant component. Alternatively recombinant gp46
may be poorly immunogenic. Serum from MVV-infected sheep does not generally
react with gp46 on Western blots of MVV infected cell lysate. This deficiency is
often considered to be due to the presence of only very low amounts of the
membrane protein in the MVV infected cell lysate preparation whereas it may
actually be due to the failure to mount an antibody response to gp46.
A problem with analysis of antibody response by Western blots is not only
that the antigen is denatured but also that the results are critical upon the amounts of
antigen and antibody used. Testing of a series of antibody dilutions against a fixed
amount of antigen may have better determined the reactivity of the sera.
The rabbit immunised with pl:TF (R193) raised antibodies to pi as well as to
components present in the pl:TF preparation but not in the pi preparation. Because
of the contaminant proteins in the pl:TF preparation and the low yield of TF
produced by cleavage of pl:TF it was not possible to determine whether antibodies
to TF itself had been raised. Western blots showed that pre-immune sera reacted
with some of the contaminating proteins (Figure 3.15 shows this more clearly than
Figure 3.14 probably due to the amount of antigen on the blot). The activity against
the contaminants was significantly increased following immunisation of R194 with
pi which highlights the fact that the pi preparation also includes contaminant
proteins. Thus the pl-Sepharose column was only partly able to separate out
antibodies against pi from the rest. Nevertheless "anti-pl" antibodies eluted from
the column should have been used to immunopurify pl:TF which might have
resulted in a much cleaner preparation for use as an immunogen and as antigen for
ELISA.
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CHAPTER 4: Expression of recombinant EV1 en46 in
a bacterial expression system and bv recombinant
vaccinia virus
INTRODUCTION
4.1.1: The pGEX bacterial expression system
pGEX2T (Smith and Corcoran, 1990) is a bacterial expression vector that
encodes the glutathione-S-transferase (GST) from Schistosoma japonicum which can
be expressed as a fusion protein with the product of a gene inserted into the multiple
cloning site. pGEX2T was chosen as the vector to express gp46 as GST fusion
proteins are generally soluble and easily purifiable: mg quantities of GST fusion
proteins have been purified from 11 cultures (Smith and Johnson, 1988). As a fusion
partner for expression of recombinant protein GST has been reported to be more
successful than LacZ or MalE in producing soluble protein. The pGEX system has
been used successfully to produce recombinant protein for a wide range of studies
including immunological studies (Toye et al., 1990) and vaccine production (Fikrig et
al., 1990).
The use of pGEX2T to express MYV gp46 was hoped to improve upon the
production of recombinant gp46 in the Ty system, in terms of purity and yield.
The GST moiety can be exploited as an affinity tag enabling purification of
fusion protein from crude bacterial lysate under non-denaturing conditions by affinity
chromotography on immobilised glutathione (glutathione-agarose beads). Bound
proteins can be eluted from the matrix by competition with free glutathione under mild
non-denaturing conditions. This helps preserve the antigenicity and functional activity
of the recombinant protein.
pGEX2T has an advantage over earlier pGEXl vectors in that it includes a
thrombin cleavage site between the GST gene and the multiple cloning site to enable
the recombinant protein to be cleaved from the GST component. After thrombin
digestion, it should be possible to remove the GST carrier and uncleaved product by
binding it to immobilised glutathione whilst leaving recombinant protein in solution.
As expression is IPTG-inducible the pGEX system enables production of
proteins which are toxic to the bacteria. The tac promoter (Ptac ) upstream of the GST
gene controls expression. Ptac is a hybrid derived from the trp and lac promoters
(Amann et al., 1983, De Boer et al., 1983). The lac repressor (lacl product) binds to
Ptac repressing expression of the GST fusion protein. When IPTG is added the laclq
gene encoded within pGEX2T is switched off and the GST fusion protein is
derepressed.
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4.1.2: Expression of rgp46 by recombinant vaccinia virus
Vaccinia expression constructs were made in order to generate recombinant
vaccinia virus expressing gp46. The aim was to use the recombinant virus to generate
antiserum against gp46 and also for use in the analysis of the cell mediated immune
response to gp46 by MVV infected sheep.
Recombinant vaccinia virus has several advantages as a eukaryotic expression
vector (reviewed by Mackett and Smith, 1986); It infects a wide range of host species
at high infectivity, it has a high capacity to incorporate foreign genetic elements (25kb
has been inserted without affecting growth or infectivity), there is no requirement for
helper virus and most importantly for our purposes it has the ability to elicit humoral
and cellular immune responses in experimental animals. Cells infected with
recombinant vaccinia virus present foreign antigen in association with MHC and may
therefore be used as targets for autologous cytotoxic T-lymphocytes directed against
the foreign antigen (Yewdell et al., 1985). Recombinant vaccinia virus is also
proposed to be particularly good for raising antisera against glycoproteins as they are
expressed in their glycosylated form. A number of virus glycoproteins expressed by
recombinant vaccinia viruses have been shown to elicit neutralising antibodies and to
protect experimental animals against subsequent challenge with the virus from which
the glycoprotein was derived (reviewed by Mackett and Smith, 1986) e.g.
recombinant vaccinia viruses containing HTLV-1 env inserted into the vaccinia HA
gene have been shown to induce humoral antibodies to HTLV-1 and are protective
against infection with HTLV-I.
Recombinant virus is created by homologous recombination in vivo between a
plasmid constructed to contain the foreign gene linked to a vaccinia virus promoter and
the vaccinia genome. Cells are infected with wt vaccinia virus at low m.o.i. (0.05
p.f.u./cell) and transfected with calcium phosphate precipitated plasmid DNA. At best
only 0.1 % of total progeny virus from a transfection experiment are recombinants so
screening or selection of recombinants is required. Insertion into the TK gene locus
allows selection for recombinant (TK-) viruses by plaquing on a TK- cell line in the
presence of 5-bromodeoxyuridine (Mackett et al., 1982). To confirm the nature of the
TK- recombinants the genomic DNA is analysed by restriction endonuclease digestion
and Southern blotting. The virus is routinely plaque purified twice before larger
stocks are grown up.
Recombinant vaccinia expressing MVV EV1 gp46 was made in this project
with the aim of using it for generating anti-sera against gp46 and for analysis of the




4.2.1: Construction of pGEX-derived Expression Vectors
Construction of the expression vectors to express gp46 as a fusion with
glutathione S-transferase (GST) was helped by the fact that the BamHI insert from the
vectors which had been constructed for expression in yeast provided a coding
fragment in the correct reading frame for pGEX2T, with the added benefit of a second
protease specific site, Factor Xa.
Plasmids pEVlTH.O and pEVlTF.O were digested with BamHI. Inserts of
approximately 0.5Kb or 1Kb, respectively, were gel purified by electrophoresis on a
1% LGT agarose gel, followed by extraction with hot phenol/chloroform or by
microcentrifugation through 3MM paper. Insert (either naTH or naTF) was added to
300ng of BamHI cut, CIP-treated pGEX2T at approximate molar ratios insert:vector
of 3:1, 6:1, 9:1. The mixture was ethanol precipitated, washed twice with 70%
ethanol and resuspended in 8pl TE pH8.0. lpl 10 x ligase buffer and lpl of ligase
were added. The ligation reaction was incubated at 16°C overnight before being used
to transform competent E.coli JM83. Transformants were selected by plating onto
LB/Amp agar incubated overnight at 37°C. Colonies were picked onto duplicate
LB/Amp plates and grown up. Lifts were made onto nylon filters (Buluwela et al.,
1989) and, after fixing, the filters were probed with 32P labelled gp41INS (Appendix
3).
4.2.2: Selection of transformants for expression of GST fusion proteins
Bacteria from blot positive cells were inoculated into 6ml L-broth/10pg/ml
Amp and incubated with shaking at 37°C for 5 hours. Filter sterilised IPTG was
added to a final concentration of 0.1 mM and incubation was continued for an hour.
The bacteria were harvested by centrifugation and resuspended in 600pl PBS. 300pl
was used to prepare BamHI or PstI digested plasmid mini-preps (Appendix 2). The
remainder was used for small-scale preparation of glutathione-binding protein; The
cells were lysed by ultra-sonication for three 10 second pulses with cooling on ice in
between. The lysate was microcentrifuged for 5 min and the supernatant was
transferred to a tube containing 50pl of a 50% slurry of glutathione-agarose beads
(Sigma). After gentle mixing for one hour, on ice, the beads were washed three times
as follows; 1ml of ice-cold PBS was added and mixed by vortexing, beads were
collected by 5 seconds microcentrifugation, and the supernatant was discarded. The
beads were resuspended in 25|il of reduced sample buffer (RSB), boiled for 3 min
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then electrophoresed on a 10% acrylamide SDS PAGE gel (Appendix 6).
Stocks of selected transformants were stored at -70°C in 20% glycerol.
4.2.3: Large scale preparation of GST or GST:fusion proteins
A loopful of bacteria from a single colony on an LB/Amp plate was inoculated
into 100ml of L-broth/lOfig/ml Amp and incubated overnight at 37°C with shaking.
1.5ml of overnight culture was used to prepare a PstI digested plasmid miniprep. The
rest of the overnight culture was added to 11 of L-broth/10pg/ml Amp at 37°C and
incubated with shaking for 1.5 hours. 24mg/ml IPTG was added to give a final
concentration of O.lmM IPTG. After a further 3 hours incubation, cells were
harvested at 5.5K for 5 min (Beckman JA-2 rotor). Bacteria from 11 of culture were
resuspended in 18ml of ice-cold PBS. 9ml of suspension was stored at -20°C. The
remainder was transferred to a glass Universal and the cells were lysed by three 1-
minute pulses of ultrasonication on ice. 10% Triton X-100 was added to a final
concentration of 1 % and the lysate was microcentrifuged for 5 min. The supernatant
was added to 1ml 50% slurry of glutathione agarose beads in a 15ml tube and mixed
for 30 min on ice. The supernatant was added to a second 1ml of glutathione-agarose
beads and again mixed for 30 min on ice. Both lots of beads were washed four times
with 15ml PBS. The beads were resuspended in 0.5ml PBS and transferred to an
Eppendorf tube. Protein was eluted by resuspending the beads in 1ml of 50mM Tris
(pH8.0), 5mM reduced glutathione and mixing gently for 5 min at room temperature.
The beads were spun down by microcentrifugation and the eluate was collected.
Elution was repeated three times. Fractions were analysed by SDS-PAGE.
The total protein concentration was estimated by Biorad protein assay using
ovalbumin as a standard.
4.2.4: Preparation of inclusion body material
Cells derived from 500ml of IPTG induced culture stored at -20°C were lysed
in 8ml PBS/1 mM EDTA by ultrasonication. Triton X-100 was added to a final
concentration of 1% and the lysate was microcentrifuged for 5 min. The supernatant
was used to prepare GST-fusion protein by binding to glutathione agarose beads as
described in the previous paragraph. The pellet from the equivalent of 20ml starting
culture was used to prepare insoluble inclusion body material. The pellet was
resuspended in 300|il of lysis buffer and 700fil of TNE, 12 pg/ml DNasel, and
incubated at 37°C for 45 min with occasional mixing. The material was
microcentrifuged for ten min. The pellet was resuspended in 1ml of lysis
buffer/0.2mg/ml lysosome for 15 min at room temperature. Insoluble material was
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pelleted by microcentrifugation for 10 min, resuspended in lysis buffer plus 0.2%
DOC, for 10 min at RT. Insoluble material was pelleted and resuspended in 50mM
Tris, 0.05% Triton X-100, lOmM EDTA, lOOmM NaCl at room temperature for 10
min. The final pellet was washed three times with water and resuspended in 1ml of
water. Samples were analysed by 10% acrylamide SDS-PAGE.
4.2.5: Growth curves of induced cultures
Cultures of the recombinant clones selected, LGPG1, LG7H19, LG2H11,
LG7F21 and LG7F22, were prepared by inoculating 10 ml L-broth plus 50pg/ml
Amp with a single colony from a plate, and incubating overnight at 37°C with
shaking. 2ml of each overnight culture was added to two flasks containing 50ml L-
broth, 10jig/ml Amp. After lh incubation at 37°C with shaking, 59(il of lOOmM
IPTG was added to one flask of each of the clones. The growth of uninduced or
IPTG-induced cultures was followed by measuring the OD600 at 30 or 60 minute
intervals for 6 hours.
4.2.6: Protease cleavage of GST:TH
80pil of eluted fusion protein (~4|ig of GST or ~3pg GST:TH) in 50 mM Tris-
C1 pH8.0, 5mM glutathione was added to 20(il 50mM Tris-Cl. pH7.0, 750mM NaCl,
12.5mM CaCl2.0pl, lpl or 3(il of thrombin (0.5U/|il, 125ng/pl) was added to each
tube. A control tube contained thrombin cleavage buffer and enzyme but no substrate.
A second set of tubes contained exactly the same reagents with the addition of 0.05%
CHAPS and 0.05% DOC. All ten tubes were incubated at 25°C. 20|il samples were
removed immediately after addition of thrombin, after 1 hour, 2 hours, 5 hours and
24hours. An equal volume of RSB was added immediately after sampling and boiled
for 3 min. 30|il was analysed by SDS-PAGE/silver-stain.
4.2.7: Construction of Vaccinia expression vector
PCR primers were designed to amplify the EVl-gp46 coding region from the
pTZ based clone, pCC18.9, and to add enzyme sites in order to give directionality of
insert, to add an ATG in frame at the 5' end, and to add a stop codon in frame at the 3'
end. PCR reactions were set up using primers 763F (C CCG GGA TCC ATG GGG
ATA GGC TTG GTG ATA GTG CTC GC) and 76IF (C CCG GGT ACC TCA ATT
CTC AAT CAT GGG CAT CTG TTC) and ~100pg of pCC18.9 (pTZ18R plus
EV1gp46 insert, described in Chapter 2) as template. PCR conditions were 30 cycles
of melting at 95°C for 0.6 min, annealing at 45°C for 1 minute and extension at 70°C
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for 5 min, with a final extension at 70°C for 5 min.
The PCR product was digested with BamHI and Kpnl, and gel purified by
electrophoresis on a 1% agarose gel. The DNA was recovered and ligated into
BamHI/Kpnl cut, CIP-treated pRK194B. Ligation reactions were set up at molar
ratios of insert:vector of 3:1 or 10:1. The ligation product was used to transform
E.coli JM101 cells. Plasmid mini-preps were prepared from transformants selected for
ampicillin resistance. Large scale plasmid preps were made (Appendix 2) of plasmids
pV769 and pV752, and pRK194B and were digested with a number of restriction
enzymes in order to map the plasmids. Sequence from plasmids pV769 and pV752
was obtained by double stranded sequencing (Appendix 4) using primer 923G, (5' -
ATT GGA TAT TAA AAT CAC GC - 3'), which is complementary to -48 to -29
with respect to ATG of the 4b promoter.
4.2.8: Analysis of recombinant vaccinia viruses
pV769 was used to generate recombinant vaccinia by the method of Smith,
Mackett and Moss (1982). Cells infected with recombinant vaccinia expressing EV1
gp46, as judged by Southern and Northern blots (Dr B.A. Blacklaws and Dr
D.R.Sargan, respectively) were harvested with glass beads, resuspended in DME and
stored at -20°C. Recombinants were also made with plasmid constructs to express the
herpes gD protein and MVV EVI p25 protein. African green monkey fibroblasts, CV-
1, were used for the transfections. Recombinant vaccinia, designated Vgp46, VgD or
Vp25, respectively, were grown up in TK-143 cells (TK- human fibroblasts).
Mice were inoculated with cells infected with recombinant vaccinia diluted in
PBS.
1st inoculation: 5 mice inoculated I/P with 106 p.f.u. of VgD
4 mice inoculated I/P with 106 p.f.u. of Vp24
3 mice inoculated I/P with 5xl05 p.f.u. of Vgp46
2nd inoculation same dose of virus I/P 24 days later
1st bleed 12 days later. Samples were collected into potassium EDTA
and the plasma from each group was pooled and stored at
-20°C
3rd inoculation same dose I/P 92 days after last inoculation
2nd bleed 14 days later. Individual samples were collected and stored
at -20°C.
Western blots of MVV EVI-infected-cell lysate and of recombinant gp46




4.3.1: Construction of pGEX expression vectors
Plasmids vectors for the expression of recombinant gp46 as a fusion with GST
were made by ligating fragments naTH and naTF from the yeast expression plasmids
pTH.O and pTF.O into the BamHI site of pGEX2T. From the known restriction sites
in the plasmid and inserts it was possible to use BamHI digestion to determine the
plasmid and insert size and to use PstI digestion to determine orientation. Restriction
fragment analysis of one clone of each sort in either orientation is shown in Figure
4.1a.
Blot positive clones were used to prepare glutathione-binding protein on a
small scale from lysate of induced cells. However SDS-PAGE of these crude
preparations did not help in selection of the desired clones. Control clones containing
pGEX2T produced a prominent band of protein running a little below the 30KDa
marker (GST is predicted to be 27.5KDa). Clones containing pTZ18R produced a
protein of the same size, but at a considerably lower yield, suggesting that GST is
produced in absence of pGEX2T, i.e. that GST is also chromosomally encoded and is
made endogenously in E.coli. None of the crude lysates prepared contained sufficient
GST fusion protein to be visible on Coomassie stained SDS-PAGE gels (data not
shown). Thus clones contained the desired plasmid construct, as shown by plasmid
minipreps made concurrently, although the above assay for GST fusion protein was
too insensitive to confirm its expression.
On the basis of the information gained from the plasmid digests, five different
JM83 transformants were selected; GPG1 (transformed with pGEX no insert),GH11-
(pGEX.TH insert in inverted orientation), GH19+ (pGEX.TH insert correct
orientation), GF21- (pGEX.TF insert inverted) and GF22+ (pGEX.TF insert correct
orientation). Maps of the plasmids are shown in Figure 4.1b.
4.3.2: Preparation of GSTrfusion proteins
Recombinant protein was prepared from transformants GPG1, GH19+,
GF22+ and GF21-. Briefly, lysate derived from 500 ml of culture 1 hour after IPTG
addition was incubated with glutathione-agarose beads. After washing, bound protein
was eluted from the beads with 50 mM Tris-Cl (pH 8.0), 5mM reduced glutathione.
Samples were run on SDS-PAGE (Figure 4.2). The three tracks on each gel show a
sample of product from the first second and third elutions. Clearly a large amount of
elutable protein still remained on the beads even after several incubations with elution
buffer.
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Figure 4.1: Restriction digests of plasmid mini-preps of clones selected
for expression of rgp46 in E.coli
Predicted restriction fragment sizes of pGEX constructs
Plasmid
pGEX2T
pGEX2T + TH insert
(correct orientation)
pGEX2T + TH insert
(inverted orientation)
pGEX2T + TF insert
(correct orientation)




































Figure 4.1b: Plasmid maps of pGEX-derived GST:gp46
expression vectors
Figure 4.2: Large scale preparations of GSTrfusion proteins
10% acrylamide SDS-PAGE was used for analysis of sequential elutions, el, e2
and e3, from glutathione agarose beads which had been incubated with lysate from
500ml IPTG-induced cultures. 5
pi samples from GH19+, GF22+, or GF21+, and lpl samples from LGPG1 were
loaded. The gels were stained with Coomassie blue.
Predicted size of GSTrfusion proteins
(Predicted using UWGCG Peptidesort)
GST 27.5KDa
GST + TF (27.5KDa + 38KDa) 65.5KDa
GST + TH (27.5KDa + 20KDa) 47.5KDa
GST + TF Inverted (FINV) (27.5KDa + 4.5KDa) 32KDa













Thenceforth, several elutions were done routinely in the preparation method and the
eluates were pooled.
This procedure yielded about 8mg GST per litre of GPG1, 1.0 mg GST:TH
from a litre culture of GH19+, but no detectable GST:TF product from GF22+.
Plasmid pGF21 contains the gp46 coding region in inverted orientation yet
GF21- produced a protein of approximately the predicted size of GST:TF (65.5 kDa),
as well as a protein just larger than pi as predicted for this clone. Restriction fragment
analysis of plasmid prepared from the same cultures as GST:fusion protein confirmed
that this was not due to mixing or contamination of the clones. Therefore the protein
of about 65kDa seems to be bacterial rather than plasmid encoded. The purity of the
product obtained from GH19 varied depending on induction time. In particular the
prominent band seen at ~67kDa from GF21- also appeared in GH19+ after 3 hours
IPTG induction but was barely visible from culture harvested after only 1 hour
induction.
From Figure 4.2 it can be estimated that GH19+ prep contains about 60-70%
GST:TH and about 30% GST. However estimates from a Coomassie stained gel may
be very inaccurate because individual proteins present at low concentrations will not be
visualised although cumulatively they might represent a significant percentage of the
preparation. As mentioned above, the proteins produced by the preparation technique
varied depending on the induction time.
4.3.3: Inclusion body preparations
Some recombinant proteins produced in E.coli are partitioned into insoluble
inclusion bodies in the cell cytoplasm. In order to determine whether rgp46 proteins
expressed in E.coli formed inclusion bodies, preparations were made using a quick
but relatively crude method (Bowden et al., 1991). As can be seen from Figure 4.3
the inclusion preparation method (tracks iii and iv) provides a degree of purification
when compared to crude lysate (track i). However the amount of contaminating
bacterial proteins still present is significantly greater than by affinity purification with
glutathione agarose beads (track v). Although GST:TH was present in the insoluble
fraction as well as in the soluble fraction the amounts in the insoluble fraction did not
warrant changing to this method of protein preparation. However, a combination of
the inclusion body preparation followed by purification using glutathione beads may
have improved upon the use of either method singly.
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Figure 4.3: Inclusion body preparations of GST:fusion proteins
500ml IPTG-induced cultures of GH19+ or GF21- were used to prepare
GST:fusion protein for comparison of preparation by binding to glutathione agarose
beads or by a crude inclusion body preparation method. The products were analysed
by 10% acrylamide SDS-PAGE. The gels were stained with Coomassie blue.
a) GST:TH preparations from GHI9+
b) GST:FINV preparations from GF21-
i Crude lysate (from 312|il starting culture).
ii Supernatant after incubation with glutathione agarose beads (from
1.25ml starting culture).
iii Inclusion body preparation (from 2.5ml starting culture).
iv Inclusion body preparation (from 5ml starting culture).
v Eluate from glutathione agarose bead preparation (from 2.5ml starting culture).
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4.3.4: Growth of transformants following induction of GST:fusion
protein production.
Growth of the transformants with or without the addition of IPTG was
measured by OD600 over 6 hours (Figure 4.4). The growth of GPG1 was slowed
down after induction in comparison to uninduced culture probably due to the burden
of producing such large amounts of GST protein. There was a dramatic change
following induction of GF22+ culture; growth ceased within 30 minutes of adding
IPTG. This indicates that recombinant protein must indeed have been produced in
order to have such an effect. The difficulty encountered in purifying GST:TF protein,
as described above, suggests it may only have been produced at low levels. It follows
then that the GST:TF was extremely toxic to the cells as it exerted an effect at low
concentration, and very quickly stopped cell division and further protein production
following induction. Production of TH protein also appeared to be toxic to the cells.
IPTG induction of GH19+ rapidly halted growth of the culture. The effect was only a
little less rapid than that seen upon induction of GST:TF. It is likely that this
difference enables more GST:TH to be produced before cell death occurs, thus
enabling its extraction, albeit at low levels, from induced cell lysate. pGHll- and
pGF21- which encode peptides of 5KDa and 4KDa, respectively, added onto GST
had no effect on the growth of transformants after IPTG induction. It is unclear why
the growth of these cultures was not affected, whilst the growth of GPG1 did slow
down after induction of GST. The yield of GST fusion protein from GH11- or
GF21- was significantly less than.the yield of GST from GPG1. One possible
explanation is that the mRNAs encoding these proteins are unstable so that less protein
was produced which was less demanding of cellular resources so that cell growth and
division was able to continue.
4.3.5: Protease digestion of GSTrTH
Attempts to digest GST:TH with Factor Xa proved unsuccessful. Secondary
structure due to the hydrophobicity of the N-terminal region of gp46 immediately
adjacent to the Factor Xa site may account for this.
Digestion of GST:TH with thrombin (Figure 4.5) was very inefficient in that
digestion of GST:TH did not near completion, as judged by the continued presence of
a visible GST:TH band even after overnight incubation with thrombin. However,
incubation of GST:TH with thrombin did lead to the appearance of a protein running
just below the 20 KDa marker. This band was not present in mock digested controls
or in GST or GST:FINV treated with thrombin showing it was specific to thrombin
treated GST:TH.
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Figure 4.4: Growth of transformed cultures after induction with IPTG
Log phase cultures of the five different pGEX-derived transformed clones
were diluted to approximately the same cell density in pre-warmed medium with or
without IPTG. The OD600 of each culture was measured at intervals over 6 hours in
order to determine the effect of induction of GSTrfusion protein expression on














Figure 4.5: Thrombin digestion of GST:TH
GST or GST:TH was incubated with thrombin at 25°C. Samples were
taken after 0, 1, 2, 5 or 24 hours and analysed by SDS-PAGE on a 5-20%
polyacrylamide gradient gel. Proteins were visualised by silver staining the gel.
Track A - thrombin
Track B - GST:TH plus 125ng thrombin
Track C - GST:TH plus 375ng thrombin
Track D - GST.TH mock digestion
Track E - GST plus thrombin
(250ng of thrombin is 1 Unit of enzyme which, in theory, should be able to cleave
24jig of fusion protein).
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A band does begin to appear running below GST and is particularly noticeable after 24
hours incubation. This appears to be a thrombin cleaved breakdown product of the
GST moiety as it was present after incubation of both GST or GST:TH with thrombin
but not after incubation without thrombin or of thrombin alone
The inclusion in the digestion buffer of 0.1 % CHAPS and 0.1 % DOC, was
tried to see if the detergents would improve the efficiency of the cleavage reaction
perhaps by partially "unfolding" the proteins. However there was no difference in the
results with or without the detergents.
4.3.6: Construction of Vaccinia expression vectors.
The pRK194B vector enables production of recombinant Vaccinia virus
expressing a foreign gene from a strong late promoter. Immediately upstream of the
plasmid promoter is a BamHI, Smal, Kpnl, EcoRl polylinker enabling insertion of a
foreign gene. PCR primers, 763F and 761F, were designed in order to amplify EV1
gp46 with restriction sites at either end to enable insertion into pRK194B in the correct
orientation for expression of rgp46. In addition the primers encoded a 5' methionine
in frame and a 3' stop codon, respectively.
763F - 5' primer :
BamHI Start EVl gp4 6
5'-C CCG GGA TCC ATG GGG ATA GGC TTG GTG ATA GTG CTC GC
-3 '
761F - 3' primer :
Kpnl Stop Complementary to 3' end of EVl gp4 6
5'- C CCG GGT ACC TCA ATT CTC AAT CAT GGG CAT CTG TTC -3'
PCR with primers 763F and 761F and pCC18.9 template resulted in ~ 100ng/p.l (total
1 Opg) of a 900-1000 base product.
The PCR product was digested with Kpnl and BamHI and ligated into
BamHIIKpnl cut, CIP-treated pRK194B. Plasmid minipreps were made from
Ampicillin resistant transformants. Two clones, V752 and V769 which contained
plasmids larger than pRK194B, as judged by electrophoresis of uncut plasmid on a
1 % agarose gel, were selected. Restriction fragment analysis of the two plasmids is
shown in Figure 4.6. Neither of the plasmids exactly matched the predicted
restriction map for the PCR product inserted into pRK194B (Figure 4.6b). pV769
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Figure 4.6: Restriction fragment analysis of pV752 and pV769
Predicted restriction fragment sizes of pRK194B plus gp46 insert































Restriction fragment sizes are given in kilobases and assume all restriction sites to be
intact. Figures in bold type represent fragments which should hybridise with a gp46
probe.
Plasmid maps deduced from restriction fragment analysis
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Figure 4.7: Results from sequencing of pV752 and pV769.
a) Sequence obtained from pV769 - "Bestfit" with EV1 gp46.
[ 5' PCR primer (763F) ]
9 GGGATAGGCTTGGTGATAGTGCTCGCTATCATGGCAATAATAGCTGCTGC 58
II I I I I I II I I II II I I II I II II I II II I I II I II I II I I II I I I I I II
5 GGGATAGGCTTGGTGATAGTGCTCGCTATCATGGCAATAATAGCTGCTGC 54
59 AGGAGCTGGTCTCGGTGTTGCAAATGCCGTGCAGCAGTCCTATAC 104
I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I II I I I I I I I II I
55 AGGAGCTGGTCTCGGTGTTGCAAATGCCGTGCAGCAGTCCTATAC 99
b) Sequence obtained from pV752 - "Bestfit" with EV1 gp46.
1 CCAAANNANTAANAATATTANANNCAANANTTNCCCGAGTGGAACTCCTG 50
I I I I I :: I : I I I : I I I I I I I : I :: I I I : I : I I : II I I I I I II I I II II I
186 CCAAAGGAGTAAGAATATTAGAGGCAAGAGTTGCCCGAGTGGAAGTCCTG 235
51 GTAGATAGGATGATGGTATATCAGGAATTAGATTGTTGGCATTATCAGCA 100
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
236 GTAGATAGGATGATGGTATATCAGGAATTAGATTGTTGGCATTATCAGCA 285
101 CTATTGTGTAACCTCAACAAAAAGTGAAGTAGCAAAGTATGTGAATTGGA 149
I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I
286 CTATTGTGTAACCTCAACAAAAAGTGAAGTAGCAAAGTATGTGAATTGGA 335
150 CAAGATACAGGGATAATT 166
I I I I II I I I I I I I I I I I I
336 CAAGATACAGGGATAATT 353
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was not cut by BamHI but was otherwise the same as expected. pV752 was not cut
by BamHI or by Pstl. The fact that pV752 was not restricted by PstI suggests a
deletion inclusive of at least fifty bases had occurred at the 5' end of gp46 in pV752.
This deletion was confirmed by double-stranded sequencing (Figure 4.7).
The pV769 sequence obtained included a large part of the 763F primer
sequence and was equivalent to nucleotides 5-99 of gp46 showing that the insert had
been ligated in the right orientation. Unfortunately the sequence obtained began one
base short of the complete BamHI site. Nevertheless, the sequencing did confirm that
the AUG start codon was intact and in frame with the gp46 sequence following on
from it. In retrospect the sequencing primer chosen was not ideal, as a primer from
further upstream of the insert site may have enabled the complete sequence through the
BamHI site to be read.
The pV752 sequence obtained using the same primer and the same reaction
conditions, resulted in sequence equivalent to nucleotides 186-353 of EVl-gp46. This
suggests that the deletion at the 5' end of the gp46 insert is of about 180 bases but not
more than 186 bases.
4.3.7: Generation of recombinant vaccinia virus
pV769 was recombined with vaccinia virus to produce recombinant vaccinia
with gp46 integrated into its genome, Vgp46. This was confirmed by Southern
blotting of cells infected with recombinant Vgp46 , and transcription of gp46 was
shown by Northern blotting. Vgp46 was slow growing compared to other
recombinant vaccinia strains generated at the same time. It also grew only to low titre;
about 1 x 108 pfu/ml for Vgp46 compared to about 3 x 109 pfu/ml for the other
recombinant strains. The cytopathic effect produced by all the strains was the same,
i.e. plaque formation. Vgp46 did not induce formation of syncytia.
4.3.8: Generation of anti-sera against recombinant vaccinia virus
Vgp46 was used to inoculate mice. Additional mice were inoculated with
recombinant vaccinia VgD, expressing the gD protein of herpes virus, or Vp25,
expressing MVV p25 protein.
Plasma samples were tested against lysate of MVV EV1 infected cells by
Western blot (Figure 4.8d). A number of non-specific bands were recognised by
Vgp46 inoculated mice in common with bands recognised by some of the VgD or
Vp25 inoculated controls. The pooled Vp25 plasma recognised a band corresponding
to p25 and to what are thought to be p25 precursors. There was no evidence of
activity against a gp46 band, however no positive control serum was available to show
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Figure 4.8: Reactivity of plasma from mice inoculated with
recombinant Vaccinia virus with EV1 antigens and with
GST :TH.
Western blots were developed with mouse plasma at 1:125 and rabbit anti-
mouse alkaline phosphotase conjugate at 1:1000
Antigen
a) EV1 infected cell lysate.
b) GST:TH.
c) GST:TH digested with thrombin.
d) GST:FX treated with thrombin.
Proteins in a) were separated by SDS-PAGE on a 5-20% polyacrylamide
gradient, b)c) and d) were electrophoresed on 10% acrylamide SDS-PAGE
gels.
Antisgra
1. Pooled plasma from mice inoculated with VgD.
2. Plasma from mouse 1 inoculated with Vgp46.
3. Plasma from mouse 2 inoculated with Vgp46.
4. Plasma from mouse 3 inoculated with Vgp46.
5. Pooled plasma from mice inoculated with Vgp46.
6. Plasma from mouse 4 inoculated with VgD.
7. Plasma from mouse 5 inoculated with VgD.
8. Plasma from mouse 6 inoculated with VgD.
9. Pooled plasma from mice inoculated with Vp25.
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a) GST:TH































c) GST:FINV thrombin digest















whether gp46 was present on the Western blots. The most striking difference between
the reactivity of the Vgp46 inoculated mice compared to the others was against smears
at just above the 94kDa marker, and near the top of the gel (perhaps the envelope
precursor).
Western blots of GST:TH, thrombin digested GST:TH or thrombin digested
GST:FINV were developed with sera from mice inoculated with Vgp46 (Figure 4.8a,
b, and c). Sera from mice inoculated with recombinant vaccinia expressing herpes gD
protein (VgD) or MVV p25 (Vp25) were tested as controls. Samples from the VgD or
Vp25 inoculated mice recognised very little on these blots whilst the Vgp46 plasma
reacted with GST:TH and against TH after digestion of GST:TH. This confirms the
expression of rgp46 by the recombinant virus which enables its potential use to
produce T-cell targets for cytotoxic T-cell assays in studies on T-cell responses to





4.4.1: Expression of recombinant gp46 in E.coli
As gp46 is very difficult to purify from whole virus, perhaps due to its
association with membranes, recombinant gp46 (rgp46) was required in order to
generate specific antisera and for studies on the immune response of MVV-infected
sheep to gp46. Recombinant gp46 was expressed in yeast but the protein preparations
contained a large amount of contaminants which were found to interfere with
interpretation of the immunoreactivity of sheep sera against rgp46 (Chapter 3). The
pGEX expression system was chosen as an alternative because of the potential
specificity and ease of the technique for purification of the recombinant GST:fusion
protein product.
As with expression in yeast, recombinant TH and TF proteins (half- and full-
length gp46, respectively) were found to be toxic to the host cell. In fact, expression
of TF in these cells was so toxic that cell division ceased after half an hour which
suggests cells which were already dividing completed the cell cycle but no new cell
division occurred. This extreme toxicity may be the reason that no GST:TF was
recoverable from the transformed cells. In contrast GST:TH was recoverable at a
better yield and purity than recovery of pi :TH or pi :TF from yeast.
A large proportion of the GST:TH produced by the bacteria was lost during the
purification procedure. Comparison of Coomassie stained bands after electrophoresis
suggests that the amount of GST:TH in crude lysate from the equivalent of only 312(il
of induced GH19+ culture was similar to the amount of GST:TH recovered from
2.5ml of the same culture by affinity purification. This indicates a recovery of only
about 12%. Loss of GST:TH may have occurred at a number of stages in the
purification procedure; it may have pelleted with insoluble material during the
centrifugation steps, some will have remained in solution instead of becoming bound
to the glutathione agarose beads and elution of GST:TH from the beads may have been
incomplete. Nevertheless, the method does significantly enrich for the recombinant
protein: The amount of GST:TH present in unpurified crude lysate from induced
GH19+ culture, estimated from SDS-PAGE gels (Figure 4.3), was about 10-20% of
total protein. After affinity purification with glutathione agarose beads the GST:TH
preparation contained about 60% GST:TH and about 30% GST. This estimation is
not very accurate since it depends upon the amount of sample loaded and the quality of
the gel and staining: Figure 4.2 shows the result of electrophoresis of ~200ng of
GST:TH preparation. In this case only GST:TH and GST protein appeared to be
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present. In contrast, the gel in Figure 4.3 revealed small amounts of numerous other
proteins in ~400ng of GST:TH preparation.
The physical characteristics of recombinant proteins have been known to cause
problems if glycosylation and disulphide cross linking are required for stability and
solubility. Glycosylation does not occur in the bacterial expression system and protein
folding and disulphide cross-linking are likely to be different from the native protein.
For this reason heterologous proteins, expressed in bacteria may occur as insoluble
aggregates known as inclusion bodies. The native form of gp46 is glycosylated and
traverses the membrane so its folding is likely to be entirely different in the bacterially
expressed form. Despite this, and the hydrophobicity of the recombinant protein,
GST:TH did not appear to be partitioned into inclusion bodies. This was shown by
comparison of a method to purify inclusion bodies with the glutathione affinity
preparation method. The purification of inclusion bodies yielded more GST:TH than
the glutathione affinity preparation method, (perhaps twice as much from the same
amount of culture), but contained a much higher proportion of bacterial proteins
(Figure 4.3). The pursuit of further methods, such as sucrose density gradients,
might have improved inclusion body purification but would not necessarily have
produced any better final yield than the affinity purification method.
4.4.2: Protease Cleavage of GST:TH
GST:TH contains specific protease cleavage sites for recognition by Factor Xa
or thrombin. The results shown are for thrombin treatment of GST:TH (Figure 4.5),
but were similar for Factor Xa. Protease treatment of GST:TH did not result in
efficient cleavage of TH from its GST fusion partner, despite attempts to improve
cleavage by increasing the incubation time and the amount of enzyme The GST:TH
protein did not disappear but a protein similar to the predicted size of TH did appear.
Serum from mice immunised with recombinant vaccinia expressing gp46 (TF) reacted
with this protein whilst control sera did not, thus confirming it to be TH.
The N-terminal end of gp46 is joined to the C-terminal end of GST. This
means that the hydrophobic region of TH lies close to the junction site encoding the
protease recognition sequences. Protein folding might internalise this hydrophobic
region and therefore may make the cleavage sites inaccessible to protease. The
addition of detergents to the buffer was tried to see whether partial "unfolding" of the
fusion protein could increase cleavage. The anionic detergent deoxycholic acid (DOC)
and the zwitterionic detergent CHAPS were added at 0.1 % and 0.2% respectively.
The concentrations chosen were approximately half the critical micelle concentration.
It is recommended that detergents should be used at their critical micelle concentration
142
for solubilisation of proteins and membrane components (Womack et al., 1983). Half
this value was chosen arbitrarily to try to balance the fact that the detergents might
make the cleavage site more accessible, but may, at the same time, reduce the activity
of the enzyme by denaturing. Titration of the detergents in the cleavage reaction
would perhaps have been better. At the concentration chosen there was no apparent
difference in the efficiency of protease cleavage in the presence or absence of
detergent.
Investigations upon the immunoreactivity of sera from MVV-infected or
uninfected sheep against GST:TH are described in Chapter 5.
4.4.3: Expression of EV1 gp46 by recombinant vaccinia virus
Two potential vectors for the production of recombinant gp46 expressing
vaccinia were isolated, and checked by restriction fragment analysis and by partial
sequencing. pV769 was selected for use as pV752 had a deletion within the gp46
coding region. One explanation for the deletion in gp46 in pV752 may be that PCR
amplification of gp46 introduced a mutation that gave rise to a new BamHI site. The
sequence of gp46 182-187 is GTAGCC which requires two base changes to become
the BamHI recognition sequence GGATCC. Alternatively BamHI star activity may
have been responsible for cutting at this sequence. The use of this junction site fits in
with the deletion size of 180-186 bases estimated from the results of parallel
sequencing reactions for pV752 and pV769.
Recombinant vaccinia virus, Vgp46, was generated and shown to express
gp46 mRNA. Vgp46 grew only slowly and to low titre suggesting gp46 decreased
virus production. Whether the reduction in virus production was due to a direct
interaction of gp46 with other virus components, or by interference with cellular
metabolism, is not known. The toxicity of gp46 when expressed in yeast and bacterial
systems suggests that the latter may occur. Nevertheless, gp46 protein was produced
by Vgp46 cells. This was shown by the activity of anti-sera, from mice immunised
with Vgp46, against bacterially-derived TH protein.
Due to lack of time I was unable to conduct the studies on cell mediated
immune responses of MVV-infected sheep against gp46. However, subsequent
studies by Dr B.A.Blacklaws have demonstrated cytotoxic activity against Vgp46-
infected cells by T-cells from MVV-infected sheep. Cytotoxicity was not shown
against Vgp46-infected target cells by immune cells from uninfected sheep, nor against
control VgD-infected target cells by T-cells from MVV-infected sheep. This shows
that the Vgp46 infected cells present gp46 peptides in association with MHC class I,
and that MVV infected sheep have T-cells that recognise and respond to gp46.
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CHAPTER 5: Effect of serum from MVV-infected or uninfected
sheep on fusion hv MVV and reactivity of sera with MVV gp46
INTRODUCTION
5.1.1: Fusion of cells by MVV
When MVV is added to sheep skin cell fibroblasts at low m.o.i. CPE in the
form of syncytia appears after 7-14 days caused by fusion of infected cells with
neighbouring uninfected cells. This is known as fusion from within. If MVV virus
is added at high m.o.i. (>10) cells fuse to form syncytia in less than 6 hours. This is
too short a time for viral replication to have taken place and is thought to be due to
fusion of viral particles with more than one cell at once. This is known as fusion
from without. Fusion-from-without (FFWO) by virus at a high m.o.i. in vitro occurs
rapidly and reproducibly and has been used in previous studies to look at virus
fusion. The mechanism by which the actual fusion event occurs during FFWO is not
known but has been assumed to be the same as during fusion of the virus with the
host cytoplasmic membrane at initial infection. Thus the results of an FFWO-based
assay may reflect the ability of the serum, antibody, or other factors to affect virus
infectivity by acting on the fusion event at initial entry into the host cell.
5.1.2: Fusion Assay
The first target of the work described in this chapter was to develop an assay
to measure modulation of MVV-mediated cell fusion by serum. This assay was used
to determine whether there was a difference between the effect on fusion by sera
from MVV infected or from uninfected sheep, and also whether fusion modulatory
activity was IgG mediated. The 37°C fusion assay which has been used here, and
similar assays used by previous researchers, can not distinguish between fusion
modulatory activity which is due to a factor affecting the step upstream of the fusion
event, i.e. virus:cell binding, and factors which act upon the fusion event itself. For
this reason a novel fusion assay, the 4°C assay, was devised to assay fusion
modulatory activity occurring after virus binding.
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5.1.3: Immunoreactivity of sheep serum with MVV gp46
The aim of the second aspect of work described in this Chapter was to
investigate whether sheep make a detectable anti-gp46 response using the
recombinant protein, the production of which is described in Chapter 4. Both
ELISAs and western blots were tried as each method has different advantages and
disadvantages. Western blots enable activity against a particular protein to be
distinguished from activity against other proteins present in the antigen preparation.
However the antigen on a western blot is in a highly denatured form, and therefore
some antibodies particularly those directed against conformational epitopes cannot
be detected by western blotting. Conversely, ELISAs are considered better for
detecting antibodies directed against conformational epitopes as the protein folding
is believed to be more like the native form than in western blots, but denaturation
may still occur upon binding of the antigen to the plastic plates. The disadvantage of
ELISAs is that activity against contaminating proteins cannot be distinguished from
activity against the antigen of interest.
5.1.4: Correlation of results
As gp46 is believed to play a critical role in the fusion process, a hypothesis
was made that immunoreactivity against gp46 could alter the ability of the virus to
mediate membrane fusion. To test this hypothesis the results of both the groups of
experiments outlined above were examined to see if fusion modulatory activity
correlated with immuno-reactivity against gp46.
Finally data on the clinical status of some of the MVV-infected animals was
obtained to see if fusion modulatory activity and/or immuno-reactivity against gp46




5.2.1: Cells for propagation of virus and for fusion assay.
YT40 cells were derived by culture of an ovine skin explant and have
fibroblastic morphology. YT40 cells were grown in T225 flasks in 45-60 ml of
DME6 (Dulbecco's MEM (Gibco Biocult, Uxbridge) supplemented with lOOU/ml
benzyl penicillin, lOOU/ml streptomycin, 2mM L-glutamine and 6% foetal calf
serum(Azo-Tek)), at 37°C in a CO2 incubator. When the cells reached confluence
they were split into three flasks using trypsin/versene. For seeding 96-well plates
cells were taken off with trypsin/versene and approximately 5X104 cells in 1 OOptl
DME6 were added to each well.
5.2.2: Fixing and staining cells in 96-well plates.
Cells were fixed overnight at 4°C in buffered neutral formalin (BNF) or for
10 min in 50% acetone, 50% methanol (100|il per well). The fixative was removed.
1% potassium dichromate was added. After 30 min at room temperature it was
replaced with ice cold 50% acetone, 50% methanol for 5 min. Plates were allowed
to drain dry for at least 10 min. A drop of Gurr's Giemsa, freshly diluted 1:1 in tap
water was added to each well for 5 min. Cells were differentiated for 1-2 min with
water until the nucleus and cytoplasm were clearly distinguishable, (pale mauve
cytoplasm, deep pink/purple nucleus).
5.2.3: Production of EV1 stocks for fusion assays
400|il of EV1 stock culture, (~105 TCIDso/ml), in 10ml of medium was
added to T225 flasks containing 100% confluent YT40 sheep skin fibroblasts, and
allowed to adsorb at 37°C for lh. A further 90ml of medium containing only 2%
FCS was added and the cells were incubated at 37°C until nearly 100% CPE was
seen. Virtually all the cells had come off the plastic by 6-7 days after addition of
virus. The medium was clarified by centrifugation in 250 ml Beckman bottles in a
J2-21 rotor for 30 min at 5000g. The virus was concentrated by a factor of about ten
using Amicon filtration through a filter with a 300kDa cut off point. The virus was
titred for TCID50 and to estimate the ability to cause fusion-from-without of sheep
skin cells within 6-24 hours incubation.
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5.2.4: Titration of cells and virus for fusion assay
Each well of four flat-bottom 96-well tissue culture plates (Technicon) was
inoculated with 100p.l of YT40 ovine skin cell fibroblasts in DME5 at concentrations
of 8 x 105 cells/ml, 5 x 105 cells/ml, 2.5 x 105 cells/ml or 5 x 10 4 cells/ml. (Two
rows of each cell density per plate). Plates were incubated at 37°C overnight in a
CO2 incubator.
Concentrated EV1 virus, (as described in the previous paragraph), was
serially diluted twofold from 1:2 to 1:32 in DME5. The medium was removed from
three plates of cells and replaced with 50|il of one dilution of virus in each well of
two columns per plate. Cells plus virus were incubated at 37°C with CO2. After 7,
23, and 31h one plate was fixed with BNF and stored at 4°C until staining. A fourth
plate was cooled to 4°C for 30 min, diluted virus was added to the cells, and the plate
was placed at 4°C for lh. Cells were then washed twice with cold DME5 and
incubated at 37°C with 50|il per well DME5. After 23 hours the cells were fixed in
BNF. The four plates of BNF-fixed cells were stained with Giemsa and scored for
the presence or absence of syncytia.
5.2.5: Fusion assay (37°C)
Dilutions of complement inactivated sera were made in DME5 in 96-well
round-bottomed plates. EV1 (concentrated stock) was diluted 1:8 in DME5. 60|il
was added to each serum dilution and incubated at room temperature for 1 hour.
5 x 104 YT40 sheep skin cells in lOOpl DME5 were inoculated into 96-well
tissue culture plates and grown to confluence overnight. The medium was removed
and 50pl of each virus/serum dilution was transferred to duplicate plates of
monolayered YT40 cells. The cells plus serum/virus were incubated overnight at
37°C with CO2, then fixed and stained with Giemsa.
Control wells containing monolayered cells without virus added, and cells
with virus but no serum, were included on every plate.
Wells were scored from -2 to +2 on comparison with the control wells
containing virus without added serum; a score of 0 was ascribed to wells with similar
number and size of syncytia to the control, -1 to wells with significantly
fewer/smaller syncytia, -2 to wells where syncytium formation was completely
blocked and no syncytia were visible, +1 where syncytium formation was enhanced
with respect to number of cells involved, and +2 where syncytium formation was
enhanced to the extent that virtually all the cells in the monolayer had become fused.
The results from duplicate tests were averaged.
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5.2.6: Fusion assay (4°C)
EV1 stock virus was diluted in DME5. 50pl/well replaced the medium on
monolayered YT40 sheep skin cells in a 96-well tissue culture plate. The cells/virus
were incubated at 4°C for lhour. Virus was removed and the cells were washed
three times on ice with cold DME5. 50pl/well of serum diluted in DME5 (4°C) was
added. Plates were incubated at 37°C for 24 hours before fixing and staining. The
wells were scored as described for the 37°C assay, above.
5.2.7: Effect of rgp46 on syncytium formation.
Recombinant gp46 (N-terminal half) produced as a fusion protein with
glutathione S-transferase, GST:TH, (as described in chapter 4) could be cleaved
from its fusion partner using the enzyme thrombin. To investigate whether the
rgp46(TH) could itself mediate membrane fusion or enhance fusion by MVV virus it
was added to in vitro YT40 skin cell monolayers as used for the fusion assay
described above. A number of control solutions were also tested; thrombin digestion
buffer alone, buffer plus thrombin, GST in digest buffer, GST plus thrombin,
GST:FINV plus thrombin, GST:TH, and GST:TH digested with thrombin. Two-fold
serial dilutions of the above preparations in DME5 were added to monlayered YT40
cells in 96 well plates with or without sufficient virus to cause fusion-from-without
overnight.
5.2.8: ELISA:Sheep sera reacting with GST or GST fusion proteins
Approximately 50pg/ml GST, GST:TH, or GST:FINV (as described in
Chapter 4) was used as antigen to coat 96-well plates for ELISAs performed as
described in Appendix VII.
5.2.9: Western blots:Sheep sera reacting with GST or GST fusion proteins
Approximately 150-200ng of GST, GST:TH, or GST:FINV (as described in
Chapter 4) was used per strip as antigen for Western blots performed as described in
Appendix VI.
MVV EV1 antigen was prepared from infected cells as described in
Appendix VI. 5pi of antigen per well was loaded and electrophoresed on a 5-20%
polyacrylamide gradient gel for subsequent western blotting (also described in
Appendix VI).
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5.2.10: Source of sheep sera
The MVV-infected sheep were from a flock from a farm in the south of
Scotland. All the sheep were Texel breed apart from ShM19 which was a Bleu de
Maine and ShMll which was a Blue-faced Leicester. They were all female and
aged between 1 and 5 years of age at the time when the serum samples were
collected. The year of birth of individual sheep is shown in Figure 5.14.
Sheep had been judged to be MVV-infected by a positive result in the agar
gel immunodiffusion test (AGIDT) (Winward et al., 1979) which detects antibodies
against MVV. The sheep were naturally infected so the date of infection is
unknown.
The uninfected control sheep were from a flock belonging to the Edinburgh
Centre for Genome Research. None of the sheep in this flock have ever tested
MVV-positive by AGIDT.
Serum was complement inactivated by incubation at 56°C for 30 min and




MVV virus was grown in vitro in sheep skin cells derived from skin explants
(Sargan et al., 1991). Sheep skin cells YT40 were passaged 4 times before stocks
were laid down in 20% glycerol in liquid nitrogen. When revived the YT40 cells
grew for at least another 16 passages providing they were split as soon as a 100%
monolayer was formed and cells were not left to overgrow.
5.3.1: Effect of sheep serum on fusion by MYV
A fusion assay was developed to investigate whether serum from MVV
infected sheep could modulate cell fusion by MVV. For clarity, sheep from an
MVV-infected flock are numbered ShM, whilst control sheep from an uninfected
flock are numbered ShU. Titration of MVV and YT40 skin cell fibroblasts showed
that the optimum density of cells that would reliably produce CPE with the
minimum amount of virus was as follows; inoculation of a 96 well plate with
approximately 5 x 104 YT40 cells per well resulted in a complete monolayer after
overnight incubation, inoculation of one of these wells with 50}il of a 1:16 dilution
of EV1 stock consistently produced 10-20 visible syncytia (with three or more
nuclei) after 20-24 hours.
As illustrated in Figure 5.1, incubation of serial dilutions of complement
inactivated sheep serum with the virus before addition to the YT40 cell monolayer
produced a range of effects when compared with addition of virus alone, from
complete inhibition of syncytium formation, to no difference compared to control, to
greatly enhanced syncytium formation.
The results for a panel of sera are shown in Figure 5.2. The sera were tested
blind i.e. before knowing which ones were MVV seropositive to avoid any
unintentional bias in reading the results.
As mentioned above, a range of results were seen. One serum, ShM9, was
able to inhibit syncytium formation at low serum dilutions and had no effect at
higher dilutions. Six of the fourteen sera from sheep from the MVV-infected flock
inhibited syncytium formation at low dilutions but enhanced at higher dilutions of
serum. ShM 17 had little effect on syncytium formation compared to the control. A
further six of the ShM sera enhanced syncytium formation and did not exhibit any
syncytium inhibitory activity. Of these, five had enhancing activity even at dilutions
down to 1:500. In particular, serum ShM 14 greatly enhanced syncytium formation
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Figure 5.1: Effect of serum from MVV-infected sheep on fusion from without
by MVV on YT40 sheep skin cells
Sufficient MVV to cause fusion-from-without (FFWO) of sheep skin
fibroblasts was incubated with dilutions of sheep sera for 1 hour at 37°C. Virus
plus serum was then added to the cells, incubated for 20 hours then fixed and
stained to determine whether the serum had any effect upon FFWO by MVV.
Examples of the results are shown opposite:
a) Serum ShU6 at 1:8 dilution; no effect on syncytium formation (relative to
control).
b) Serum ShM4.1 at 1:8 dilution; inhibition of syncytium formation.
c) Serum S14.1 at 1:8 dilution; enhancement of syncytium formation.
In the absence of virus, the addition of serum to the cells has no apparent
affect, i.e. the appearance of the cells is the same as with medium alone.
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Figure 5.2 Fusion assay results - Blind trial on sera from MVV-infected flock
and from MVV-negative flock.
Serum 8
Reciprocal serum dilution
16 32 64 128 256 512
ShM3.1 1 1 0 0 0 0 0
ShM4.1 -2 -1.5 -1 -0.5 0 0 1
ShM5.1 -1 0 1 1 0 0 1
ShM6.1 -1 0 1 0 0 0 0
ShM7.1 0.5 0 1 2 1 1 1
ShM8.1 -2 0 2 2 1 2 1
ShM9.1 -2 -1 0 0 0 0 0
ShMlO.l 0 1 1 2 2 2 1
ShM 11.1 -2 -1 1 2 2 2 2
ShM12.1 0 1 2 2 2 2 2
ShM13.1 0 2 2 2 2 2 2
ShM14.1 2 2 2 2 2 2 2
ShM16.1 -2 -1.5 -0.5 1 1 2 2
ShM17.1 1 0 0 0 0 0 0
ShU4 1 1 0 0 0 0 0
ShU5 2 2 0 -0.5 0 0 0
ShU6 0 0 0 0 0 0 0
ShU7 2 2 2 1 0 0 0
ShU8 0 2 2 0 0 0 0
Sheep ShU are from an uninfected flock. Sheep ShM are from a MVV-
infected flock.
The scores are the average from four plates.
The results are also shown opposite in a graphical form. Bars above the zero
line represent enhancement of virus mediated cell fusion. Bars below zero
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at all the dilutions tested. Of the negative controls, ShU, four of the five had some
enhancing activity, although only at higher serum concentrations. The highest
dilution which mediated enhancement was 1:64.
The results of the two groups of sera, ShU and ShM, from sheep from an
uninfected or MVV-infected flock respectively, were compared to see if there was
any significant difference in the way they acted in the fusion assay. The null
hypothesis is that the two populations are the same with respect to this assay. The
calculated values of t when comparing the results of ShU with ShM are listed below.
The formulae for calculating t are shown in Appendix IX.










8 1 -0.54 2.228
16 1.4 0.14 2.144
32 0.8 0.82 0.036
64 0.1 1.11 2.138
128 0 0.93 2.159
256 0 1.07 2.290
512 0 0.687 2.754
The critical value for to.05 with 17 degrees of freedom is 2.11. For all
dilutions except 1:32 the calculated value of t is greater than the critical value. Thus
the null hypothesis can be rejected with 95% confidence, i.e., the two populations
are significantly different in the way the sera react in the fusion assay.
A graph of the mean fusion scores for the ShM and ShU groups is shown in
Figure 5.3. This shows that on average sera from MVV-infected sheep inhibit fusion
at the highest concentration and enhance at lower concentrations. In contrast sera
from uninfected sheep tend to enhance fusion at higher concentrations but
enhancement titres out by 1:64. The dilution of 1:32 at which there is no significant
difference between the two populations is where the average values cross-over.
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Figure 5.3: Mean fusion scores for sera from MVV-infected sheep and
uninfected sheep.
The mean score at each dilution in the 37°C fusion assay shown in Figure 5.2






Serial bleeds taken from sheep in the MVV-infected flock at 6 weekly
intervals were tested in the 37°C fusion assay to see if the activity remained
consistent. The results, shown in Figure 5.4, were broadly similar for the serial
samples from any one sheep, except in the case of ShM2 where the first 2 samples
had no effect on syncytium formation whilst the third and fourth bleeds had
enhancing activity and ShM8 where the results were variable.
5.3.2: Reproducibility of the 37°C fusion assay
Ten sera were common to both the assays whose results are shown in Figure
5.2 and Figure 5.4. Clearly there are some discrepancies between the results of the
different assays. There is inherent variability in this assay despite the fact that the
same cells (but different passages), aliquots of the same virus stock, and the same
serum samples were used on each occasion. Although the fusion scores showed
some variation at all dilutions tested, direct comparison of the sera common to both
assays showed the results were not as dissimilar as they at first appeared: 29 of the
fusion scores were the same for the same serum at the same dilution factor, 29
differed by 0.5-1, and 12 differed by more than 1. Thus 82% of the individual scores
did not differ by more than 1 point, indicating that most results were similar if not
the same, in both assays. In most cases the overall pattern of activity for each
individual serum was conserved. Comparison of the fusion assay results of the ShM
sera in Figure 5.2 with those of the ShMn.l sera in Figure 5.4, bearing in mind that
three sera in each assay were not used in the other, shows that they were not
significantly different since at each dilution the calcualted t value was less than the
critical value.
Comparison of results of different fusion assays
Serum ShM (Fig 5.2) ShM (Fig 5.4) t
dilution factor mean value mean value value
8 -0.54 -0.57 0.09
16 0.14 -0.04 0.67
32 0.75 0.50 1.17
64 1.11 0.89 1.37
128 0.93 1.18 1.92
256 1.07 1.32 1.85
512 1.07 1.32 1.85
n=14 The critical value for to.os with 13 degrees of freedom is 2.16.
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Figure 5.4: Fusion assay results- Serial bleeds from sheep from an MVV-
infected flock.
Blood samples were taken at 6 weekly intervals. Sample n.l represents the first
sample, (taken at week 0), n.2 the second, (taken at week 6), etc.
Reciprocal serum dilution
Serum 8 16 32 64 128 256 512,
ShMl.l -1.5 -0.5 2 2 2 2 2
ShM1.2 -2 -1.5 0 1 2 2 2
ShM1.3 -2 -1 0 0 2 2 2
ShM2.1 -1 0 0 0 0 0 0
ShM2.2 0 0 0 0 0 0 0
ShM2.3 0 1 1 1 2 1 0
ShM2.4 0 2 2 1 2 1 0
ShM3.1 -1.5 0 0 0 0 0 0
ShM3.2 -1 0 0 0 0 0 0
ShM3.3 -1.5 1 0 0 0 0 0
ShM4.1 -1.5 0 1 1 1 2 2
ShM4.2 0 0 0 1 1 1 2
ShM5.1 -2 -1.5 -0.5 0 2 2 2
ShM5.2 -2 -1.5 1 1 2 1 2
ShM5.3 -2 -1.5 0 1 2 2 2
ShM5.4 -2 -1.5 -0.5 0 1 1 1
ShM6.1 -2 -2 -1 0 1 1 1
ShM6.2 -2 -0.5 0 1 1 1 2
ShM6.3 -1 0 0 0 1 1 1
ShM6.4 -2 -0.5 1 1 1 1 2
ShM8.1 -1 0 0 1 1 1 1
ShM8.2 -2 -2 0 0 0 0 2
ShM8.3 0 1 1 1 1 2 2
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Reciprocal serum dilution
Serum 8 16 22 64 128 256 511
ShM9.1 -2 -2 -1 1 1 1 1
ShM9.2 -2 -2 -1 0 0 0 1
ShM9.3 -2 -2 -2 -0.5 0 0 1
ShMlO.l 2 2 2 2 2 2 2
ShM10.2 2 2 2 2 2 2 2
ShM10.3 2 2 2 2 2 2 2
ShM10.4 2 2 2 2 2 2 2
ShM12.1 -1 0 1 1 2 2 2
ShM12.2 -1 0 1 1 1 1 1
ShM12.3 -0.5 0 0 1 1 1 2
ShM12.4 0 0 0 1 1 1 1
ShM13.1 1 2 2 2 2 2 2
ShM13.2 1 2 2 2 2 2 2
ShM13.3 1 2 2 2 2 2 2
ShM14.1 2 2 2 2 2 2 2
ShM14.2 2 2 2 2 2 2 2
ShM14.3 2 2 2 2 2 2 2
ShM14.4 1.5 2 2 2 2 2 2
ShM15.1 -1.5 -1.5 -1.5 -1.5 -1.5 -0.5 -0.5
ShM15.2 -1.5 -1.5 -1.5 -1.5 -0.5 -0.5 0
ShM15.3 -2 -1.5 -2 -1.5 -0.5 -0.5 0
ShM15.4 -2 -2 -2 -1 -1 -0.5 -0.5
ShM17.1 2 2 2 2 2 2 2
ShM17.2 1 1 1 1 1 1 1
ShM17.3 2 2 2 2 0 0 0
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5.3.3: Effect of IgG and IgG-depleted serum in the 37°C fusion assay
Eight sera were selected covering the range of activities seen in the fusion
assay and including two MVV negative controls. They were recoded and shuffled in
order to screen them blind.
1- MVV positive, neutral in fusion assay (ShM2.1)
2- MVV positive, blocked syncytium formation (ShM10.3)
3- MVV positive, enhanced syncytium formation (ShM13.3)
4- MVV negative, neutral in fusion assay (ShU4)
5- MVV negative, neutral in fusion assay (ShU6)
6- MVV positive, blocked syncytium formation at low dilutions, enhanced at
higher dilutions (ShM5.4)
7- MVV positive, blocked syncytium formation at low dilutions, enhanced at
higher dilutions (ShM1.3)
8- MVV positive, blocked syncytium formation at low dilutions, neutral at
higher dilutions (ShM3.3)
IgG was prepared from these sera using a Sepharose-G column. The
approximate protein concentrations of the pooled peak IgG fractions, (B), and the
column flow through (C), are shown in Figure 5.5. The IgG concentration in the
flow-through shows that the Sepharose G column had removed the majority of the
IgG from the serum. The IgG eluted from the column had been diluted compared to
the expected IgG concentration in serum (~10mg/ml) during elution from the
column.
The sera, IgG preparations and column flow-through (serum with most of the
IgG removed) were tested alongside each other in the fusion assay to investigate
which components of the serum might be exerting an effect on syncytium formation
by MVV virus (Figure 5.6). The control for comparison with the IgG preparation,
(which had been eluted in Tris, glycine before dialysis into PBS), was Tris, glycine
pH7.0. This had no effect on syncytium formation. Control wells with the test
samples at the highest concentrations used in the assay showed that serum, IgG or
column flow-through did not cause fusion or have a visible detrimental effect on the
cells in the absence of MVV.
As predicted a range of results were seen in the fusion assay with whole
serum. The IgG preparations all showed fusion enhancing activity but the titres
varied, whereas the IgG depleted sera had very little fusion enhancing activity. This
indicates that fusion enhancing activity was mediated principally by the IgG fraction.
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Figure 5.5: Fractions prepared from sheep sera.
IgG was prepared using a Sepharose-G column. The protein concentration in
the pooled IgG fractions eluted from the column was measured using a colourimetric
assay (Biorad protein assay). The approximate dilution factor in the pooled fractions
compared to serum assumes a concentration of approx. lOmg/ml IgG in serum. The





























Figure 5.6: Fusion assay results - Ig preparations from selected sera.
The results are tabulated below and illustrated as bar charts opposite.
KEY:- A-Serum.
B-Ig eluted from Sepharose-G column.
C-Serum depleted of IgG (i.e. flow-through from Sepharose-G column)
Reciprocal dilution
4 8 16 22 64 128 256 500 1000 2000
ShM1.3A 1.5 1.5 2 2 2 2 2 1.5 1 1
ShM1.3B 2 2 2 2 1.5 1.5 1.5 0.5 0 0
ShM1.3C 1 0.5 0 0 0 0 0 0 0 0
ShM2.1A 0 1 0 0 0 0 0 0 0 0
ShM2.1B 2 1.5 0.5 1 1 0.5 0.5 0 0 0
ShM2.1C 0.5 0 0 0 0 0 0 0 0 0
ShM3.3A 0 0 0 0.5 0.5 0 0 0 0 0
ShM3.3B 2 2 2 1 0.5 0 0 0 0 0
ShM3.3C 0.5 0 0 0 0 0 0 0 0 0
ShM5.4A -2 -1 0 2 2 2 1.5 1.5 1 0.5
ShM5.4B 2 2 2 1.5 1.5 1 0.5 0 0 0
ShM5.4C 0 0 0 0 0 0 0 0 0 0
ShM10.3A -1.5 -1 -1.5 0 0.5 1 1 1 0 0
ShM10.3B 2 1.5 1.5 1 0 0.5 0 0 0 0
ShM10.3C 0 0 0 0 0 0 0 0 0 0
ShM13.3A 2 2 2 2 2 2 2 2 1.5 1.5
ShM13.3B 2 2 2 2 2 2 1.5 1.5 0 0
ShM13.3C 1 1 1 0 0 0 0 0 0 0
ShU4A 1.5 1 0.5 0 0 0 0 0 0 0
ShU4B 2 1.5 0.5 0 0 0 0 0 0 0
ShU4C 0.5 0 0 0 0 0 0 0 0 0
ShU6A 0 0 0 0 0 0 0 0 0 0
ShU6B 1 0.5 0 0 0 0 0 0 0 0
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Reciprocal dilution
It is interesting to note that ShM13.3C and ShM1.3C, which were the flow-through
fractions with the most enhancing activity in the fusion assay, were two of the three
samples which still contained measurable amounts of IgG.
IgG prepared from ShU4 and ShU6 exhibited fusion enhancing activity only
down to dilutions of 1:16 and 1:8 respectively, whilst enhancement by the ShM sera
titred out at 1:128-1:500. Although the ShU results suggest that specific anti-MVV
antibodies are not necessarily required for fusion enhancement, the difference in
titres between ShU and ShM does indicate that antibodies against MVV are
important. The lowest concentration of IgG required to enhance fusion can be
estimated by dividing the protein concentration in the IgG preparation by the highest
dilution which had a positive score in the fusion assay. For the MVV seropositive
group this figure ranged from 3-24|ig/ml, compared to 50-140(1g/ml for the
uninfected group. Admittedly the numbers tested here were too small for the
difference to be statistically significant.
The fact that syncytium inhibition was seen by sera but not by IgG may be
explained by the dilution factor between the amount of IgG normally found in serum
and the concentration at which it could be purified. Since the sheep sera only have
fusion blocking activity at low dilutions a good recovery of IgG from the serum is
neccessary to attempt to show a similar effect, if the activity is indeed IgG mediated.
The concentration of IgG eluted from the column varied between 1/3 and 1/13 of the
concentration of IgG in normal serum.
There are some unexpected results in Figure 5.6: ShM2.1A serum has little
effect in the assay whilst the IgG prep ShM2.1B enhances fusion. The same is seen
for ShU6 and ShM3.3. Since IgG-depleted serum does not inhibit fusion, it does not
appear to contain factors acting directly with cells or virus to inhibit fusion. Thus it
appears that factors in serum may interact with IgG and block the activity that
enhances syncytium formation when IgG is tested in the fusion assay in the absence
of other serum factors.
ShM1.3 serum was previously shown to block syncytium formation at high
concentrations and to enhance at low concentrations, yet in this assay only
enhancing activity was seen. This is an extreme case in the variability of the fusion
assay.
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5.3.4: The 4°C fusion assay
The 4°C fusion assay was devised to try to distinguish between inhibition of
MVV-mediated fusion by prevention of binding of the virus to the cell surface or by
a mechanism which specifically blocks the fusion event. The 37°C assay where
virus is preincubated with antibody cannot distinguish between the two, and at 37°C
the interval between virus binding to the cell and membrane fusion taking place may
be to short to assay for factors acting upon the post-binding fusion event. At 4°C
cell membranes lose their fluidity and membrane fusion is prevented, or at least
greatly slowed, but binding of virus to the cell surface can happen at this
temperature. The hypothesis is that by binding virus at 4°C and removing any
unbound virus before adding serum and shifting to 37°C that factors which affect
fusion should be detectable which may otherwise be masked by factors which affect
viral binding.
In the 4°C fusion assay monolayered YT40 cells were incubated with high
titre MVV at 4°C for 60 min. Unbound virus was washed off using cold DME2.
Dilutions of serum were added initially at 4°C then the plates were incubated at 37°C
overnight. The effect of the serum on fusion-from-without was scored by
comparison with wells to which virus but no serum was added. Preliminary
experiments were done to optimise the cell density and virus concentrations. It was
neccessary to have the cells slightly overconfluent as they "shrank back" during
incubation at 4°C so that a less mature monolayer did not form syncytia during
subsequent incubation at 37°C. In addition the concentration of MVV virus used had
to be increased to allow for the fact that much of the virus remained unbound and
was removed from the culture.
As can be seen in Figure 5.7 the results of the 4°C assay were different from
the results of the 37°C assay. For example ShM4.1 blocked fusion in the 37°C assay
but enhanced in the 4°C assay, whilst ShMU7 and ShMU8 were both neutral at 37°C
but enhanced at 4°C. ShU6 inhibited syncytium formation in the 4°C assay.
The results showed that enhancement of syncytium formation can occur after
the virus has already been bound to the cell surface. Sera that inhibit fusion in the
37°C but not in the 4°C assay probably act by blocking binding of the virus to the
cell.
Statisical analysis revealed a significant difference between sera from the
ShU and ShM populations with respect to fusion modulatory activity at dilutions
1:32 and 1:128, but not at 1:8, 1:16, nor 1:64. The sera from MVV-infected sheep
tended to have greater enhancing activity in the 4°C fusion assay than sera from
uninfected controls.
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Figure 5.7: Comparison of results from the 4°C and 37°C fusion assays.
The table below shows the results of the 4°C fusion assay for seven
sera from sheep from an MVV-infected flock and four sera from uninfected control
sheep.
The bar graphs opposite illustrate the results of the 4°C fusion assay
alongside the results of the 37°C fusion assay (shown in figure 5.2).
Serum Reciprocal serum dilution
8 16 32 64 128.
ShM4.1 1 2 2 1 1
ShMS.l 1 1 1 1 1
ShM8.1 1.5 2 2 2 2
ShM9.1 -1 -0.5 0.5 0.5 0.5
ShMlO.l 2 2 2 2 2
ShMll.l 2 2 2 2 2
ShM14.1 -1 0 0 0 1
ShU5 -1.5 0 0 0 0
ShU6 1 1 0 1 0
ShU7 0 0 0 1 1
ShU8 0 0 0 0 0
Statistics
Reciprocal serum dilution
8 16 32 64 128
ShU mean -0.125 0.25 0 0.5 0.25
ShU variance 0.797 0.187 0 0.25 0.187
ShM mean 0.785 1.214 1.357 1.214 1.357
ShM variance 1.418 0.990 0.622 0.561 0.336
t value 1.244 0.055 3.17 1.58 3.109






































































































































































































Figure 5.8: 4°C fusion assay results- selected sera Ig preparations.
The results are tabulated below and illustrated as bar charts opposite.
KEY:- A-Serum.
B-Ig eluted from Sepharose-G column.
C-Serum depleted of IgG (i.e. flow-through from Sepharose-G column)
Reciprocal Dilution
1 4 8 16 22 64 12&
ShM1.3A 0 0 0 1.5 0 1 0
ShM1.3B 2 2 2 1 1.5 1 0
ShM1.3C 1 0.5 0.5 0 0 0 0
ShM2.1A 0 0 0 0 0 0 0
ShM2.1B 2 2 2 1 1 0 0
ShM2.1C 2 0.5 0 0 0 0 0
ShM3.3A 0 1 0 0 0 0 0
ShM3.3B 2 1 1.5 0 0 0 0
ShM3.3C 0 0 0 0 0 0 0
ShM5.4A 0 0 0 1 1 2 0.5
ShM5.4B 2 2 2 2 1 1.5 1
ShM5.4C 0 0.5 0.5 0 0 0 0
ShM10.3A 1 2 2 2 2 2 1
ShM10.3B 2 2 2 2 1 0 0
ShM10.3C 1 0.5 1 0 0 0 0
ShM13.3A 0 1 1 1 1 1 0.5
ShM13.3B 2 2 2 1.5 1 1 0
ShM13.3C 2 2 2 1 0 0 0
ShU4A 1 1 0 0 0 0 0
ShU4B 2 0.5 1.5 0.5 0 0 0
ShU4C 2 2 0 0 0 0 0
ShU6A 0 0 0 0 0 0 0
ShU6B 2 2 2 1 0 0 0



















□ C: IgG-deplcted scrum
al mI 1 1
T T T T








-| 1 1 1 1 1 1—



























—i 1 1 1—














-2.0 1 1 1 1 1 1 1—
2 4 8 16 32 64 128
M.
-| 1 1 1 1—


























2 4 8 16 32 64 128
Reciprocal serum dilution
Eight IgG preparations, as described previously, were tested in the 4°C assay
alongside whole serum and IgG depleted serum (Figure 5.8). All eight of the IgG
preparations enhanced fusion whilst only three of the eight serum samples showed
enhancing activity at more than two different dilutions. This suggests that, as in the
37°C fusion assay, other factors in serum may mask the enhancing activity of the
IgG which it contains.
5.3.5: Effect of rgp46 on syncytium formation.
Two-fold serial dilutions of GST:TH, GST:TH digested with thrombin, or a
range of appropriate controls were added to monlayered YT40 cells with or without
sufficient virus to cause fusion-from-without overnight, in order to investigate
whether recombinant gp46(TH) could itself mediate membrane fusion or enhance
fusion at 37°C by MVV virus . TH, at the concentration available, (about 50}ig/ml
GST:TH), had no apparent affect on the cells without virus, when compared to
control wells incubated with medium alone. In the presence of MVV, the
recombinant GST:TH appeared to neither enhance nor reduce syncytium formation.
Ideally a higher concentration would have been used for this experiment.
Larger amounts of recombinant gp46 would also have enabled an experiment to mop
up anti-gp46 activity from sheep sera/IgG preparations to see how this affected the
results of the fusion assays.
5.3.6: Immunoreactivity of sheep sera against recombinant gp46 ELISA
against GST:TH
The results of an ELISA of sera from four MVV-infected sheep (as assessed
by AGIDT) and one negative control against GST or GST:TH antigen is shown in
Figure 5.9. The MVV negative serum reacted to a similar low titre with GST as with
GST:TH which confirmed the amount of antigen in each preparation was similar.
The MVV-positive sheep had antibodies reactive more strongly with GST:TH than
with GST suggesting a specific reactivity with the TH moiety by the sheep with
antibodies against MVV.
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Figure 5.9: ELISA of sheep sera against GST:TH or GST
As an initial assessment of the ELISA, sera from a small number of MVV-
infected (ShM) and one uninfected sheep (ShU) were tested for reactivity against
recombinant gp46 TH by comparison of ELISA against GST or GST:TH fusion
protein.
Reciprocal Serum Dilution
"♦ ShMlB.l - GST
— ShM18.1 - GST:TH
* ShM7.1 - GST
■*— ShM7.1 - GST.TH
'♦ ShM19.1 - GST
"*— ShM19.1 - GST:TH
* ShM8.1 - GST
"*— ShM8.1 - GST:TH
° ShU9 - GST
— ShU9 - GST:TH
A larger group of sheep sera, including some serial samples taken at 6
weekly intervals, from 18 sheep from a MVV-infected flock and 7 sheep from a
negative control flock were tested against GST and GST:TH by ELISA (Figure
5.10). None of the sheep had high levels of activity against GST and all were more
reactive against GST:TH than against GST. The difference between reactivity
against GST and GST:TH ELISA varied from sheep to sheep. If the OD460 values
for ELISA against GST are subtracted from those for ELISA against GST:TH, to
compensate for any reactivity against GST, then the ShM and ShU sheep form two
overlapping groups with the majority of the ShM sheep having higher reactivity
against TH than sheep from the uninfected group.
5.3.7: Correlation of ELISA and fusion assay results
A scatterplot (Figure 5.11) was drawn to see if the ELISA results correlated
with results of the fusion assay. The difference between the ELISA OD460 against
GST:TH and against GST at a serum dilution of 1:300 was calculated. (This value
is described below as the "ELISA value"). This value was plotted against the fusion
scores obtained with the same serum at 1:8 or 1:128 dilution (Figure 5.2). 1:300
dilution was chosen as the differences between GST and GST:TH ELISA results
were greatest at this dilution. Fusion assay results for 1:8 and 1:128 dilutions were
chosen since they were both values at which there was a significant difference
between the uninfected and MVV-seropositve groups.
Sera which enhanced fusion at 1:128 dilution all had relatively high ELISA
values in the range 0.7-1.4 whilst sera which had no effect in the fusion assay at
1:128 spanned a range from 0.1-1.4. In contrast, sera which enhanced fusion at 1:8
dilution had low ELISA values whilst sera which inhibited fusion had high ELISA
values. Thus high ELISA values tend to correlate with fusion inhibition at high
serum concentrations and fusion enhancement at lower serum concentrations. The
scattergraphs also show that, although there were some exceptions, sera from
uninfected sheep tended to have low ELISA values, have enhancing activity in the
fusion assay at high serum concentrations, but no effect upon fusion at low serum
concentrations., whilst sera from MVV seropositive sheep spanned a broader range
of results in both assays.
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Figure 5.10: ELISA of sheep sera against GST:TH or GST (ii).
The reactivity of a larger group of sheep sera was tested against GST or
GST:TH by ELISA. Eighteen sera tested were from sheep from the MVV-infected
flock and seven were from sheep from the uninfected control flock. The results for
sera from the six MVV-positive and two uninfected controls used in the previous
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Figure 5.11: Correlation of the results of ELISA against GST:TH with the
results of the fusion assay.
The anti-GST:TH activity of each sera was estimated by deducting the
ELISA result against GST from the ELISA result against GST:TH: for each
individual sheep an "ELISA value" was calculated by deducting the result (OD460)
of ELISA against GST at a serum dilution of 1:300, from the result of ELISA
against GST:TH (1:300 serum dilution). This value was plotted against the fusion
scores obtained with the same serum at 1:8 or 1:128 dilution (from Figure 5.2).
Open squares on the scatterplots represent sera from uninfected sheep, black
squares represent sera from MVV-infected sheep.
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Scatterplot: ELISA results at 1:300 serum dilution against fusion






















Fusion score at 1:8 serum dilution
Scatterplot: ELISA results at 1:300 serum dilution against fusion






























Fusion score at 1:128 serum dilution
5.3.8: Immunoreactivity of sheep sera sheep against recombinant gp46,
GST:TH, on western blots
Sheep sera were reacted with Western blots of GST or GST:FINV. As can
be seen from Figure 5.12, nearly all the sera reacted against a protein running just
below the 67kDa marker in both GST and GST:FINV preparations. This appears to
be the bacterial protein identified as a major contaminant in preparations made from
GF21- (see Figure 4.2) and which was also present under some conditions in
preparations from other clones. Only sera from MVV-positive sheep reacted with
the 43kDa protein predicted to be GST:TH, with one MVV-negative exception,
ShU3. ShU3 also reacted with a band below 30 kDa which was probably
endogenous GST. Thus activity by ShU3 against the GST:TH product can be
explained by recognition of the GST moiety. This is a clear indication that
recognition of recombinant gp46 (TH) is specific to sheep seroreactive with MVV.
Seven of the nine ShM sera tested reacted with GST:TH, which suggests that a high
proportion of MVV-infected sheep raise antibodies against the external half of gp46.
The recombinant protein is probably unglycosylated suggesting these antibodies are
not dependent upon glycosylation of the protein for their reactivity.
There was also some minor antibody reactivity against other bands which
merely confirms the presence of contaminating bacterial proteins in the GST:TH
preparation, as was visualised on silver stained SDS-PAGE gels (Figure 4.3a).
5.3.9: ELISA of sheep sera against GST:TH with GSTrFINV as control
antigen
Western blotting against GST and GST:FINV, (Figure 5.12), showed that
sera from both ShU and ShM groups reacted with some of the contaminating
bacterial proteins in the preparations. The GST preparation contained very little
contaminating E.coli protein whereas GST:FINV contained a similar proportion of
contaminating bacterial proteins to the GST:TH preparation. Therefore GST:FINV
is a better negative control antigen for ELISA than GST.
The eight IgG preparations, described in Figure 5.5 were assayed by ELISA
against GST:TH and GST:FINV (Figure 5.13). The results for each serum differed
little between the two antigens. Consequently the difference found in ELISA
activity against GST:TH compared to GST cannot be concluded to be necessarily
due to activity against the TH moiety as reactivity against the additional bacterial
proteins present in the GST:TH preparation cannot be ruled out. This does not
negate the correlation between ELISA and fusion assay results described in Figure
5.11, but does alter the interpetation of the results in that a high ELISA value cannot
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Figure 5.12: Reactivity of sheep sera with western blots of GST:TH.
Sera from MVV-infected sheep, (ShM), or from uninfected sheep,
(ShU),were reacted with Western blots of a) GST:TH or b) GST:FINV. (Sera from
uninfected sheep are further emphasised with a *).
The constituents of GST:TH or GST:FINV preparations were separated by
SDS-PAGE on a 10% polyacrylamide preparative gel and western blotted onto
nitrocellulose. Strips were developed with sheep sera at 1:200 and anti-sheep
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Figure 5.13: ELISA of IgG from MVV-infected or uninfected sheep against
GST:TH or GST:FINV
IgG prepared from the serum of six MVV-infected (ShM) and two uninfected
sheep (ShU) were tested for reactivity against recombinant gp46 TH by comparison
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be assumed to be due solely to anti-rgp46 activity. If the main reactivity measured
by the ELISA was directed against contaminating bacterial proteins then it could be
concluded that, in general, sera from MVV-infected sheep had greater reactivity with
bacterial proteins than sera from uninfected sheep. Another explanation would be
that the first ELISA did indeed detect substantial anti-TH activity but that much of
this could have been mediated by IgM rather than IgG.
5.3.10: Summary of results from fusion assays and antibody detection.
Figure 5.14 summarises the analysis of activity of serum from a small group
of sheep from an MVV-infected flock and two sheep from an uninfected flock. It is
clear that the antibody reactivity against whole MVV as measured in the Ministry of
Agriculture AGIDT correlates with activity in the fusion assay when comparing
seropositive to seronegatives. However, the degree of positivity in the AGIDT, i.e.,
+/-, +, or ++, is not predictive of what activity the individual serum will have in the
fusion assay.
Since antibodies against the external envelope protein are also known to
interfere with virus fusion it is not surprising that although the majority of ShM sera
are reactive against rgp46 TH on Western blots, (Figure 5.11), this does not show a
complete correlation with activity in the fusion assays.
5.3.11: Correlates of clinical status
Figure 5.16 summarises the results from the larger group of sheep sera.
Unfortunately the data is incomplete in places especially concerning reactivity to
EVl-lysate on Western blots. The final column gives a crude indication of the
clinical status of the sheep and is derived from data compiled by Dr N.J. Watt and
shown in Figure 5.15. A +/-scoring system was used to grade the severity of
pathological lesions found at post-mortem in the lung, CNS, and mammmary tissue
of each sheep. The score for pathology status was derived by adding the total
number of +s, thus a higher pathology score indicates more serious disease. There is
no apparent correlation between fusion activity and disease in individual sheep.
However this is by no means automatic e.g. sera from sheep ShM13 and ShM14
both have high enhancing activity (+2) right down to a 1:500 dilution in each of the
serial samples yet at post-mortem ShM14 had no significant clinical pathology
(score = 0) whilst ShM 13 had pathology of maedi in the lung and also had mastitis
(score = 4).
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Figure 5.14 Clinical-pathological status of MVV-infected sheep *
Sheep Year of Date of Respiratory CNS Mammary PATH.
No. Birth PM+ Maedi Other Visna Mastitis SCORE
ShMl 1986 6.5.91 ++ ++ 4
ShM2 1989 A
ShM3 1986 7.3.91 + ++ 3
ShM4 1986 22.1.91 - ++ 2
ShM5 1986 A
ShM6 1986 31.5.93 (sudden death, no PM).
ShM7 <1985 29.5.92 +++ + - + 5
ShM8 1986 11.12.92 - meningioma 1
ShM9 1986 17.6.91 + fibrosis 2
ShMlO 1986 A
ShMl 1 <1985 24.6.91 - ND 0
ShMl 2 1986 24.6.91 - ND 0
ShMl 3 <1985 24.4.91 +++ + 4
ShM14 1986 16.9.91 - - 0
ShMl 5 1987 9.9.92 +++ + 4
ShMl 6 1986 18.12.90 + +++ 4
ShMl 7 1987 <1.11.90 ++ + + 4
ShMl 8 1986 29.5.92 + ++ - ++ 5
ShMl 9 1987 17.3.93 + - 0
ShM20 <1985 12.6.92 oedema 1
* Score of disease severity from clinical data compiled at post-mortem by Dr
N.J.Watt.
f Date of post-mortem. Sheep not yet post-mortemed are shown as A (Alive).
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Figure 5.15: Summary of activity of sheep sera.
AGIDT* Western blots Fusion assayt Patholog
GST GST:TH TH MVV 1:8 1:256 score00
ShMl + - p24+ b e 4
ShM2 +/- - 0 0 ND
ShM3 +/- b 0 3
ShM4 ++ ? + b e 2
ShM5 + p24+ b e ND
ShM6 + + b e ND
ShM7 ++ + + 0 e 5
ShM8 ++ + + b e 1
ShM9 + + b e 2
ShMlO + + + e e ND
ShMl 1 ++ + b e 0
ShM12.1 + + b e 0
ShM13 ++ e e 4
ShM14 + + e e 0
ShM15 b b 4
ShM16 ? + b e 4
ShM17 ? - e 0 4
ShU2 + e 0
ShU4 - - - e 0
ShU5 - - e 0
ShU6 - - - 0 0
ShU7 - - e 0
ShU8 - + 0 0
* AGIDT Agar gel immunodiffusion test for seroreactivity against whole MVV
t Fusion assay (37°C) results are shown for 1:8 and 1:256 serum dilutions and are
summarised as e (fusion enhancing), b (fusion blocking), and 0 (no effect on MVV
induced fusion).




5.4.1: The fusion assay
The fusion assay was devised as a read out for virus/cell fusion to ask
whether serum from infected sheep could modulate cell fusion by MVV. Although
fusion-from-without (FFWO) by virus at high m.o.i. has been used in previous
studies of viral fusion the mechanism by which the actual fusion event occurs is not
known. It has been assumed to be the same mechanism as for initial viral entry. The
assumption may be correct if syncytia are formed during FFWO by individual virus
particles fusing with more than one cell at the same time. This could explain why
confluent cells and high concentrations of virus are necessary for FFWO as this
would maximise the chances of virus particles landing between two adjoining cells.
An alternative mechanism for FFWO may be that the virus binds to and fuses first
with one cell and subsequently mediates fusion with a neighbouring cell. Fusion
with the first cell would release the capsid into the cytoplasm and the viral envelope
would become incorporated into the cell cytoplasmic membrane. If the envelope
proteins remain functional and are laterally mobile within the membrane they may
move to an area of contact with an adjacent cell and may be able to mediate fusion
between the two membranes. High concentrations of virus could enhance this
process by increasing the chances of multiple infection so that the concentration of
envelope proteins on the infected cell surface would be increased thereby increasing
the probability of fusion with a neighbouring cell. The latter hypothetical pathway is
likely to be a slower mechanism than the former.
5.4.2: Effects of sheep serum on fusion-from-without by MVV
The fusion assay showed that the individual pattern of fusion modulatory
activity was variable from sheep to sheep but taken overall there was a significant
difference between the effect of sera from uninfected sheep compared to sera from
MVV-seropositive sheep upon cell fusion mediated by MVV. Serum from
uninfected sheep generally enhanced fusion at low dilutions of serum (<1:64) and
had no effect at higher dilutions, whereas serum from MVV infected animals tended
to inhibit fusion at low serum dilutions (<1:16) and enhance at higher dilutions.
The effect of purified IgG compared with the corresponding serum or serum
depleted of IgG, in the fusion assay showed that enhancement of MVV syncytium
formation was mediated by antibody. IgG from MVV infected sheep was shown to
enhance fusion down to concentrations ranging from 3-24(ig/ml (total IgG) whereas
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the IgG from uninfected sheep enhanced fusion only at greater than 50-140|ig/ml.
This shows that although non-specific IgG can enhance fusion, IgG which includes
antibodies against MVV has greater enhancing activity than non-specific IgG.
Although inhibition of fusion by IgG could not be shown directly this may
have been due to dilution of IgG relative to the concentration in serum. As fusion
inhibition was not shown by IgG depleted serum where there was no dilution factor
relative to whole serum, it may be concluded that IgG is required for fusion
inhibitory activity. A requirement for IgG in association with some other serum
components cannot be ruled out.
Clearly the effect in the fusion assay was dependent on the dilution of the
serum. The relative amount of antibody to virus probably determines the outcome of
the of the fusion assay. Sera which inhibited at higher concentrations almost always
enhanced fusion at lower concentrations of serum. This is in agreement with reports
in the HIV literature that when antibody was in excess fusion/infection could be
blocked, whilst low amounts of antibody could actually facilitate infection (Takeda,
1988, Pemo et al„ 1990).
The 37°C fusion assay could not differentiate between inhibition by blocking
of virus attachment or by blocking of fusion. The 4°C fusion assay was designed to
try to detect only antibodies which block fusion after binding of the virus to the cell
surface. In this assay virus was bound to the cells at 4°C and free virus was removed
before addition of serum and shifting to a temperature permissive for membrane
fusion. This differs from the 37°C assay where antibody was reacted with virus
before adding both to the cells. In the 4°C assay serum was shown also to have
either an inhibitory or enhancing effect on FFWO. The fact that enhancement can
occur after virus has bound to the cell suggests that increasing binding to the cell
surface is not the only mechanism of enhancement. Similarly it is clear prevention
of virus binding to the cell surface is not the only mechanism of fusion inhibition.
Possible mechanisms of fusion enhancement and inhibition by serum are
discussed in Section 6.7 and 6.8.
5.4.3: Problems and possible improvements to the fusion assay
Despite care being taken to try to make the assays reproducible repeated
assays did not produce exactly the same results on different occasions, although the
general trends remained the same. There are a number of reasons why results may
have varied. Although the same cell line was used throughout, the passage number
of the cells increased over time. Changes in the cells such as time from previous
passage possibly had some effect on the rate of fusion. The results of fusion assays
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with serum with the majority of the IgG removed shows that serum factors other
than IgG can have an effect. Different batches of FCS may contain different cellular
growth factors. However, a single batch of FCS was used for the media throughout
these experiments and therefore should not have contributed to variation. The
degree of syncytium formation in the control wells remained fairly constant
suggesting the amount of virus in different aliquots did not vary significantly.
The relatively subjective scoring system used in this chapter only noted
striking effects upon virus mediated syncytium formation: Scoring was by
comparison with control wells containing virus without added serum and a score of 0
for similar number and size of syncytia to the control, -1 where the syncytia were
significantly fewer/smaller, -2 where no syncytia were visible, +1 where there were
larger and more numerous than in the control, and +2 where syncytium formation
was enhanced to the extent that virtually all the cells in the monolayer had become
fused. (Scores of + or - 0.5 and 1.5 sometimes resulted due to averaging the score
from duplicate wells). An assay which measured fusion index by counting the
number of nuclei and number of cells in a given field of view could have improved
the sensitivity of the assay by detecting more minor effects on fusion. However,
given the variability of the assay a fusion index would probably have been no more
informative than the +/- system of scoring and the conclusions from the assays
would have remained the same, i.e, that sera from MVV-infected and uninfected
sheep have different fusion modulatory activities, (as described above).
5.4.4: Alternatives to the fusion assay
I devised a method based on FACScan analysis and anti-MVV antibodies to
differentiate infected and/or cell with virus bound or fused from uninfected cells
Unfortunately the anti-MVV polyclonal rabbit anti-sera tried had anti-cellular
activity and therefore the background against uninfected cells was too high for this
method to be successful. Now that recombinant MVV envelope proteins are
available it should be possible to generate anti-sera or monoclonal antibodies which
could be used for this method.
A system which has been used to study membrane fusion is resonance energy
transfer or flourescence dequenching. This assay takes advantage of the resonance
energy transfer between two fluorescent lipids (N-NBD-PE and N-Rh-PE). When
they are both present in the labelled membrane, fusion with an unlabelled membrane
causes dilution of the fluorescent lipids resulting in decreased energy transfer and an
increase in fluorescence emission from the energy donor N-NBD-PE. This
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technique has been used to monitor fusion between membrane vesicles (liposomes),
or between membrane vesicles and virions, erythrocyte ghosts or living cultured
cells (Struck et al., 1981, Chejanovsky and Loyter, 1986, Chejanovsky etal., 1986).
This technique requires sophisticated equipment so a simpler method was tried
which involved labelling of the viral envelope or cell membrane with a fluorescent
marker, NBD, detectable by FACScan. However, this marker did not remain stably
bound to the cell membrane. When an NBD-labelled population of uninfected cells
was mixed with an unlabelled population of cells all the cells became labelled. Even
extensive washing after labelling did not prevent this problem. Therefore the
method was not pursued. Better fluorescent labels now on the market, which are
reported to remain stably bound to labelled cells, may have enabled a successful
assay to have been developed along these lines.
5.4.5: Recombinant gp46 TH
The effect of rgp46 TH on cells and on FFWO by MVV was tested. No
conclusions can be drawn from the fact that it did not induce cell-to-cell fusion nor
have any apparent modulatory effect on MVV mediated fusion. Firstly the
concentration and purity of the recombinant protein was very poor. Secondly, if, as
predicted, the secondary structure of the protein is important for fusion function such
recombinant protein would be unlikely to be functional as both protein folding and
oligomerisation might be very different from native protein.
The problems with expression of recombinant gp46 meant that many of the
planned experiments were not possible. These included an experiment to see if
rgp46 could bind to cellular receptors and block virus fusion, and experiments to
remove or extract anti-gp46 antibodies from sera to determine whether such
antibodies are important in fusion modulation.
5.4.6: Immunoreactivity of sheep sera to rgp46
The sheep in the ShM group had been judged to be MVV-infected by the
AGIDT (agar gel immunodiffusion test) which detects antibody reactivity to MVV
proteins but does not differentiate between activity against individual viral proteins
(Winward et al., 1979). Western blots with MVV-infected-cell lysate as antigen
detects antibodies against some MVV proteins but no protein corresponding to gp46
can be identified on such blots. An example is included in Figure 3.13, which shows
that all six of the MVV-infected sheep had antibodies reactive with gpl60 and four
of these also reacted with p24. It is not clear whether the failure to detect good gp46
reactivity on western blots is due to a lack of gp46 in the antigen preparation or to
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non-reactivity of infected sheep to this protein. Thus recombinant gp46 was
necessary to determine whether an antibody response to gp46 is elicited in the
MVV-infected animal.
Recognition of recombinant gp46 (TH) was shown to be specific to MVV-
infected sheep. 78% of the MVV seropositive sera tested reacted with GST:TH.
Although the number of sera tested was small, the result nevertheless suggests that a
high proportion of MVV-infected sheep raise antibodies against the external domain
of gp46.
ELISA against GST:TH, with GST as control antigen suggested that sera
from MVV-infected sheep had greater activity against GST:TH than sera from
uninfected sheep, and that the ELISA could be used for screening for antibodies to
the recombinant protein. In contrast when ELISA of IgG prepared from sheep sera
against GST:TH was compared with GSTrFINV as control there was no apparent
difference between reactivity of each individual sheep to either antigen preparation
nor between MVV-infected and uninfected. This can be partly explained by re¬
examination of the western blots (Figure 5.12) which showed that nearly all the
sheep sera reacted with a bacterial protein of about 67kDa which was present in both
the GST and GST:TH, but not GST, protein preparations.
The higher ELISA reactivity of sera from MVV-infected sheep compared to
uninfected controls may therefore not be entirely TH specific, but may also reflect
greater reactivity with bacterial proteins. This might suggest that the ShM group had
been subjected to more bacterial infections than the other, perhaps because of a
lower non-specific immunity; a higher incidence of various infections is apparent in
MVV-infected flocks although specific immune deficiencies have not been reported
(discussed in Chapter 1).
Another explanation for higher reactivity by MVV-infected animals could be
a cross reaction autoimmune reactivity. Recent experiments by G. Harkiss and
colleagues (personal communication) showed that sheep infected with MVV had
increased seroreactivity to heat shock protein HSP65 from Mycobacterium leprae
and Mycobacterium bovis. Heat shock proteins are well conserved across all phyla,
thus the bacterial protein, running level with the 67kDa marker on western blots
(Figure 5.12) could be the E.coli homologue of HSP65. If so, the fact that Harkiss et
al„ found that IgM but not IgG reactive with HSP65 was elevated in MVV-infected
sheep might explain why the ELISA using whole sera detected a significant
difference between ShU andShM whereas the ELISA using IgG preparations
(lacking IgM) did not (Figures 5.11 and 5.13, respectively). However this is not a
very convincing explanation since both ShU and ShM sera reacted with this 67kDa
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protein on western blots.
5.4.7: Correlation of fusion assay results with other data
If considering the uninfected sheep (ShU) and MVV seropositive sheep
(ShM) as two groups rather than as individuals some clear correlations do emerge
from the data. The ShM group tend to have high ELISA values against GST:TH
antigen preparation and to inhibit MVV-mediated fusion at high serum
concentrations whilst enhancing fusion at lower serum concentrations. In contrast
ShU sera tended to have low ELISA values, and had enhancing activity in the fusion
assay at high serum concentrations, but no effect upon fusion at low concentrations.
5.4.8: Relevance to MVV infection in vivo
There was no apparent correlation between either fusion modulatory activity
or the presence of antibodies to rgp46TH and prognosis for the infected animal.
However the sheep in this study had been infected for at least 1 year and probably
for several years. Antibodies against gp46 may not protect from disease pathology
late in infection, although the hope is that they could protect from the establishment
of MVV infection if they were present at the time of viral challenge. In vivo the
relative amounts of virus:antibody are likely to be quite different from the fusion
assay in which a very high infectious dose of virus is used. At initial infection in the
non-immune sheep, even if the viral challenge is very low, virus will be in vast
excess to specific antibody. As the fusion assay showed, at this antibody:virus ratio
non-specific antibodies may actually enhance the ability of the virus to fuse with
target cells. If instead vaccinated animals could raise specific antibodies to MVV,
(but preferably not strain specific), then when challenged with virus, antibodies
would be in excess and fusion of the virus with the target cell might be halted.
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CHAPTER 6: Final Discussion
6.1: INTRODUCTION
MVV is an important sheep disease internationally and in some flocks in this
country . MVV in sheep has also been proposed as an animal model for some aspects
of HIV infection in that MVV infects macrophage/monocytes but not lymphocytes
whereas HIV infects both these cell types. In lentiviral infections the host mounts an
immune response yet this is not effective in eliminating the infection. Much effort is
going into trying to find ways to prevent HIV infection or halt the spread of disease.
The results from studies on MVV may be applicable to HIV. The principal problem
seems to be induction of a protective immune response which is effective and also
broadly reactive rather than type-specific. The transmembrane protein mediates an
essential virus function and as such is a candidate target for a protective immune
response. A number of questions need to be answered to determine the suitability of
gp46 as a vaccine component.: e.g. Is the protein immunogenic? Are antibodies
against gp46 strain specific? Can antibodies against gp46 control virus
infection/spread?
MVV does not grow to high titre in culture making it very difficult to purify
gp46 in quantity from virus preparations. Therefore recombinant gp46 was required
for studies to answer the questions posed above. Prior to this the region of env
encoding the transmembrane subunit had to be cloned. Nucleic acid sequencing of the
clone enabled comparison with other strains of MVV and with other viruses.
The aim of the final section of work was to see whether serum from MVV-
infected sheep had any affect on fusion by MVV to determine whether induction of
antibodies which affect fusion could potentially alter the progression or outcome of
maedi visna disease.
6.2: THE TRANSMEMBRANE ENVELOPE GLYCOPROTEIN, gp46, OF MVV
Cloning of gp46, i.e. the 3' part of env that encodes gp46, enabled its
sequence to be determined for MVV strain EV1. Comparison with the nucleic acid or
amino acid sequences of other MVV strains revealed conserved and variable regions.
Overall there was about 20% divergence within gp46 between strain EV1, 1514 and
SAOMVV. This compares to approximately 10% for gag, 15% for pol, 20% for vif,
21% for tat and 35% for rev (Sargan et al., 1992).
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Comparison of the amino acid translations of gp46 between different MVV
isolates revealed both conserved and variable sequences. Most of the conserved
regions can be linked with a particular function either directly from mutational studies
on MVV or by analogy with regions identified in studies on other viruses. In
particular the amino-terminal end of gp46 is conserved in all MVV isolates sequenced
to date which suggests that most changes in amino-acid sequence and tertiary structure
in this region are disadvantageous. In contrast some regions of the surface envelope
glycoprotein are very variable and antibody resistant viruses can be generated rapidly.
Studies have shown that HIV gpl20 induces protective neutralising antibodies only
against homologous strains of virus. The same is likely to be true of MVV gpllO.
The sequence conservation of parts of gp46 suggests that these may be candidate
epitopes for induction of cross-protective rather than type specific immunity.
By analogy with other retroviruses, gp46 has been assumed to be important in
fusion of the viral and host cell membrane to facilitate infection. Hydrophobicity and
secondary structure plots, derived using the sequence data, showed that gp46 is a
typical fusion protein; It has a hydrophobic alpha-helical region which probably
traverses the cell membrane/virus envelope, and it has an alanine/glycine rich
hydrophobic region at the amino-terminal end. The latter is analogous to fusion
peptides from other enveloped viruses and is conserved between different MVV
isolates. The extracellular domain has potential glycosylation sites. gp46 has a
leucine-zipper like motif carboxy-terminal of the fusion peptide and has conserved
cysteine residues, as have other viral fusion proteins. Conservation of the cysteines is
thought to be necessary in maintaining the required secondary structure for
functionality.
The function of the MVV fusion peptide has been confirmed by Crane et al.
(1991); a peptide GIGLVLAIMAIIAAAGAGLGVA, which is conserved between the
sequenced isolates of MVV, was used to immunise 4 rabbits. One of the rabbits
produced antibodies against this peptide. The serum blocked MVV-induced
syncytium formation by 64% at 1:10 and by 50% at 1:160. The fusion mediating role
of this region was further confirmed by site-directed mutagenesis; when two
hydrophobic amino acids within this region were replaced with non-hydrophobic
amino acids fusion was ablated.
The authors also showed that the peptide described above could itself induce
cell fusion in the absence of virus. The rabbit antiserum against the fusion peptide
blocked the peptide-mediated cell fusion. It has been shown that hydrophobic
peptides spontaneously insert into membranes (Engelman and Steitz, 1981) and that
viral fusion proteins may interact directly with phospholipid components of the cell
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Figure 6.1: Hypothetical stages in peptide mediated membrane fusion
a) Destabilisation of opposing phospholipid bilayers
c) Reformation of lipid bilayers in a new plane resulting in cell fusion
membrane. This leads to the hypothesis that the hydrophobic peptides insert into and
perturb the bilayer structures of closely opposed membranes resulting in mixing and
then resolution with the re-formation of stable bilayers (Figure 6.1). In peptide-
mediated fusion "abortive fusion reactions", i.e. reformation of the original bilayers,
may well be occurring although only the forward reaction, fusion of cells, is
measurable. In virus-mediated fusion the fusion peptide most probably initiates fusion
by destabilising the opposing bi-layer whilst the envelope glycoproteins may be
important in providing a bias towards the forward reaction, e.g. the influenza fusion
model described in Chapter 1 envisages the opening of a fusion pore.
6.3: EXPRESSION OF RECOMBINANT gp46 PROTEIN
The cloned gp46 coding sequence was used to generate vectors to express
recombinant gp46 which was required as antigen to study the immune response to
gp46. Yeast and bacterial expression systems were tried. In the absence of gp46
specific antiserum the criteria for the production of the required protein had to be
verification of the expression vector, identification of the protein fusion partner and a
shift in the size of the fusion partner. The exact size of the recombinant protein was
difficult to determine because mobility on SDS-PAGE gels is not an exact relationship
with molecular weight. Finally the fact that most MVV seropositive but no MVV
seronegative sera recognised the recombinant proteins confirmed their identification.
Vectors were constructed for expression of two different forms of recombinant
gp46; TH, the external region of the transmembrane protein, and TF the full-length
TM sequence, in recognition of the potential problems that expression of the
hydrophobic transmembrane domain might cause upon cytoplasmic expression.
Expression of rgp46 in yeast, as a fusion protein with pi, enabled recovery of
pl:TF and pl:TH although only at low yield and very poor purity. In yeast pl:TF
could be recovered nearly as well as pl:TH so production of pl:TF was concentrated
upon. Unfortunately the poor yield and purity made it impossible to recover TF after
cleavage from pi. This is why an alternative system was tried, namely, expression of
rgp46 inE.coli as a fusion with GST. The E.coli expression system did enable
production of GST:TH at a better yield than pl:TH, but GST:TF was not recoverable
at all. Fewer contaminating proteins were present in the GST:TH preparation than in
pl:TH or pl:TF. The introduction of extra steps, such as a further round of binding
to glutathione agarose beads or purification through a Sepharose size exclusion
column might have improved purification further but probably with a concomitant loss
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of yield.
gp46 (TF) was expressed in cells using recombinant vaccinia virus. Although
the amount of rgp46 was very low, it was sufficient as immunogen in the form of
whole recombinant vaccinia virus and also for the use of infected cells as targets in
cytotoxic T cell assays. Whether the recombinant gp46 was expressed in
transmembrane form by Vgp46 is not clear: Recognition of specific leader "signal"
sequences on a nascent polypeptide is required to initiate translocation of the ensuing
protein domains across the lipid bilayer (Walter et al., 1984) and the transmembrane
domain acts as a "stop transfer" signal. As neither TK nor gp46 included a leader
signal sequence, rgp46 was probably not expressed in a transmembrane form.
However it is possible that the hydrophobic N-terminal of gp46 could act as a signal
sequence since signal sequences consist of hydrophobic amino acids but do not have
conserved primary structures or lengths (Blobel and Dobberstein, 1975). Signal
sequences are subsequently cleaved from the rest of the protein so this would result in
an aberrant transmembrane form of gp46. More detailed studies would be required to
determine whether gp46 expressed by recombinant vaccinia virus took this form.
Antibodies elicited by this gp46 could cross-react with TH, so the fact that sera from
Vgp46 immunised mice reacted with TH on western blots does not indicate whether or
not the protein was expressed in a transmembrane form.
Recombination of gp46 into the HA gene of vaccinia virus, which does include
a leader sequence may have enabled expression of gp46 in nearer native form,
probably glycosylated and as a transmembrane protein, as was described for
expression of bovine PIV-3 envelope glycoproteins by recombinant vaccinia viruses
(Sakai and Shibutah, 1989). Unfortunately plasmids for generation of HA gene
recombinants were not available to us at the time.
The amount of recombinant gp46 expressed in each of the three of the systems
tried was very poor and thus limited the experiments for which rgp46 could be used.
Previous use of each of the expression systems has shown that the vector promoters
etc are not at fault. There are a number of other reasons for poor yields of
recombinant proteins: Low yields of fusion proteins are sometimes found to be due to
more rapid turnover of the recombinant protein than of the fusion partner alone, or due
to more rapid turnover of mRNA, since there is some influence of codon usage on the
stability of mRNA (Hoekema et al., 1987). The activity of host cell proteases may
also lead to low yields of heterologous proteins (Gottesman, 1989). Although such
factors may have contributed to the problem of low yield, toxicity of the expressed
protein was probably the major reason.
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Even at very low or undetectable levels of recombinant protein, induction of its
expression had a profound inhibitory or toxic effect on growth of the host cells. Other
hydrophobic proteins have also been shown to be toxic when expressed intra-
cellularly, although the mechanism for this toxicity has not been ascertained. One
possibility is that interaction of the hydrophobic regions of the protein with cellular
proteins may disrupt various cellular biochemical pathways resulting in cell death.
Interaction with cellular proteins could also account for the high level of contaminating
proteins carried through the purification procedures.
An alternative/additional mechanism of rgp46 toxicity is the potential
immunosuppressive peptide which has been identified as amino acids 64 to 79 (Ruegg
et al., 1990). It is present in both TH and TF recombinant proteins. The
immunosuppressive peptide is thought to inhibit the enzyme protein kinase C which is
involved in signalling pathways. Thus rgp46 may be toxic to the cells which express
it by inhibiting of protein kinase C and disrupting the pathways in which it is
involved. A related sequence found in HIV gp41 inhibits NK cell function, monocyte
chemotactic responses and proliferation in response to mitogens or specific antigens
(Harris et al., 1987, Miedema etal., 1988).
6.4: IMMUNE RESPONSES TO rgp46
Mice immunised with Vgp46 raised antibodies specific to rgp46 produced by
E.coli. A rabbit immunised with pl:TF raised specific antibodies to TF as well as to
pi and other yeast protein contaminants. Although none of these sera appeared to
react with gp46 on western blots of EV1 lysate, there was no positive control to
confirm the presence of EV1 gp46 on the blots and it cannot be concluded that they did
not recognise native gp46.
A peptide corresponding to amino acids 116-134 of EV1 gp46 and linked to
ovalbumin was used to immunise two rabbits. Both rabbits raised antibodies to the
peptide but the antibodies did not react against native protein (neither GST:TH nor
pl:TF by ELISA and western blot nor EV1 lysate by western blot), nor did they have
any effect in the fusion assay.
78% of sera tested from MVV infected sheep and none of the sera from
uninfected sheep reacted with GST:TH but not GST on Western blots. This shows
that gp46 is immunogenic in the infected animal, and that the majority of MVV-
infected animals generate antibodies against the external domain of gp46. There are a
number of possible reasons why serum from some MVV infected sheep failed to react
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with the TH on western blots, i) The animal may not have raised antibodies to gp46.
ii) Any antibodies raised may have been unreactive with denatured proteins, or been
glycosylation dependent, iii) Some antibodies against gp46 may be type specific. If
the most variable epitopes are immunodominant testing of sera from sheep infected
with field strains of MVV against EV1 protein may not be ideal. Later in infection the
humoral immune response is thought to be more broadly reactive to the envelope
epitopes. Thus the sera reacting with EV1 rgp46 may be reacting to conserved
epitopes recognised late in infection. Unfortunately the time of infection of individuals
in this flock is unknown.
ELISA may be preferable to western blots as a way to measure antibody
responses because proteins are not denatured as much by coating onto ELISA plates.
Western blots detect primarily antibodies against linear epitopes but are better at
separating out reactivity with the protein in question from reactivity with contaminating
proteins. The high levels of contaminating yeast or bacterial proteins in the
preparations of recombinant gp46 makes the ELISA results difficult to interpet.
6.5: THE FUSION ASSAY AND THE EFFECT OF SERUM ON MVV FUSION-
FROM-WITHOUT
The fusion assay was devised as a method to determine whether MVV-infected
animals mount an immune response which can alter the ability of MVV to fuse with
host cells. It basically involved preincubation of MVV with serum, prior to addition to
cells. The fusion assay demonstrated that some sera can dramatically alter the ability
of the virus to fuse cells. Both enhancement and inhibition of MVV mediated cell
fusion was demonstrated. Surprisingly, it was clear that the same serum could inhibit
fusion at high concentrations of serum yet enhance when diluted.
It was initially assumed that the mechanism of FFWO in the assay would be
the same as for fusion of virus with cell at initial infection. The results of my studies,
and of others, suggest this is not necessarily so. As discussed in Chapter 5 the actual
mechanism of FFWO is not known. Two alternative hypotheses were proposed; i) A
virus happens to land between two cells so that it is able to bind and fuse with two
cells at the same time, thus fusing the two cells, ii) The virus fuses first with one cell,
but envelope proteins remaining on the cell surface mediate fusion with a neighbouring
cell. Both mechanisms would require high concentrations of virus to maximise the
chances of cell fusion.
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Sera from uninfected sheep had some effect on MVV fusion in that
preincubation of MVV with low dilutions of serum increased the number and size of
syncytia formed compared to MVV preincubated with medium alone. More dilute
serum from uninfected sheep did not affect syncytium formation. There was a
significant difference between the pattern of activity by sera from MVV-infected
(ShM) or uninfected (ShU) sheep in the fusion assay. The activity of ShM sera
ranged from fusion inhibition at low serum dilutions and enhancement at high
dilutions of the same serum to fusion enhancement at all serum dilutions down to the
lowest tested which was 1:512. Averaging all the ShM fusion assay results showed
that the typical pattern of activity of ShM sera was fusion inhibition at dilutions <1:8
and enhancement of fusion at dilutions >1:16.
6.5.1: Hypothetical mechanisms of fusion inhibition in the fusion assay
Most of the mechanisms of virus neutralisation could, if antibody is present at
sufficient concentration, lead to inhibition in the fusion assay. Examples include
aggregation of virus particles, blocking of binding to receptor, and blocking of
epitopes necessary for fusion including prevention of conformational changes.
Fusion efficiency may also be affected by alterations in the cell rather than the
virus. A candidate factor which could be active in this assay, as it is not affected by
heat treatment, is the unique form of interferon induced by lentiviruses (Narayan et al.,
1985). This "lentiferon" has been reported to block fusion of infected macrophages
with synovial membrane cells and to cause a dramatic reduction in the fusion function
of CAEV (Zink and Narayan, 1989). Although fusion inhibition activity was detected
in serum, it was not detected in serum depleted of IgG i.e.the fraction in which LV-
IFN would be expected. This suggests that LV-IFN was not a significant factor in
fusion inhibition in these assays. It could be that LV-IFN was not present at sufficient
concentration in the sera for its fusion inhibitory activity to be detectable or it may be
that fibroblasts are not affected by LV-IFN.
6.5.2: Hypothetical mechanisms of enhancement in the fusion assay
The fusion assay described in Chapter 5 clearly showed that high
concentrations of normal serum from most of the uninfected sheep tested enhanced
fusion-from-without by MVV. This titred out quite quickly (1:64 maximum) whereas
sera from some of the MVV infected sheep enhanced fusion at least to 1:512.
The mechanism by which fusion enhancement occurs in vitro has important
consequences for assessing how relevant the fusion assay result is to enhancement of
infection or cell-to-cell fusion (FFWI) in vivo. Several hypothetical mechanisms of
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enhancement of fusion in the assay are described below.
i) Formation of fusogenic immune complexes:
At a given ratio of antibody to antigen the multi-valency of antibodies allows
antibody:antigen aggregates or immune complexes to form. In vivo this generally aids
the clearance of antigen by phagocytic cells. In the in vitro fusion assay aggregation
of virus particles may enhance fusion purely physically; larger, heavier particles may
settle more rapidly and also may be more likely to end up lying between cells in the
monolayer. If this is so, it may actually be aiding delivery of virus to a site where a
single virus or more than one in the complex may be able to fuse with two cells
simultaneously.
ii) Cross-linking of envelope on the cell surface:
If FFWO occurs by fusion of the virus with first one cell, leaving functional
envelope proteins on the cell surface to subsequently mediate fusion with a
neighbouring cell, then antibodies could conceivably enhance fusion by cross-linking
envelope proteins, effectively increasing the surface density of envelope proteins.
Low affinity antibodies would probably be better at aiding formation of fusion
complexes without blocking fusion.
Another potential enhancement mechanism also assumes the two-step model of
FFWO; Capping is a phenomenon whereby antibodies bound to cell surface proteins
tend to move together in the membrane so that an area with a high concentration of
bound antibodies is formed and this is pinched off to remove it from the cell surface.
If in fibroblasts capping occurs at the margins of the cells i.e. where they are in closest
contact with their neighbours then low affinity (or gpl 10 stripping) antibodies might
help to deliver the envelope proteins to regions proximal with an opposing membrane
and thus enhance fusion.
IgG cross-linking of cellular bound virus to incoming virus may enhance
virus/cell interaction and therefore increase fusion.
iii) Antibody enhancement via Fc receptors:
Antibody enhancement of infection generally occurs via Fc receptors (FcR) or
complement receptors. Skin-derived fibroblastic cells are not normally thought to
express such receptors, but the YT40 skin cell fibroblast line used in these
experiments had been extensively passaged and aberrant expression of surface
molecules cannot be ruled out. Also some viruses can upregulate FcR, including on
fibroblastic cells, but no studies have been reported on upregulation of FcR by MVV.
Antibodies specific for ovine FcR were not available to check this simply, although
rosetting with RBCs coated with anti-RBC sheep antibody could have been used as a
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crude test for FcRs. Fab fragments of the IgG from the enhancing sera would have
been useful to determine whether or not FcRs were implicated in antibody
enhancement of FFWO.
iv) "Stripping" of gpl 10 from virus particles:
Antibodies against gpl 10 could alter its interaction with gp46, perhaps to
induce dissociation, although, because of the lack of appropriate antisera, it is not
known how readily MVV gpl 10 dissociates from gp46. If antibodies could induce
dissociation of the MVV envelope glycoproteins then stripping of gpl 10 from the viral
membrane might expose gp46 enabling it to interact with the cell membrane. Such a
mechanism is more likely to enhance fusion if an optimal SUrreceptor interaction is not
possible. MHCII has been identified as a receptor for MVV, yet is undetectable on
YT40 fibroblast cells, so that in the fusion assay the virus may be making use of a
sub-optimal receptor on fibroblast cells. Thus a case can be made for enhancement by
increasing the ability of gp46 to interact directly with the cell membrane. The same
hypothesis can be proposed if anti-envelope antibodies can mediate a change in the
conformation of the envelope proteins without actually dissociating gpl 10.
Antibodies binding to the SU glycoprotein may "activate" or expose the fusion
peptide, in the same way that binding of the SU to its receptor might do.
There are arguments both for and against exposure of the fusion peptide as a
mechanism of fusion enhancement. Acid pre-treatment of influenza HA irreversibly
renders it incapable of subsequently mediating membrane fusion apparently by
overshooting the conformational change normally required for fusion (Wilson et al.,
1981). On the other hand acid pre-treatment of another pH-dependent virus, VSV,
enhances subsequent fusion (Puri, et al., 1988). Soluble CD4 has been shown to
block HIV infection by removing the gpl20 protein from the viral envelope (Moore et
al., 1990), while SIV infection was enhanced in the presence of sCD4 perhaps by
exposure of the fusogenic domains (Allan, 1991).
The hypothesis that in sheep skin cell fibroblasts the virus is using an
alternative receptor to the one it normally recognises might be important in this. It
would be interesting to see if the sera used in the fusion assay described here would
have similar effects on MVV fusion of macrophages.
v) Cross-linking of cellular membrane proteins
It has been shown that antibodies directed against the host cells can enhance
virus mediated fusion; anti-cellular antibodies enhanced FFWI by Newcastle disease
virus (NDV) but did not alter the fusion inhibition by antibodies against NDV F
protein (Ito et al., 1987). The enhancement was narrowed down to antibodies against
cell surface proteins, called fusion regulatory proteins (FRPs) (Ito et al., 1992).
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Monoclonal antibodies against FRPs, like antibodies against other cell surface
proteins, can cross-link and aggregate cells. However, fusion enhancement appears to
be specific to anti-FRP antibodies. It was suggested that antibody cross-linking of
FRPs could trigger disturbance of the cytoskeleton and thereby enhance fusion.
There is some evidence for the generation of autoreactive antibodies during
MVV infection. Such antibodies could be involved in mediating enhancement in the
fusion assay by sera from MVV infected sheep. One way to determine whether this is
the case would be to test the same sera in a fusion assay using a different fusogenic
virus which could fuse sheep cells.
vi) If non-Ig serum factors affected FFWO, perhaps by altering expression of
cellular receptors, then this could only be a minor component of fusion enhancement
since serum with IgG removed had a much lower fusion enhancing effect than sera
containing IgG.
6.5.3: The balance between fusion inhibition and enhancement
The effects seen in the fusion assay were dependent upon serum concentration
since the same serum at low dilution can inhibit fusion yet at higher dilution enhanced
fusion. Thus there appears to be a balance between fusion inhibition and
enhancement. This balance could either be due to different factors with positive and
negative effects on fusion or due to the same factors having different effects when
present at high or low concentration.
A model to explain the balance between fusion inhibition and enhancement
which fits with the results obtained is shown in Figure 6.2.: Virus fusion is blocked
when antibody is in excess and binds to the virus thus preventing interaction with the
cell surface. At low proportions of virus only a few sites on each virion bind virus,
leaving most of the envelope glycoproteins free to mediate fusion which is enhanced
by by cross-linking of virus particles or virus to cell incorporated viral proteins, or via
FcRs.
This is no doubt an over-simplification; the results of fusion assays with IgG
preparations and IgG depleted sera suggested that other serum factors can affect fusion
either independently or by interactions with IgG.
Serial serum samples taken at 6 weekly intervals were tested in the fusion
assay. For most sheep the activity in the assay was the same for each serum sample.
However in ShM2.1 the first sample was blocking, the second was neutral and the
third and fourth were enhancing. This suggests that over the course of twelve weeks
the balance of activity in this sheep had changed from fusion inhibiting to fusion
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Figure 6.2: Hypothesis to explain the balance between enhancement
and inhibition in the fusion assay

























Figure 6.3: Hypothesis for a balance between fusion enhancement and fusion
inhibition over the course of MVV infection
The diagram below is an attempt to illustrate the hypothesis that the pattern
of activity in the fusion assay may change as disease progresses. It requires the
acceptance of the hypothesis illustrated in Figure 6.2 that whether fusion is enhanced
or inhibited is dependent on the ratio of virus to antibody.
It is postulated that fusion modulatory activity changes from blocking to
enhancing after a variable period of infection. A decrease in MVV-specific
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enhancing. The fact that the activity moved through zero shows that this is probably a
real effect. Sampling may have fortuitously caught the window in time when the shift
of balance occured in this sheep. Sheep M4, M8 and M12 also appeared to shift away
from fusion inhibition in the later serum samples. None of the serial assays changed
from fusion enhancement to fusion inhibition or even neutrality. Also the shift is to
fusion enhancement at high and low dilutions, so it is not the same as the fusion
activity exhibited by sera from uninfected sheep.
A pattern of inhibition/enhancement over the course of MVV infection can be
postulated from the fusion assay results and the hypothesis that fusion enhancement
results from low concentration/ low affinity antibodies and fusion inhibition results
from high concentration / high affinity antibodies: Before production of anti-MVV
antibodies some cross-reactive antibodies in preimmune serum may mediate fusion
enhancement. Development of a specific anti-viral response produces antibodies at
higher concentration and affinity which inhibit MVV fusion but when diluted down in
the assay enhance fusion. If a shift towards fusion enhancement in the assay is indeed
a consequence of continuing MVV infection, this suggests that the amount of MVV
specific antibody decreases.
It would be very interesting to assay serial samples over a longer time course,
preferably from before and after experimental infection right through to disease
appearance, to see if the pattern of fusion inhibition/enhancement during MVV
infection fits the prediction above.
In HIV infection a decrease in antibodies reactive with peptides representing
HIV envelope has been shown to coincide with progression to clinical AIDS (Neurath
et al., 1990). This decrease appears to be HIV-specific as immunoglobulin levels are
not decreased between asymptomatic and AIDS patients and the antibody response to
another viral protein, hepatitis B surface protein did not decrease. In particular a
relationship has been shown between disease and declining levels of antibodies to
regions of gpl20 and to the C-terminal end of gp41 (Neurath et al., 1990).
6.5.4: Comparison to results of related studies
The strain of virus used in the assay and the strain against which antibodies
were generated may affect the results of the fusion assay. The sheep sera tested in the
fusion assay described in Chapter 5 were from a flock infected with an unclassified
field isolate(s) and strain EV1 was used in the fusion assay. In contrast, Crane et al.
(1988) tested sera from sheep which had been hyperimmunised with MVV strain 1514
for fusion inhibitory activity against 1514 or its antigenic variant LV-1. The results
differ in that Crane et al. (1988) detected syncytium inhibition but do not describe
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fusion enhancement. This can be extrapolated to suggest that the difference in results
may be due to type-specificity such that antibodies against a different strain from the
challenge may enhance fusion. This fits with the model proposed for the balance
between inhibition and enhancement; different variants of MVV are likely to have
epitopes in common as well as some type-specific epitopes so testing serum against a
heterologous variant effectively reduces the concentration of virus specific (high
affinity) antibodies and shifts the balance towards fusion enhancement. The
suggestion that sera appears to have greater fusion enhancement activity against
heterologous strains of MVV demonstrates a way in which the emergence of a new
variant might not only allow neutralisation escape but also actually enhance spread of
infection within the host. Further experiments are required to clarify the MVV strain
specificity of fusion enhancement and inhibition.
Similar results as was shown here for MVV fusion have been reported in
experiments with assays of the effect of immune sera on HIV infection. Significant
enhancement of HIV infection was reported with higher dilutions of HIV antibody
positive sera whilst neutralising activity was detected at lower dilutions (Takeda,
1988). Enhancing activity of antibody is HIV isolate/strain dependent. (Prince et al.,
1987, Cheng-Mayer et al., 1988, Homsy et al., 1990,). It was shown that sera from
some HIV infected patients enhanced infection of macrophages by a homotypic strain
of virus, that is virus isolated from the same patient as the serum tested, whilst
neutralising another strain of virus (Homsy et al., 1990). This is in contrast to the
hypothesis made above, that sera from MVV seropositive sheep may enhance fusion
by heterotypic strains, but may reflect more rapid appearance of variants in HIV, such
that the antiserum was generated against variants circulating before the virus isolated
for the assays.
6.5.5: Relationship between neutralisation and fusion inhibition
Fusion inhibition may occur with occupation of a smaller number of critical
sites by antibody than is sufficient for neutralisation. If most of the envelope
glycoprotein spikes on the incoming virus are coated with antibody, any remaining
free sites may be able to mediate fusion and therefore enable infection whilst the
chances of the virus being able to fuse with two cells at once (single event model of
FFWO) would be very low. Thus fusion-blocking antibodies may block FFWO but
still allow a rare fusion event. If the two step model of FFWO is considered then
antibodies may block fusion by cross-linking proteins and preventing their movement
within the membrane or by denaturing them without actually being able to block fusion
by incoming virus. Alternatively, in the presence of fusion blocking antibodies entry
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may be via the endocytic route instead of by fusion with the cytoplasmic membrane,
which would allow infection .
Immune sera from sheep hyperimmunised with MVV-1514 were shown to
neutralise virus infectivity and prevent cell fusion, suggesting a linkage between these
phenomena (Crane et al., 1991). LV-1 was a variant isolated from a sheep which had
originally been inoculated with MVV 1514. Monospecific sera which neutralised
1514 but not LV-1 prevented FFWO by both. They suggested their results showed
that different epitopes are responsible for fusion and neutralisation. The difference in
kinetics between the two assays may be a better explanation, in that the fusion assay
read-out requires very many fusion events whereas the neutralisation read-out requires
very few infection events, so lower affinity and/or lower titre antibodies may block
fusion in the FFWO assay than are necessary to block infection.
Dalziel et al., (1991), demonstrated that soluble MHCII could block fusion but
not infection of skin cell fibroblasts (YT40 cells as used in my experiments). Again
this may be explained by the kinetics for virus fusion being much greater than that
required for infection. Only a small number of free receptor binding sites, sufficient to
form one fusion complex, may be required for infection whereas at least enough for
two complexes (one per cell) are required for the virus to bind two cells at once and
thereby initiate fusion (assuming this is the mechanism of cell fusion in the assay).
Thus binding of sMHCII to MVV may block the viral binding site for the cellular
receptor to an extent whereby visible cell-to-cell fusion does not occur but infection
may still be possible.
6.5.6: Relevance of fusion assay results to in vivo viral fusion
One would predict that inhibition of the fusion assay would reflect the ability
of the antiserum to reduce viral infectivity in vivo, perhaps reducing the rate of initial
infection as well as limiting subsequent spread of virus to new cells or tissues. In
addition, fusion inhibiting antibodies might reduce syncytium formation in the infected
tissues thus minimising cell-to-cell spread as a way to elude the immune system.
Functional antibodies which inhibit this process could potentially reduce cytopathic
damage and perhaps reduce disease severity. Enhancement of FFWO in vitro may
correspond to enhancement of viral infectivity in the host animal.
Fusion inhibiting antibodies in HIV infected children have been shown to
correlate with a more benign outcome with respect to lung disease (Brenner et al.,
1991) whilst the appearance of increased enhancing antibodies/enhanced strains of
HIV was associated with progression towards disease suggesting that enhancement
may contribute to the severity of infection (Homsy et al., 1990). The results of the
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fusion assay did not appear to have any relationship with the disease state of the sheep
except that sera from infected sheep, which are therefore those that eventually
succumb to disease, tend to differ in serum fusion-modulatory activity compared to
uninfected sheep. However this does not rule out an association being found if larger
numbers were tested and if different criteria for disease state were chosen.
The fusion assay results for sera from uninfected sheep suggest that free virus
may be helped to fuse with and infect cells by components in pre-immune sera. As
sera from uninfected sheep varied in the ability to enhance MVV fusion, it would be
interesting to see if fusion enhancement by pre-immune serum has any correlation with
susceptibility of the sheep to MVV infection.
As discussed above, the results of the MVV fusion assay show that the relative
amounts of antibody and virus may be crucial in determining enhancement or
inhibition of fusion, and potentially of infection. However, the considerable
differences between the in vitro fusion assay and the situation occuring in tissues of
the infected animal should be taken into account when extrapolating from one to the
other. In the seropositive animal there is probably more fusion inhibition and less
fusion enhancement than is suggested from the fusion assay results: Very high
concentrations of virus were used in the assay so the ratio of virus to antibody was
much higher than would be found in vivo where MVV has only been detected at
relatively low levels. According to the model proposed this would shift the balance in
the assay towards fusion enhancement. In addition, some of the potential mechanisms
of fusion enhancement proposed in vitro may not be applicable in vivo where cells of
the immune system and also complement are present. For example, limited
aggregation in vitro might enhance in the fusion assay by forming larger particles
which sink to the bottom of the well more quickly thus increasing virusxell contact,
whereas in vivo such aggregates (immune complexes) should be cleared rapidly by
phagocytic cells.
The balance between fusion enhancement and inhibition may have important
implications for the use and design of vaccines; Infecting virus entering a new host is
most likely to be at very low titre either in the form of cell-free virus or virus produced
by a small number of transferred infected cells. Non-specific crossreactive antibodies
may facilitate or enhance infection, whereas specific antiviral antibodies may be able to
inhibit fusion and possibly prevent infection.
The fusion assay suggests that induction of type specific antibodies may
protect against one variant but act as lower affinity fusion enhancing antibodies if
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challenged with a different strain of virus. This is of importance to consideration of
potential vaccines as induction of a type specific immune response might do more
harm than good. The mechanism of enhancement needs to be elucidatedin order to
determine whether some epitopes would be better for induction of protective as
opposed to enhancing antibodies, e.g., enhancement might be mediated by activity
against MVV epitopes other than the fusion peptide, but immunisation with the
conserved fusion peptide might be protective.
6.6: CONCLUSIONS
Sera from most MVV-infected sheep recognised recombinant gp46 (EV1).
The difficulty of producing rgp46, due to its toxicity to the host cell, meant that some
of the planned experiments could not be done in the time available. However the
project generated reagents which could be used to further define the relationship
between antibodies to gp46 and fusion modulatory activity.
MVV-seropositivity appeared to be associated with antibodies to recombinant
gp46 and with a particular pattern of activity in the in vitro MVV FFWO assay.
However, it was not possible to show conclusively that the increased ELISA reactivity
of MVV infected sheep to GST:TH was entirely against TH or whether it was partly
due to reactivity with bacterial proteins contaminating the GST:TH preparation. There
was insufficient time to test all the sheep sera on western blots of GST:TH, but of
those tested there was no apparent relationship to fusion assay activity. This may be at
least partly because antibodies directed against the external envelope glycoprotein,
gpllO, as well as antibodies against gp46, would affect fusion. Although the 4°C
fusion assay attempted to separate the effect of antibodies which block binding of
virus to the host cell from those that subsequently inhibit fusion, the reproducibility of
this assay was very poor, so the 37°C assay was used more extensively.
Assays of the effect of sheep serum upon fusion by MVV produced some
interesting results: The same MVV-seropositive serum could inhibit fusion when at
low dilutions yet enhance fusion when diluted further. This led to the hypothesis that
the balance between fusion inhibition and enhancement is determined by the relative
amount of virus and anti-viral antibody. Non-specific antiserum from uninfected
sheep could also enhance fusion perhaps due to the presence of cross-reactive
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antibodies which suggests that pre-immune serum may actually help initial MVV
infection. MVV FFWO was inhibited by serum from most of the MVV-seropositive
sheep when at low dilutions. Since in the assay virus was in vast excess to antibody,
it is likely that in vivo, antibodies would be in sufficient excess to MVV to be able to
inhibit its fusion with host cells. Nevertheless the virus persists and the sheep still
succumb to disease showing that a fusion inhibitory response generated after infection
is not protective. Whether such a response could be protective if generated before
challenge has yet to be determined. Comparison with similar studies suggested that
antiserum to a different MVV strain from that used in the assay may be more likely to
enhance than to inhibit fusion. Further studies are required to elucidate the
mechanisms of inhibition and enhancement in the assay as the results of this assay





APPENDIX I: Bacterial culture medium and transformation of E.coli




Yeast extract 2.5g } Autoclave
SDW 490ml }
1M MgS04 (24.6g) }
0.5M NaCl (2.9g) } Filter sterilise and add 10ml





Glycerol (75g) } Filter sterilise
pH to 5.9 with acetic acid. }




MOPS (0.209g) } pH to 6.8 with KOH
RbCl (0.12g) } Make up to 100ml
CaCl2.6H20 (1.64g) } Filter sterilise
Glycerol (15g) )
Method:
A colony from an LB agar plate was inoculated into 10ml L-broth and grown
overnight at 37 °C with shaking. 1ml of overnight culture was added to 50ml of Psi
broth and incubated until an OD550 of ~0.48 was reached. (Takes about 3h). The
culture was cooled briefly on ice and then the cells were spun down by
centrifugation (2,000rpm bench centrifuge). Cells from 100ml of culture were
resuspended in 33ml of ice-cold TfBI and incubated on ice for 10-15 min. The cells
were spun down and resuspended in 4ml TfBII on ice for 20 min. 0.2ml amounts
were aliquoted into 1.5ml Eppendorfs, frozen rapidly on dry ice and stored at -20° C.
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Transformation of competent cells
Competent cells were thawed on ice. DNA was added (in small volume if
possible). The tubes were placed on ice for 30 miniutes. The cells were heat-
shocked by transferring the tubes to a 42°C water bath for 60-90 sec. After cooling
briefly on ice, 0.8ml of L-broth was added to each tube. The tubes were incubated at
37°C for 60 min. Cells were spun down by 30 sec microcentrifugation and
resuspended in 200|il of L-broth. 100(0.1 aliquots were spread on selective agar plates
(LB/Amp, or LB/Amp/X-Gal/IPTG) which were then incubated overnight at 37°C.
LB/Amp agar plates
15g of agarose was added per litre of L-broth. The agar was placed in a steamer
until it had dissolved then it was autoclaved. The agar was cooled to 55°C before
addition of Ampicillin to 150(ig/ml. About 20ml of agar was used for each plate.
LB/Amp plates were stored at 4°C for up to 2 weeks.
LB/Amp/X-Gal/IPTG plates
Base agar was made by dissolving 15gof bacteriological agar per litre of L-
broth. Top agar contained 8g of agar per litre of L-broth. The agar was dissolved by
placing in a steamer before autoclaving. It was then cooled to 55°C. Ampicillin was
added to 150|ig/ml. About 20ml of base agar was poured per plate. When the base
agar had set it was overlaid with about 6ml per plate of top agar containing
150(ig/ml of ampicillin, 20(tg/ml X-Gal (made up in dimethyl formamide) and
17(ig/ml of IPTG (in SDW).
Alternatively, 25(il of 24mg/ml IPTG (in SDW) and 40(tl of 20mg/ml X-Gal
(in DMF) were spread directly onto LB/Amp plates using a glass spreader.
LB/Amp/X-Gal/IPTG plates were stored at 4°C for up to 4 days.
Storage of bacterial stocks
An overnight culture was grown up in L-broth (plus 150(lg/ml ampicillin if
required). The bacteria were spun down by 5 min at 6,00rpm in a bench centrifuge.
The medium was removed and the cells were resuspended in L-broth/15% glycerol.
(3.4ml LB + 0.6ml glycerol) 1ml aliquots were transferred to Eppendorf tubes and
snap frozen on dry ice. Stocks were stored at -70°C.
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APPENDIX II: Preparation and electrophoresis of DNA
Preparation of Phenol
Redistilled phenol was stored at -40°C. Phenol was melted in a water bath at
68°C then cooled to RT. Hydroxyquinilone was added to 0.1%, i.e. O.lg to 100ml of
phenol. An equal volume of 0.1 M Tris pH8.0 was added and mixed well. The two
layers were allowed to separate and the aqueous layer was removed. Addition of
0.1M Tris pH8.0, mixing and separation was repeated at least four times, until the
pH of the Tris remained at pH8.0 after mixing and separation.
The phenol/Tris was stored in the dark at 4°C.
Preparation of Phenol/chloroform/isoamyl alcohol
Phenol was equilibrated with 0.1M Tris (pH8.0) as described above.
Chloroform and isoamyl alcohol were added at a ratio of 25:24:1 of
phenokchloroform: isoamyl alcohol. The solution was stored with Tris in the dark at
4°C.
Phenol extraction and ethanol precipitation
An equal volume of phenol (pH8.0) was added to the solution of DNA and
mixed vigorously by vortexing for 30sec. The aqueous and solvent layers were
separated by microcentrifugation for 5min. The top layer was collected to a new
tube taking care to avoid any material at the interface. An equal volume of
phenol/chloroform/isoamyl alcohol was added and mixed by vortexing for 30sec.
After microfuging for 5min the aqueous (top) layer was again transferred to a new
tube. An equal volume of chloroform was added, mixed and separated by spinning
for 2 min. The aqueous layer was collected. 0.1 volumes of 3M sodium acetate and
2.5 volumes of ethanol was added. The tube was placed at -20°C overnight, at -70°C
for 30min or on dry ice for 15-20min. The DNA was precipitated by 15min
microcentrifugation at 4°C. The pellet was washed twice with 70% ethanol, dried
and resuspended in SDW.
Restriction endonuclease digestion
The optimum conditions required for digestion vary between each restriction
enzyme. This information was supplied by the manufacturer. Generally lOx
concentrated digestion buffers supplied with each enzyme were used to create
optimum buffer conditions. One tenth volume of lOx digestion buffer was added to
a DNA solution in water or, in the case of plasmid minipreps, in TE/RNase. Excess
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restriction enzyme was then added depending on the estimated amount of DNA to be
digested. Digestions were incubated in a dry hot block at 37°C for the required
amount of time (1 hour or more for most enzymes, overnight for BamHI digestion).
When digestion with two enzymes was required both were added at once if
both had similar optimal buffer conditions. Alternatively the enzyme requiring the
lower salt/ionic molarities was used first, then the molarity required for the second
enzyme was obtained by the addition of appropriate solutions and the second
restriction enzyme was added.
CIP treatment
After incubation of plasmid with restriction enzyme for lh (or as required) at
37°C 1 pi (15 Units) of Calf Intestinal Phosphatase (CIP) (Sigma) was added. After




50xTAE- 242g Tris, 57.1ml glacial acetic acid,
made up to 11 with deionised water.
Loading buffer- lOOmM EDTA, 30% Ficoll,
0.025% Xylene cyanol.
Method
Agarose was dissolved by boiling in TAE buffer then allowed to cool a little.
Ethidium Bromide was added to a concentration of 0.6pg/ml. The gel was poured
and left to set. TAE running buffer was made up and enough was added to the tank
to just cover the gel. 0.2 volumes of loading buffer was added to each sample.
Samples were loaded and the gel was run at 70-80Y (or 40-50V at 4°C for low-
gelling temperature (LGT) gels). Nucleic acid in the gels was visualised on a UV
transilluminator.
Recovery of DNA from agarose
1. Hot Phenol/chloroform
The agarose slice containing the DNA was melted at 65°C. An equal volume of
65°C phenol/chloroform was added and vortexed. The aqueous and solvent phases
were seperated by microcentrifugation for five min. The aqueous phase was
collected then extracted once with phenol, once with phenol/ chloroform (RT), once
100ml 0.5M EDTA pH(8.0),
0.025% bromophenol blue,
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twice with 70% ethanol, dried and resuspended in water or buffer.
2. Geneclean.
DNA was recovered from LGT agarose by binding to then elution from silica.
"Geneclean" reagents were used according to the manufacturers instructions.
Briefly, a slice of gel containing the DNA of interest was excised and weighed to
estimate its volume. 2.5-3 volumes of Nal stock solution was added and the gel was
melted by heating to 60°C. Glassmilk suspension (silica) was added (5|il for 5p.g or
less) and placed on ice for 5 min with mixing every 1-2 min. The silica matrix and
bound DNA were pelleted by microcentrifuging for 5 sec. The supernatant was
removed. The pellet was washed three times with "NEWWASH". After the third
wash as much supernatant as possible was removed. The DNA was eluted from the
glassmilk by resuspending the pellet in lOp.1 of SDW and incubating at 50°C for 2-3
min. The supernatant was collected after microcentrifuging for 30 sec. The elution
was repeated once more and the supernatants were pooled. The DNA concentration
in the supernatant was estimated by running a sample on an agarose gel alongside
markers.
3. Centrifugation through 3MM paper
DNA was recovered from agarose (not LGT) as described by Weichenman,
(1991). Briefly 3MM paper was formed into a beaker inside a 0.5 ml Eppendorf tube
with a hole pierced in the bottom. The agarose slice was placed into the paper
beaker. The first tube is mounted inside a 1.5ml Eppendorf tube and
microcentrifuged for 1 minute. The buffer and DNA are collected in the second tube
leaving behind dehydrated agarose in the blotting buffer. Recovery of DNA from
the gel is predicted to be greater than 50%.
Minipreps for the isolation of plasmid DNA (Adapted from Serghini et al., 1989)
Transformants grown on selective agarose plates were inoculated into L-
broth/Amp and grown up overnight at 37°C with shaking. 3ml of overnight culture
was pelleted by 30s microcentrifugation and resuspended in lOOjil of TNE. 100|il of
phenol/chloroform was added. The mixture was vortexed for 60 sec. After 5 min
microcentrifugation the aqueous (top) layer was transferred to a fresh Eppendorf.
An equal volume of phenol/chloroform was added. The mixture was vortexed for 60
sec. Again the aqueous and solvent layers were separated by microcentrifugation
for 5 min. The aqueous layer was collected and heated to 70°C for 5 min to denature
any DNAses. One tenth volume of 3M NaOAc and 2.5 volumes of ethanol was
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added. After one hour at -20°C or 5 min on dry ice precipitated DNA was pelleted
by microcentrifugation for 15 min at 4°C. The pellet was washed twice with 70%
ethanol, dried and resuspended in TE/25|ig/ml of RNAseA. If restriction digestion
was required the DNA was resuspended in TE/RNAse plus the approriate buffer and
enzyme. The resuspended DNA was incubated at 37°C for 1 hour. Samples were
run on a 1% agarose gel alongside DNA size markers and the appropriate control
plasmids.
Large Scale plasmid preparation
20ml of overnight culture was inoculated into 11 of L-broth/150|ig/ml
ampicillin. The 11 culture was incubated overnight then harvested in 250ml Beckman
bottles in J2-21 rotor at 15K for 15 min. The cells were washed once in STE (0.1M
NaCl, lOmM Tris-Cl pH8.0, ImM EDTA) The pellet from 500ml of culture was
resuspended gently in 10ml of cold solution I plus 5mg/ml lysosyme and placed at
RT for 15 min. 20ml of 0.2M NaOH, 1% SDS was added, mixed gently and placed
on ice for 10 min. 15ml 5M Potassium acetate was added mixed and placed on ice
for a further 10 min. The mixture was centrifuged for 20 min at 11K. The
supernatant was recovered into a fresh 250ml Beckman bottle taking care to avoid
any floating or pelleted material. 0.6 volumes of isopropanol was added. The
mixture was incubated at RT for 20 min. DNA was precipitated by centrifuging for
10 min at 10K at 4°C. The pellet was washed once with 30ml 70% ethanol, air
dried, resuspended in 5.0ml TE/lOjig/ml RNAse A and incubated at 37°C for 1 hour.
The DNA was extracted 3 times with phenol/chloroform and once with chloroform.
The supernatant was transferred to a Corex tube. 10M ammonium acetate was added
to a final concentration of 2M. 0.6 volumes of isopropanol was added. The tube was
placed at RT for 20-30 min then centrifuged at 8K for 10 min. The pellet was
washed with 70% ethanol, air dried and resuspended in exactly 1.8ml of lOmM
Tris-Cl pH8.0, ImM EDTA, 1M NaCl. A PZ523 (5'-3' Inc.) column was prepared by
removing the top and bottom closures and spinning for 1 minute at 1500rpm to
remove the storage buffer. 1.8ml of sample was loaded and spun for 12 min at
1500rpm. The collected solution was extracted twice with phenol chloroform, once
with chloroform . The DNA was precipitated by adding 0.6 volumes of isopropanol,
mixing, incubating for 20 min at RT, then microfuging for 15 min. The precipitate
was washed twice with 70% ethanol, air dried and resuspended in 200jil of SDW.
(The resulting plasmid concentration was normally in the range of 2-8|J.g/|al).
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APPENDIX III: DNA blotting and hybridisation protocols
Labelling probe DNA with 32P
50ng of probe DNA (plasmid insert) was made up to 26|ll with SDW and
boiled for 5 min. The solution was cooled to 37°C. 10[il 5 x OLB buffer, ljil BSA
(lmg/ml), lOjul (lOOqCi) 32PdCTP and 3pl Klenow DNA polymerase was added.
The mixture was incubated for 4 hours at 37°C. The reaction was stopped by adding
50|al of lOxTE. The radioactivity incorporation was measured.
Southern blotting onto nitrocellulose
After electrophoresis to separate the DNA fragments the gel was washed for
15min in 0.2M HC1, washed in two changes of denaturing solution (0.5M NaOH,
1.5M NaCl) for 15 min each, and in several changes of neutralising solution (0.5M
Tris-HCl pH7.0, 1.5M NaCl) for a total of 45 min. The gel was rinsed in waterand
was placed on top of two pieces of 3MM paper acting as a wick to draw up 10 x SSC
buffer from the trough below. Nescofilm was placed around the gel. A piece of
nitrocellulose cut to size and soaked in 10 x SSC was placed on the gel. 8-10 pieces
of 3MM paper soaked in 10 x SSC were placed on top of this, followed by a stack of
dry paper towels. A glass plate and a weight were placed on top. The assembly was
left overnight in which time the towels had drawn up buffer by cappillary action and
transferred the DNA to the nitrocellulose. The nitrocellulose was air dried and then
baked at 60° C under vaccuum for 2h to fix the DNA to it. Once baked the blot could
be stored at room temperature until required.
Southern blotting onto nylon filters
After running the gel it was soaked in 10 x SSC. The apparatus was set up as
above but using a nylon filter instead of nitrocellulose, and left to blot overnight.
The nylon filter was fixed and denatured by placing on top of 3MM paper soaked in









2ml lOmg/ml yeast RNA
152.7ml SDW
Filters were prehybridised for at least 4 hours at 65°C in prehybridisation
buffer. Most of the buffer was removed leaving just enough to cover the filters.
Labelled probe was boiled for 2 min then added to the filters (about 2 x 106
counts/minute per filter) and incubated overnight at 65°C. The filters were washed
at least 6 times for 10 min with 3xSSC, 0.1%SDS, at room temperature, then twice
for 30 min with 0.3xSSC, 0.01% SDS, at 65°C. The filters were dried at room
temperature then put down against XS autoradiography film and stored at
-20°C for lh to several days as required depending on the signal intensity.
Colony screening using nylon filters (Adapted from Buluwela et al, 1989)
Transformants selected by spread plating on LB agar 150(ig/ml Amp were
picked onto duplicate fresh plates. When these had grown sufficiently lifts were
made onto nylon filters (Hybond-N) by placing dry filters onto plates to contact
colonies then peeling off the filter. Filters were laid colony side up on a piece of
3MM paper soaked in 2 x SSC, 5%SDS, and microwaved (650W) on a rotating
turntable for 4 min. The filters were prehybridised for 2 hours at 65°C then labelled
probe was added directly to the prehybridisation buffer and incubated at 65°C
overnight with mixing. Filters were washed 6 times with 3 x SSC, 0.1%SDS at
room temperature and twice with 0.3 x SSC, 0.01 %SDS at 65°C, then dried and
placed against XAR film for 3 days.
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APPENDIX IV: DNA Sequencing methods
Production of single stranded pTZ derivatives
JM101 cells transformed with recombinant pTZ were grown in 2 x YT
medium plus 150(tg/ml ampicillin at 37°C to OD660 0.5-0.8. 2ml of this culture was
inoculated with phage M13K07 at a multiplicity of infection of 10 (assuming 1
OD660 to be equivalent to 8xl08 cells/ml). The culture was incubated with vigorous
shaking at 37°C for 1 hour. 400|i.l of these infected cells was added to 10ml 2xYT
medium plus 70(ig/ml kanamycin and incubated at 37°C for 14-18 hours with good
aeration. The culture was centrifuged to remove cells. The supernatant was
collected and recentrifuged until a cell pellet was no longer observed. 0.25 volumes
of 20% polyethylene glycol in 3.5M NaCl was added and placed on ice for 30 min to
precipitate the phage containing single strand pTZ DNA (as well as a small amount
of M13K07 helper phage). The precipitate was pelleted by centrifugation at 1 l,000g
for 30 min at 4°C for 30 min. The supernatant was removed and the pellet was
resuspended in 0.4ml of 20mM Tris-HCl (pH7.5), 20mM NaCl, ImM EDTA. The
DNA was phenol/chloroform extracted and ethanol precipitated. The precipitate
was washed with 70% ethanol, dried and dissolved in 50|il of lOmM Tris-HCl
(pH7.5), ImM EDTA. Samples were electrophoresed on a 1% agarose gel to check
concentration and purity prior to sequencing.
Sequencing gels
The gel plates were cleaned thoroughly, siliconised, and polished before
assembling the apparatus. 120(0.1 TEMED and 110pl 25% ammonium persulphate
(freshly made) was added to 40ml 6% acrylamide/urea/TBE and used to seal the
base. 110ml of 6% acryl./urea/TBE was filtered and de-gassed then 1lOjol TEMED
and 110(0.1 25% APS was added. The gel was poured and the comb was put in place.
100ml. 10 by TBE was made up to 21. with millipore water and used to fill the
running buffer tank. After removing the comb, the gel was prewarmed by running at
90W for 20-30 mins. The wells were flushed out with buffer immmediately before
loading. Samples were heated at 75°C for 2-3 min and 5(0.1 of each was loaded.
Sequencing gels were run at at 90W or 2950V for 2-8 hours. The apparatus was
disassembled and the gel was transferred onto 3M paper and dried on a vacuum drier
at 80°C for 1-2 hours. The dried down gel was placed against X-ray film in an




Sequencing reactions were conducted as shown below using the Sequenase
Version 2.0 kit (United States Biochemical Corporation).
Single-stranded sequencing reactions
Annealing: 2(tl (~2|ig) single-stranded DNA, l(il reverse primer, lpl DMSO, 2jol
reaction buffer and 4|ol SDW were added together, heated to 65°C for 2 min and then
cooled slowly to room temperature in a beaker of water.
Labelling: 5(tl DTT, lOpl dGTP labelling mix (diluted 1:5 in SDW), 2.5(0.1
35SdATP, and 10(il sequenase enzyme (diluted 1:8 in enzyme dilution buffer) was
added and incubated at room temperature for 2-5 min.
Termination: 3.5|il of each labelling reaction was added to pre-warmed tubes each
containing 2.5(0.1 of one of the four ddNTP termination mixes, ddATP, ddCTP,
ddGTP or ddTTP. The termination reactions were incubated at 37°C for 5 min,
before addition of 4(0.1 of stop buffer to each tube.
Double-stranded sequencing reactions
~0.5pmole of sequencing primer was annealed to -lpmole of double-
stranded DNA, in annealing buffer, by boiling for five min then snap cooling on ice.
5(0.1 of elongation mix (made up of 4(0.1 DTT, 4(0.1 DMSO, 1 (0.1 dGTP mix, 2(0.1
35SdATP, 7(0.1 sequenase buffer, and 1 (0.1 of sequenase enzyme) was added to each
tube. The elongation reaction was allowed to proceed for ten min on ice. 3.5|ol of
each reaction was added to 2.5|ol of each of the four ddNTP termination mixes in
seperate pre-warmed tubes, and incubated at 37°C for 5 min. 4(0.1 of stop buffer was
then added.
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APPENDIX V: Yeast transformationand veast culture media
Culture media for yeast
YEPD: peptone 20g/l, yeast extract 10g/l, glucose 20g/l
SC-glc: yeast nitrogen base (without amino acids) 6.7g/l, glucose 10g/l, amino acids
added as required after autoclaving.
For SC-glc plates 20g/l Bacto agar was added before autoclaving.
SC-Gal: yeast nitrogen base (without amino acids) 6.7g/l, glucose 3g/l, galactose
10g/l, amino acids added as required after autoclaving.
Amino acid stocks: lOmg/ml L-tryptophan, lOmg/ml uracil, lOmg/ml leucine
lOmg/ml L-tryptophan, lOmg/ml uracil
lOmg/ml L-tryptophan
Amino acid stocks were dissolved by boiling briefly, filter sterilised and stored at
4°C in the dark. 2ml of amino acid stock was added per litre of medium
Regeneration agar: 5g ammonium sulphate, 1.7g yeast nitrogen base, 20g
dextrose, 30g agar, 1 pellet NaOH, 500ml 2M sorbitol, 20ml YPD medium, 480ml
water.
The mixture was melted in a steamer and 20 ml aliquots were transferred to
Universals. After autoclaving, the agar was cooled to 55°C and amino acids were
added as appropriate.
Solutions for yeast transformation (All filter sterilised)
CaCl2 solution: 0.1M Tris-Cl pH7.4, 0.1M CaCl2
Lithium acetate solution: 0.1M lithium acetate, lOmM Tris-Cl, pH8.0, ImM EDTA
PEG solution: 40% wt/vol polyethylene glycol 3350, 0.1M lithium acetate, lOmM
Tris-Cl, pH8.0, ImM EDTA
PEG/CaCl2 solution: 40% wt/vol polyethylene glycol 3350,lOmM Tris-Cl, pH7.4,
lOmM CaCl2
Sorbitol/CaCl2 solution: 1M sorbitol, lOmM Tris-Cl, pH7.4, lOmM CaCl2
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Lithium acetate transformation method
50ml YEPD was inoculated with 25, 50 or lOOfj.1 of a saturated of yeast and
incubated at 30°C with shaking for 16 hours. The OD600 was measured and cultures
were checked for contamination. 50ml of whichever culture had an OD600 of 0.5-1
was spun down at llOOg for 10 min. The pellet was washed in 10ml lOmM
Tris(pH8), 1 mM EDTA then resuspended in 10ml lithium acetate solution. Cells
were spun down for 10 min at llOOg, resuspended in 500pl of lithium acetate
solution, and incubated for 1 hour at 30°C with gentle shaking. lOOpl aliquots were
transferred to sterile Eppendorfs. 1-lOpg of donor DNA with 0-20pg of carrier
DNA (salmon sperm DNA) was added. The tubes were incubated at 30°C for 30
min without shaking. 0.7ml of PEG solution was added and incubated at 37°C for a
further 45 min. The tubes were placed at 42°C for 5 min without shaking. For each
transformation four 200|ll aliquots were mix plated onto selective agar and incubated
at 30°C for several days until transformant colonies were visible.
Spheroplast transformation
A 10ml culture of yeast was grown overnight at 30°C. 5, 10, 25, or 50|il was
used to inoculate 50ml of YPD to achieve an OD600 of 0.5-1 (equivalent to l-2xl07
cells/ml) after overnight culture. The cells were pelleted by 5 min centrifugation at
1 lOOg and resuspended in 5ml of 1M sorbitol. This was repeated twice then 150|ll
of glusulase was added and incubated at 30°C with occasional gentle shaking for 60
min. Spheroplasts were pelleted for 4 min at 400g. The supernatant was carefully
removed and the pellet was gently resuspended in 10ml 1M sorbitol. Pelleting and
resuspension in 10ml Sorbitol was repeated. The spheroplasts were pelleted and
resuspended in 9ml of sorbitol plus 1ml of CaCl2 solution, mixed gently by swirling,
and pelleted again at 400g. The pellet was resuspended in 1ml sorbitol/CaCl2
solution. 200|il aliquots were transferred to sterile Eppendorfs. Plasmid DNA with
or without carrier DNA was addedand incubated for 10 min at room temperature. 10
volumes of PEG/CaCl2 solution was added to each aliquot and incubated at room
temperature for 10 min. Spheroplasts were pelleted at 400g and the supernatant was
removed. The pellet was gently resuspended in 0.5ml of sorbitol/CaCh solution,
mixed with to 20 ml of 55°C regeneration containing the appropriate amino acids
and poured into a sterile petri dish. The plates were incubated at 30°C until small
colonies were visible. Individual colonies were then picked and streak plated on
selective SC-glc agar.
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APPENDIX VI: SDS-PAGE and Western blotting
SDS-PAGE protein gels
The Biorad Mini Protean II slab gel apparatus was used. Either 10% or 5-20%
gradient separating gels were used, using a 30% acrylamide/0.8% bis stock solution
and a final concentration of 0.38M Tris-Cl pH8.8, 2mM EDTA, 0.1% SDS, 0.08%
APS, 0.05% TEMED. The stacking gel was 3.48 % acrylamide/0.093%
bisacrylamide, 0.145M Tris-Cl pH6.8, 0.12% SDS, 0.12% APS, 0.17% TEMED.
Running buffer contained 0,05M Tris, 0.37M glycine, 19.5(iM EDTA, 0.1% SDS
Samples were boiled for 2-3 min with an equal volume of reducing sample
buffer (0.1M Tris pH6.8, 2% 2-mercaptoethanol, 30% glycerol, 1% SDS, 0.001%
bromophenol blue) before being loaded into the wells using a Hamilton micro-
syringe. Molecular weight markers (Pharmacia) were run in at least one well of each
gel. Electrophoresis was performed at 150V for approximately 45 min. or until the
dye front had reached the bottom of the gel.
Coomassie Staining
The PAGE gel was placed in a tray of 0.2% Coomassie stain (0.2%
Coomassie blue R250 (Sigma, UK), 20% methanol, 5% acetic acid ), for 20 min
followed by extensive destaining with 5% acetic acid, 20% ethanol. The gel was
dried down under vacuum at 80°C for lhr.
Silver staining
All solutions for silver staining were made using Milli-Q deionised water. The gel
was fixed for 15 min in 50%methanol, 10% acetic acid, for 30 min in 5% methanol,
7% acetic acid, and then for 30 min in 10% formaldehyde. The gel was rinsed
overnight in several changes of water. 0.1% silver nitrate was added and incubated
with the gel for 15 min. The gel was rinsed briefly with water then 500ml 3%
Na2CC>3 and 250(0.1 37% formaldehyde was added. When the colour had developed
sufficiently, solid citric acid was added to stop the reaction. The gel was rinsed for
30 min in water, fixed for 1 minute in 10% Ilfofix, and rinsed thoroughly in water
before drying down onto paper.
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Western blotting
The polypeptides separated by SDS-PAGE were transferred from the gel
onto nitrocellulose (Hybond-C, Amersham, UK),using a semi-dry electroblotter
(Ancos) with 25mM Tris, 20% methanol, 123mM glycine as buffer. A current of
120mA was applied across the blotter for 1 hour. The marker track was cut off,
stained with 0.5% Amido black for 30 min and destained in several changes of 50%
methanol, 5% acetic acid . The rest of the nitrocellulose blot was blocked with PBS,
5% milk powder (Marvel), 0.5% Tween 20 (Sigma UK) for 1 hour at room
temperature or overnight at 4°C. Blots were developed at once or stored at -20°C.
Developing a blot
Pre-blocked blots were incubated for 60 mins at room temperature or
overnight at 4°C in anti-serum diluted in PBS, 1% marvel, 0.1% Tween 20. After
five washes five times over at least 30 min with PBS, 1% marvel, 0.1% Tween 20,
the second antibody (alkaline phosphotase conjugated antiglobulin diluted according
to the manufacturers instructions in PBS, 1% marvel, 0.1% Tween 20) was added to
the blot and incubated for 1 hour at room temperature. The blot was washed at least
5 times in PBS, 1% marvel, 0.1% Tween 20, and twice in 0.1M Tris pH9.5. Blots
were developed with 0.1M Tris pH9.5, 0.2 mg/ml nitro blue tetrazolium (NBT),
O.lmg/ml bromo-chloro-indolyl-phosphate toluidine salt (BCIP), 20mM MgCU-
When development was complete the blots were washed with water then dried.
Production of Visna EV1 antigen for Western blots
Sheep skin cells 657 were grown in DME plus 6% FCS , pen/strep, L-
glutamine, and fungizone, in T225 flasks. Confluent monolayers were infected with
EV1. Initially , 400(ll of EV1 stock culture in 10ml of medium was added to each
flask and allowed to adsorb at 37°C for one hour. A further 90ml of medium was
added and the cells were incubated at 37°C until nearly 100% CPE was seen.
Virtually all the cells had come off the plastic by 6-7 days after addition of virus.
The medium was then transferred to 250 ml Beckman bottles and centrifuged in a
J2-21 rotor overnight at 10,000g. The pellet was resuspended in 12ml PBS then
centrifuged for 2 hours at 30K in an SW40 rotor . The pellet was finally




96-well plates (Falcon) were coated with 75pl of diluted antigen per well at
4°C overnight. Excess antigen was removed and plates were washed at least three
times in 0.1% Tween 20 in PBS. 75|il 2% BSA in PBS was added to each well and
incubated at room temperature for 30min. Plates were washed at least three times in
0.1% Tween 20 and lOOp.1 of serum or antibody sample, diluted in PBS, was added
to each well and incubated at 37°C for lh. Plates were washed at least three times in
0.1% Tween 20 in PBS. Alkaline phosphatase-conjugated antiglobulin was diluted
in 2% BSA/PBS according to the manufacturers instructions. 75fil was added per
well and incubated at 37°C for 60min. Plates were washed at least three times in
0.1% Tween 20 in PBS then 75p.l of HPX substrate was added to each well.
Substrate was allowed to develop in the dark for no more than lOmin. 50pl of 2M
H2SO4 was added to stop the reaction and OD492 was read using a Titertek
Multiskan blanked against an empty plate.
HPX substrate: (made up fresh each time) 0.8ml OPD mixture, 12.1ml H2O,
6.2ml 0.2M Na2HPC>4, 5.8ml 0.1M citric acid, 4|il H2O2.
OPD mixture: (Stored in 0.8ml aliquots at -70°C) 0.5g OPD, 10.04ml H2O,
5.14ml 0.2M Na2HP04, 4.82ml citric acid
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APPENDIX VIII: IgG
Preparation of IgG from sheep sera
A 2ml Sepharose-G column (1cm diameter) and a 2ml Sepharose pre-column
were pre-eluted with four column volumes of 0.1M glycine/HCl (pH2.7) then re-
equilibrated with PBS (pH8.0). 1ml of serum was complement inactivated by
heating for 30 min at 56°C. The serum was loaded through the pre-column then
through the Sepharose-G column at least four times. Unbound material was washed
off by flushing the column through with more than six volumes of PBS (pH8.0).
Bound protein was eluted with 0.1M Glycine/HCl (pH2.7) and 0.5ml fractions were
collected. The pH of each fraction was adjusted to pH7-8 with 0.5M Tris (pH8.0).
The OD280 of each fraction was measured and fractions containing protein
were dialysed into PBS overnight at 4°C. Finally the protein concentration in the
pooled fractions was estimated from the OD280- 1 M-l samples were electrophoresed
on a 10% acrylamide SDS-PAGE gel which was then silver stained.
The column was washed extensively with PBS (pH8.0) between application
of each sample, and was finally washed and stored in PBS/0.01% Sodium azide.
IgG capture ELISA
Falcon PVC plates were coated with lOpg/ml mouse anti-sheep IgG
monoclonal antibody (VPM6) in borate buffered saline (BBS), pH8.2, overnight at
4°C. After washing three times with BBS, 0.05% Tween-20, twofold dilutions of
the samples were made down the plate. A standard of sheep IgG was included
beginning at a concentration of 500ng/ml. The plates were incubated for 1 hour at
37°C then washed with BBS, 0.05% Tween-20. Rabbit anti-sheep horse radish
peroxidase conjugate was added at 1:4000 in BBS/1%BSA and incubated for 1 hour
at 37°C. The plates were developed with H2O2 and orthophenyldiamine (OPD) in
citrate phosphate buffer (pH5.2) for fifteen min. The reaction was stopped by adding
2M H2SO4 and the optical density was measured at 492nm.
230
APPENDIX IX: Formulae used for statistical calculations




The pooled variance, sp2, was estimated using the equation:
(n!- l)si2 + (n2- l)s22
s 2 =
(ni-l) + (n2-2)
The pooled variance was used in the formula below for calculating t:
xi - x2
t =
Sp2 [ 1/ni + l/n2 ]
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